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2A bstract
Human papillomaviruses (HPVs) are linked to over 99 % of cervical cancers and 
HPV16 is found in approximately half of all cases. The 16E1AE4 protein is abundantly 
expressed in productive infections but is downregulated or lost in cancers. The protein 
colocalises with and induces the collapse of cytokeratin networks, and in doing so, may 
facilitate virus release from cells. 16E1AE4 also causes cell cycle arrest by binding to 
and affecting the function of CDKl/cyclin B, which may enhance the virus’ ability to 
use cellular DNA replication machinery to amplify its viral genome. 16E1AE4 has also 
been shown to colocalise with CDK2/cyclin A.
Phosphorylation of 1E1AE4 and 11E1AE4 has been shown in vivo. In this study, 
phosphorylation of 16E1AE4 was investigated. When 16E1AE4 is expressed in cell 
culture, a slower-migrating, phosphorylated form is seen after SDS-PAGE. 16E1AE4 is 
phosphorylated by CDK1, CDK2, p42MAPK, PKA and PKCa in vitro. p42MAPK in 
vitro phosphorylation results in a slower-migrating form of 16E1AE4 similar to that 
seen in cell culture. Mass spectrometry and mutagenesis was used to map some in vitro 
phosphorylation sites. Mutagenesis, isoelectric focusing and the use of kinase 
inhibitors, suggest that when 16E1AE4 is expressed in cell culture, serine 32 is 
phosphorylated by CDK1/2 and threonine 57 by p42/p44MAPK. Threonine 57 
phosphorylation causes the observed change in migration with SDS-PAGE. A 
bacterially-expressed 16E1AE4 with threonine 57 mutated to aspartic acid to mimic 
phosphorylation, was shown to bind keratin more strongly than the unphosphorylated, 
wild-type 16E1AE4. Phosphorylation may therefore have a role in regulating 16E1AE4 
activity in vivo. Coexpression of the HPV16 E5 protein was found to enhance 
threonine 57 phosphorylation by activating p42/44MAPK, suggesting another function 
for E5.
By studying the regulation and functions of HPV proteins, the virus life cycle will be 
better understood, expanding the opportunity to develop new diagnostic and therapeutic 
tools.
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Chapter 1: Introduction
C hapter 1: Introduction
1.1 Viruses
Viruses are small (~ 10'8-10'7 m) obligate parasites that replicate in host cells (Cann, 
1997; Dimmock, 2001; Levine, 1996). They have a protein coat containing genetic 
material in the form of DNA or RNA, and sometimes an outer lipid envelope. 
Globally, viruses have been and will continue to be a major cause of disease, for 
example smallpox, influenza, polio, acquired immunodeficiency syndrome (AIDS) and 
Ebola. In the late 1800s, scientists working with plants infected with tobacco mosaic 
virus, first demonstrated transmission of an infectious agent that could pass through a 
porcelain filter known to block bacteria. The first filterable disease agent from animals, 
causing foot and mouth disease, was discovered thereafter. The disease agent was 
considered to be a ‘contagious living liquid’ for some time and it was not until 1939 
that a virus, the tobacco mosaic virus, was first visualised by EM.
1.2 Introduction to papillomaviruses
Papillomaviruses are small (55 nm), non-enveloped, viruses with a double-stranded 
DNA genome of about 8 kb (Favre et al., 1997). They have an icosahedral protein coat 
(capsid) composed of the major viral capsid protein, LI and the minor capsid protein, 
L2 (Zhou et al., 1991). Papillomaviruses infect epithelial tissues to cause proliferative 
lesions (or warts). More than 200 human papillomaviruses (HPVs) have been 
identified (de Villiers, 1999). Papillomavirus infections have also been detected in 
many higher vertebrates (Antonsson and Hansson, 2002), birds (Tachezy et al., 2002) 
and more recently, in aquatic mammals (Rector et al., 2004). Papillomaviruses are of 
clinical importance today because of their association with 99.7 % of cervical cancers 
(Walboomers et al., 1999). Worldwide, every year there are 450,000 new cases of 
cervical cancer and 300,000 deaths, 80 % of deaths being in less developed nations 
(Damasus-Awatai and Freeman-Wang, 2003).
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1.3 Identification of papillomaviruses
Human warts were first shown to be infectious using cell-free filtrates in 1907 (Ciuffo, 
1907). The first papillomavirus to be described was the cottontail rabbit papillomavirus 
(CRPV), originally called Shope papillomavirus after the discoverer (Shope and Hurst, 
1933). The carcinogenic potential of a papillomavirus was first proven by inducing 
tumours in domestic rabbits using CRPV (Ito and Evans C.A., 1961). In 1959 bovine 
papillomavirus type 1 (BPV1) was shown to induce bladder tumours in cows (Olson et 
al., 1959). The first visualisation of papillomavirus particles in warts by EM was 
reported in 1949 (Strauss et al., 1949) and the first isolation of HPV DNA was in 1963 
(Crawford and Crawford, 1963). The first HPV to be characterised was from a plantar 
wart (Klung and Finch, 1965; Rowson and Mahy, 1967). The existence of different 
HPVs was later demonstrated when plantar wart virus genes did not hybridise with 
genetic material from all warts tested (zur Hausen et al., 1974), so gradually more HPV 
isolates were discovered (Gissmann et al., 1977; Orth et al., 1977).
In the 1970’s and 1980’s interest grew in the role of HPVs in cervical cancer and they 
were finally recognised to be the causative agent of the second most common form of 
female carcinoma in the world (Boshart et al., 1984; Durst et al., 1983; zur Hausen et 
al., 1974).
1.4 Papillomavirus genomic organisation
Papillomaviruses have similar genomic organisation (Figure 1.1 shows HPV 16 as an 
example of HPV genomic organisation) with well-conserved open reading frames 
(ORFs), all encoded on one DNA strand of the genome, with some degree of overlap. 
There is a non-coding region of DNA called the long control region (LCR) or the 
upstream regulatory region (URR; Figure 1.2). This contains the origin of DNA 
replication (ori; Chiang et al., 1992), an epithelial-specific enhancer element 
(containing AP-1 sites; Chong et al., 1991) and the early promoter (Cripe et al., 1987). 
Most papillomavirus types have eight ORFs; E l, E2, E1AE4, E5, E6, E7, LI and L2, 
but some animal viruses have additional ORFs, for example, BPVI has E3 and E8 
(Stephens and Hentschel, 1987) and reindeer papillomavirus (RPV), European elk
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HPV16
7905 bp
Figure 1.1 Genomic organisation of HPVI6
The HPV 16 genome is an 8 kb double-stranded DNA molecule that encodes eight 
ORFs. The two major promoters which regulate viral gene transcription are the 
early promoter, p97, and the late promoter, p670, which are named according to 
their nucleotide position. The LCR is a non-coding region but has regulatory 
sequences for replication and transcription.
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Figure 1.2 Schematic representation of the HPV 16 LCR
The important elements of the LCR and the flanking ORFs are 
indicated in the diagram, and some nucleotide positions shown 
(not to scale). The relative positions of the origin of replication 
(ori), epithelial-specific enhancer, E l and E2 binding sites 
(labelled #1-4) are shown. The binding sites of the transcription 
factors AP-1 and Spl are also indicated.
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papillomavirus (EEPV) and deer papillomavirus (DPV) have E9 (Eriksson et al., 1994).
Genes are first transcribed from the early promoter and subsequently, the late promoter 
becomes active, however, the late promoter is dependent on the differentiation of the 
epithelium (Grassmann et al., 1996; Ruesch et al., 1998). The ORFs can be loosely 
described as ‘early’ or Tate’ depending on which promoter they are mainly expressed 
from. For many viruses, however, more than two promoters have been identified, for 
example in HPV 6a (Karlen et al., 1996), HPV18 (Karlen and Beard, 1993) and 
HPV31b (Ozbun and Meyers, 1998b).
1.5 Classification of Papillomaviruses
Virus classification is decided by the International Committee on Viral Taxonomy 
(ICTV), which was set up in 1973. Papillomaviruses have been sub-divided into 
different types depending on conservation of the LI sequence (de Villiers et al., 2004). 
Papillomaviruses that differ by more than 10 % in their L 1 sequence, can be described 
as a different type. A difference of 2-10 % is a sub-type and a difference of < 2 % is a 
variant.
Papillomaviruses and polyomaviruses were first grouped together in the Papovaviridae 
family. However, the two virus groups were later recognised as being significantly 
different, so they were then classed as two separate families, Papillomaviridae and 
Polyomaviridae. In the late 1970’s when new papillomavirus isolates were being 
found, the numbering system, e.g. ‘HPV1’, ‘HPV11’, became useful. In attempts to 
correlate the LI sequence homologies with biological and pathological features of the 
virus, descriptions of phylogenetic groups, genera and species have emerged, the most 
recent system described by de Villiers et al. (2004; see Appendix. 1). For example, the 
genus of alpha papillomaviruses includes all the species associated with genital lesions 
and the genus of beta papillomaviruses include species that frequently cause lesions in 
epidermodysplasia verruciformis (EV) patients. Furthermore, viruses can be classed as 
cutaneous or mucosal, depending on their preferred epithelial tissue tropism, or low-, 
intermediate- or high-risk, depending on their ability to cause cancer (Lorincz et al., 
1992; Lowy and Howley, 2001).
Chapter 1: Introduction 17
1.6 Diseases associated with papillomaviruses
The majority of papillomavirus infections lead to proliferative, localised lesions in the 
infected stratified squamous epithelium (Figure 1.3). In humans, these epithelial sites 
are either in skin (cutaneous epithelium) or ano-genital areas, oral cavity or larynx 
(mucosal areas). The lesions may be referred to as warts and those in genital sites can 
be alternatively described as condylomas. Most of these lesions will spontaneously 
regress after months or years of persistence. However, in a small percentage of 
infections of ‘high-risk’ HPVs or certain animal papillomaviruses, the lesion can 
progress to malignancy (Lowy and Howley, 2001).
1.6.1 Site of infection; the epithelium
Papillomaviruses enter the stratified squamous epithelium by a microwound and infect 
the basal cells. The viral life cycle is tightly linked to the differentiation of the 
epithelium (Howley and Lowy, 2001).
Epithelial tissue is avascular and lines internal cavities and external body surfaces. The 
terminology used to describe epithelium, is based on the structure and is defined below.
simple one cell layer thick
stratified two or more cell layers
squamous cell width > cell height
cuboidal cell height = cell depth
columnar cell height > cell width
The predominant cell type is the keratinocyte, but antigen-presenting cells 
(Langerhans’ cells) and sensory cells (Merkel’s cells) are also present. In addition, 
cutaneous epithelium (skin) contains melanin-producing cells (melanocytes). The 
deepest layer of the epithelium is the basal layer, a single layer of mitotically active 
cells. The keratinocytes arise by division of the basal cells. Keratinocytes undergo a 
program of differentiation as they move upwards through the epithelial layers, and 
finally, they are sloughed off from the superficial or cornified layer (Fuchs, 1993; Ross 
M. H., 2003).
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Figure 1.3 Stratified squamous epithelium
Haematoxylin and Eosin stains (H and E) of cervical epithelium and skin are shown 
(taken from http: //www. inc 5 8. pwp. bluevonder. co. uk/MicroAnatomv/epithel ia/) as 
examples of mucosal and cutaneous epithelia, respectively. The characteristic layers of 
these types of epithelia are also indicated, and described in brief in the table.
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Cervical Epithelium (mucosal)
Superficial layer 
Intermediate layer 
Parabasal layer
Basal layer 
dermis
Com ified Superficial filled with keratin 
filaments, cells are 
flattened, nuclei lost in 
cutaneous, comified cell 
envelope in cutaneous 
(made of loricrin, 
involucrin, filaggrin & 
keratin)
Granular contain keratohyalin 
granules (made of 
filaggrin precursors and 
loricrin)
Intermediate keratin filaments form
Spinous Parabasal post-mitotic, 
differentiation specific 
keratins, cytoplasmic 
extensions / spines in 
cutaneous,
Basal Basal mitotically active
Skin (cutaneous)
Comified layer
Granular layer 
Spinous layer
Basal layer 
dermis
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Keratins constitiute up to 85 % of the total protein in a fully differentiated keratinocyte 
(Ross M. H., 2003). They belong to the intermediate filament family of proteins and 
other members include vimentin, desmin and lamins. Keratins can be divided into 
acidic/type I (keratins 9-20) or basic/type II (keratins 1-8) and these 2 types form 
heterodimers. The keratin type expressed varies according to the body site (Moll et al., 
1982) and the differentiation status (Fuchs and Weber, 1994). For example, keratins 5 
and 14 are expressed in epithelial basal cells, but following differentiation, keratins 1 
and 10 are expressed in the cutaneous epithelium, and keratins 4 and 13 are expressed 
in mucosal epithelium (Omary et al., 1998). The importance of keratin filament 
formation is demonstrated by the array of diseases caused by mutations affecting 
filament assembly (Corden and McLean, 1996).
1.6.2 Pathology of human papillomavirus infections
1.6.2.1 Benign lesions
Infection of low-risk HPVs are associated with benign lesions. These are mostly 
harmless and common within the population. For example, HPV1 can cause plantar 
warts and verrucas (Egawa et al., 1993) and HPV2 also causes common warts. 
Interestingly, HPV2 can occasionally also infect mucosal tissues such as genital or 
nasopharyngeal areas (Chan et al., 1997). Most cases of genital warts are caused by 
HPV6 and 11 (Chang et al., 1990), but these types can also occasionally cause 
laryngeal lesions (Quiney et al., 1989). Although benign, genital warts are particularly 
troublesome because of their unsightly appearance and tendency to reoccur after 
treatment, making them problematic for health authorities (O'Mahony, 2005).
1.6.2.2 Cancer
Viruses frequently found in anogenital cancers are classified as high-risk HPVs (zur 
Hausen and Schneider, 1987). HPV 16 and 18 are detected in most cervical cancers, 
with type 16 causing ~50 % of all cases (Bosch et al., 1995). Other virus types seen in 
cervical neoplasia include 31, 33, 39, 45, 52 and 58 (Walboomers et al., 1999). HPV- 
induced transformation progresses with defined stages of ‘cervical intraepithelial 
neoplasia’ (CIN), from CIN 1 which is a low-grade lesion, to CIN 3 which is a high- 
grade lesion showing severe dysplasia or cancer (Richart, 1968).
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Mucosal HPVs are also linked to cancers of the oral cavity and larynx (de Villiers et 
al., 1985; Scheurlen et a l, 1986; Scully, 2005). Some cutaneous HPVs are associated 
with non-melanoma cancers of the skin and this was originally found in patients with 
the disease, EV. This is a rare inherited cutaneous disorder, possibly associated with 
truncating mutations of the EVER1 or EVER2 genes, the functions of which are 
unknown (Ramoz et al., 2002), or polymorphisms in the promoter of the IL-10 gene 
that cause low expression of the cytokine (de Oliveira et al., 2003). The disease is 
characterised by persistent lesions, a high susceptibility to some HPVs, described as 
EV HPVs (e.g. HPV5, 8, 12 and 23), and about half of patients suffer from squamous 
cell carcinoma (Orth et al., 2001). A significant association has been found between 
non-melanoma skin cancer and EV HPV DNA but not other types of cutaneous HPV 
DNA (Harwood et al., 2004).
The prevalence of cervical cancers, especially in developing countries, makes HPV a 
worldwide burden, but considering its roles in vulvar, penile, anal, oral, laryngeal and 
non-melanoma skin cancers, HPV may account for almost 10 % of all cancers (Parkin 
et al., 2001; Zur Hausen, 1996).
1.7 Cervical cancer prevention
1.7.1 Education
A recent survey (September 2005) by Cancer Research UK, suggested that 2/3 of 
British women are not aware that smear tests are for cancer prevention. A similar study 
revealed that less than 1 % of British women surveyed were able to name HPV as a risk 
factor for cervical cancer (Waller et al., 2004). There is clearly a gap in knowledge, 
however, the need for education in countries with organised screening programmes is 
not as great as the need in less developed countries where the cervical cancer death 
incidence is 11.2 per 100,000 (compared to 3.1 per 100,000 in the U.K; from  
GLOBOCAN 2002, http://www-dep.iarc.fr/).
1.7.2 Screening and diagnosis
Pap smears have reduced the incidence of cervical cancer deaths by 70-75 % in many 
countries since their introduction around 50 years ago (Bergstrom et al., 1999). This 
method of detecting cytological abnormalities in smears of cervical cells, was
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developed by George Papanicolaou (Papanicolaou, 1941). Although, this strategy has 
proved to be a great success story of cancer screening, smear tests are laborious to 
analyse and give a high rate of false-negatives (Mannino, 1998). In the near future, 
several countries are likely to convert to liquid-based cytologic collection instead of 
smears on slides, and this, together with computer-automated rather than manual 
analysis, should provide more sensitive and more cost-effective screening (Austin and 
Ramzy, 1998). Another basis for screening is to actually test for the presence of HPV 
DNA (Lorincz, 1996), and although accuracy for virus presence is high, the results may 
cause undue stress in patients as the majority of high-risk HPV infections will clear 
naturally and not progress to cancer. A more useful approach could be to use cellular 
markers for cervical dysplasia, for example, increased staining of mini chromosome 
maintanance proteins (MCMs) and CDC6 (Williams et al., 1998), and p l6 INK4A (Klaes 
et al., 2002). MCMs and CDC6 are required for human DNA replication and p i6 INK4A 
is a cellular inhibitor of CDK4/6, and these markers may be upregulated in CINs as a 
consequence of E7 activity.
1.7.3 Prophylactic vaccine
As for any other infectious disease, the vaccination approach for cervical cancer 
prevention has been attractive for some time. Early studies suggested that the E7 
(Tindle et al., 1991) and LI (Jenkins et al., 1990) proteins have immunogenic potential. 
LI was then shown to induce specific neutralising antibodies in rabbits when allowed 
to self-assemble into virus-like particles (VLPs) but not when injected as monomers 
(Kirnbauer et al., 1992). VLP vaccine research therefore dominated (Chen et al., 2000; 
Evans et al., 2001) and then in 2002, scientists announced 100 % efficacy in 
preliminary trials of a HPV16 LI VLP vaccine (Koutsky et al., 2002). Immunology 
studies suggest that this type of vaccine will induce sufficient neutralising antibody 
production and cell-mediated immune response (T cell proliferation and cytokine 
production) for a prophylactic effect (Harro et al., 2001; Pinto et al., 2003). Merck and 
GlaxoSmithKline are currently developing VLP vaccines. Merck recently (October 
2005) announced the success of its VLP vaccine in phase III trials, and hope that this 
vaccine, which targets HPV types 16, 18, 6 and 11 (named GARDASIL™), will be 
marketed in 2006.
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The vaccine success is certainly a great advancement in cervical cancer and genital 
wart therapy, however, there are limitations to its potential. LI is not expressed in 
HPV-transformed cells or in the lower epithelial layers where there is greater immune 
surveillance, so the vaccine will be effective against new infection by viruses, but not 
against existing infections or cancer. For this reason, the vaccine is likely to be 
administered only to girls before they become sexually active. Therefore, the need for 
a therapeutic vaccine or continued cervical screening still remains for the present 
generation. An additional problem is that the current vaccines will not give 100 % 
protection against cervical cancer or genital warts because types 16 and 18 cause ~70 
% of all cervical cancers and types 6 and 11 cause -90  % of all genital warts (Shaw, 
2005). Development of vaccines that cover a broader range of HPVs may therefore 
prove to be necessary.
Research continues for a therapeutic vaccine that will provoke a sufficient cell- 
mediated immune response for clearance of virus-infected or virus-transformed cells. 
The majority of studies use E6- or E7-targeted approaches (Baldwin et al., 2003; Hallez 
et al., 2004), but E2 has also been investigated for immunogenicity (Brandsma et al., 
2004; Corona Gutierrez et al., 2004).
1.8 Progression to cancer
Upregulation of the viral oncogenes E6 and E7 is required to initiate and maintain 
transformation, and this is attributed to their ability to disregulate normal cellular 
controls for example by inactivating p53 and pRB (retinoblastoma protein) respectively 
(Kubbutat and Vousden, 1996; See 1.13). E6 and E7 levels are generally low in benign 
lesions, but in cancer, there is high expression throughout the epithelium (Durst et al., 
1992). Cellular disregulation caused by the HPV oncogenes leads to genomic 
instability (Duensing and Munger, 2004) which contributes to the development of the 
hallmarks of cancer (Hanahan and Weinberg, 2000). E5 may also have a role in 
initiating transformation although it is not required to maintain transformation 
(Leechanachai et al., 1992).
An important step that accelerates cancer progression is the integration of the viral 
DNA into the host DNA. In benign infections or low grade CINs, HPV genomes are
Chapter 1: Introduction 24
maintained as autonomously replicating episomes, whereas in high grade CINs and 
cancer, the viral DNA is frequently integrated into the host cellular genome (Durst et 
al., 1985; Melsheimer et al., 2004). Integration does not appear to occur at specific 
sites in the host DNA, although common fragile sites (CFSs) may be preferred. 
Examples of such sites favoured by HPV16 include regions 13q22, 3pl4 and 17q23 
(Thorland et al., 2003). Integration can cause alterations in host gene expression, for 
example, disruption of chromosome segment 3pl4, causes the downregulation of a 
candidate tumour suppressor gene, fragile histidine triad (FHIT; Hendricks et al., 
1997). In some cases integration has occurred near cellular oncogenes such as c-myc, 
particularly with HPV18 (Durst et al., 1987; Ferber et al., 2003). Integration does seem 
to follow a pattern in context of the viral DNA; integration in the El or E2/E4 ORF 
appears to be favoured for the progression of cancer (Baker et al., 1987; Schwarz et al., 
1985). E2 is able to repress expression of E6 and E7 and both E2 and E1AE4 can 
induce growth arrest and apoptosis (see 1.13). These integration events therefore cause 
the upregulation of E6 and E7, and give the cells a growth advantage that may lead to 
cancer.
Integration and the activity of E6 and E7 can also give rise to structural changes in the 
host genome. One mechanism is abnormal centrosome duplication, which can cause 
the loss or gain of chromosomes (Duensing et al., 2000). A common example of 
genetic instability in cervical cancers, is the presence of multiple copies of the long arm 
of chromosome 3 (Heselmeyer-Haddad et al., 2003). This region encodes the RNA 
component of the telomerase gene, TERC, so its overexpression aids transformation.
1.9 Transmission of human papillomaviruses
Papillomaviruses do not have lipid envelopes, so are relatively resistant to dessication 
and have been shown to remain infectious after dehydration and heating to 65 °C 
(Roden et al., 1997). These viruses are therefore easy to transmit, for example, 
barefoot walking in swimming pools is associated with the spread of verrucas/plantar 
warts (Vaile et al., 2003). Anogenital infections are mainly acquired by sexual contact 
(Kjaer et al., 2001) and the presence of anogenital HPV types in oral lesions, indicates 
transmission by the genital-oral route (Scully, 2005). However, the rare detection of 
anogenital HPVs in virgins and in children, suggests that there are other modes of
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transmission, for example from mother to child during childbirth (Cason and Mant, 
2005) or from environmental surfaces (Strauss et al., 2002).
1.10 Papillomavirus receptor and entry
Papillomaviruses must enter the basal cells of the epithelium in order to establish an 
infection and this access is likely via an epithelial microwound (Doorbar, 2005). It has 
been suggested that for infections to persist, viruses must also infect epithelial stem 
cells (Egawa, 2003). The major capsid protein, LI is considered to be more important 
than the L2 protein for viral attachment and entry (Volpers et al., 1995).
Studies on HPV6 proposed that alpha-6-integrin is the cellular receptor for entry 
(Evander et al., 1997), however, further experiments showed that alpha-6-integrin was 
not required for either BPV4 virions or HPV11 VLPs (Joyce et al., 1999; Sibbet et al., 
2000). Instead, several studies suggested that heparin sulphate is necessary for viral 
entry (Combita et al., 2001; Giroglou et al., 2001; Joyce et al., 1999). Indeed, heparin 
sulphate has been shown to be the receptor for several viruses including herpesvirus 
(Lycke et al., 1991). However, the earlier studies claiming the importance of heparin 
suphate, had used VLPs rather than actual infectious viruses. When HPV31 infectious 
viruses were investigated, it was found that heparin sulphate was involved in infection 
of COS-7 cells (transformed monkey kidney cell line) and C33A cells (HPV-negative 
cervical cancer cell line) but not required for infection of HaCaT cells (HPV-negative 
human keratinocyte cell line that can undergo differentiation; Patterson et al., 2005). 
This suggests that more investigation is needed, particularly using real viruses and the 
natural target cells.
Little is known about the steps involved in viral entry and subsequent events, however, 
studies suggest that HPV VLP entry and uptake is slow compared to other viruses, and 
dependent on clathrin-mediated uptake (Day et al., 2003) and the endosomal pathway 
(Selinka et al., 2002).
Chapter 1: Introduction 26
1.11 The study of papillomavirus infections in the laboratory
Investigation of real infections is a good approach to study the papillomavirus life
cycle, so animal papillomavirus infections of the natural hosts and analysis of human 
clinical samples, have been widely used by scientists. However, using animal models 
is controversial and not always ideal for representing infections in humans, and clinical 
material is difficult to obtain and biopsies mostly demonstrate dysplasia, rather than a 
productive viral infection. For more functional studies and manipulative experiments, 
growing viruses in cells is desirable. However, papillomaviruses do not propagate in 
normal monolayer cell culture (Lowy and Howley, 2001). For this reason, other 
strategies have been employed and these are described below.
1.11.1 Xenotransplantation
Human epithelia can be excised then experimentally infected with virus particles, and 
to complete the viral life cycle, this tissue can be implanted into research animals. 
Examples of this xenotransplantation technique include the implanation of HPV- 
infected human foreskin tissue under the kidney capsule of athymic mice (Kreider et 
al., 1986) and the grafting of human foreskin cells onto the back of Severe Combined 
Immunodeficiency (SCID) mice followed by inoculation of the human cells with HPV 
(Bonnez, 1998; Brandsma et al., 1995).
1.11.2 Cell culture
Papillomavirus studies using undifferentiated keratinocyte monolayer cultures have 
been satisfactory for studying the early stages of the virus life cycle, but viral genome 
amplification and late viral protein expression is dependent upon keratinocyte 
differentiation (Bedell et al., 1991). However, there are methods to induce 
differentiation of monolayer keratinocytes, for example by using medium with a high 
calcium concentration (Stanley and Yuspa, 1983) or by suspending in a semisolid 
medium such as methylcellulose (Ruesch et al., 1998).
1.11.3 Epithelial raft culture
HPV-infected epithelia can now be grown from HPV-containing primary basal 
keratinocytes or keratinocyte cell lines, using the raft system (Blanton et al., 1991;
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Dollard et al., 1992; Flores et al., 1999; Meyers et al., 1992). Epithelial rafts are made 
by growing keratinocytes at the air-medium interface, on a collagen matrix that 
contains fibroblasts. Nutrients and necessary growth and differentiation factors are 
present in the medium and reach the keratinocytes by capillary action through the 
collagen. In this way, a culture that resembles differentiated epithelium can be 
produced and HPV infections can be mimicked.
The raft system provides an excellent tool for functional studies, as mutant HPV 
genomes can be expressed and analysed. Examples include knockouts of HPV 16 E5 
and HPV31 E1AE4 genes (Genther et al., 2003; Wilson et al., 2005).
1.12 An outline of the papillomavirus life cycle
Following viral entry in basal keratinocytes, the viral genome is replicated and 
maintained at a low copy number. Approximately 10-200 copies of the viral episomal 
DNA are maintained at this stage, and the early viral proteins, E6, E7, El and E2, are 
expressed at low level (De Geest et al., 1993; Stanley et al., 1989). This genome 
maintenance phase is a necessary early infection step, but is prolonged during latent or 
subclinical papillomavirus infections. In latent infections, El is perhaps the main viral 
protein expressed as it is necessary for viral genome replication (Zhang et al., 1999).
During the next phase of the viral life cycle, cell proliferation is stimulated so that viral 
genome amplification can occur. This is achieved by E6 and E7, overriding normal 
cell cycle regulation by targeting the cellular proteins p53 and pRB respectively. 
Genome amplification favours a cycling host cell because this can provide all the 
necessary cellular factors, such as replication protein A (RPA) and DNA polymerase a  
(Wilson et al., 2002). Before viral genome amplification can occur, levels of E l, E2, 
E1AE4 and E5 increase due to activation of the late (or differentiation dependent) 
promoter (Hummel et al., 1992; Middleton, 2003). El is essential for genome 
amplification as it acts as a DNA helicase to unwind the viral genome, and E2 is 
needed to recruit El to the viral DNA, so an increase in both proteins correlates with an 
increase in genome amplification (Ozbun and Meyers, 1998a). E1AE4 (Peh et al.,
2004) and E5 (Fehrmann et al., 2003) are also believed to be necessary for efficient 
genome amplification and other late viral events.
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Finally, for completion of the life cycle, new capsid proteins must be expressed to 
package the newly amplified genomes. LI and L2 expression begins in a subset of 
E lAE4-expressing cells in the upper layers of the epithelium (Doorbar et al., 1997). L2 
translocates to the nucleus and then recruits LI to the nucleus and it is here that 
encapsidation of the viral genome is thought to occur (Becker et al., 2004; Florin et al., 
2002a). The capsid is assembled in an icosahedral arrangement, consisting of 360 
copies of LI arranged as 72 pentamers, and about 12 copies of L2 (Finnen et al., 2003). 
Virus transmission is achieved by shedding of cells of the upper epithelial layer (Bryan 
and Brown, 2001). The virus E1AE4 protein may facilitate transmission by making 
keratinocytes more fragile by pertubation of normal cytokeratin networks (Doorbar et 
al., 1991) and by affecting cornified envelope assembly in the skin (Brown and Bryan, 
2000).
The functions and characteristics of each HPV protein is further detailed in section 
1.13.
1.13 The human papillomavirus proteins
1.13.1 The E6 protein
The E6 protein is a small, basic protein, with two zinc finger domains (Barbosa et al.,
1989). E6 of high-risk viruses also have a PDZ binding motif (Kiyono et al., 1997). 
The full-length protein is the predominant form, but different truncated splice variants, 
called E6*(I-IV), have also been detected (Smotkin et al., 1989). E6 has a major role 
in cellular transformation (Bedell et al., 1987; Munger et al., 1989a).
1.13.1.1 Association with p53
The ability of E6 to contribute to transformation is largely due its ability to inactivate 
the cellular tumour suppressor, p53. E6 of low-risk and high-risk viruses can bind p53 
(Crook et al., 1991; Werness et al., 1990). However, only E6 from high-risk viruses 
can promote the degradation of p53 (Crook et al., 1991; Scheffner et al., 1990). 
Degradation is achieved by E6 recruiting a cellular ubiquitin ligase, E6-associated 
protein (E6-AP), so that a complex of E6/p53/E6-AP forms, resulting in the 
ubiquitination and degradation of p53 via the ubiquitin-proteasome pathway (Scheffner
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et al., 1993). p53 has a pivotal role in the regulation of many cellular events including 
apoptosis, DNA repair, cell cycle checkpoints and senescence (Levine, 1997; Zhao et 
al., 2000). p53 inactivation, and indeed several other anti-apoptotic effects of E6, are 
thought to have evolved as a safety mechanism to avoid the cell’s natural responses to 
viral replication and E7-driven proliferation. For example, it has been shown that for 
maintenance of high-risk viral episomes, p53 must be inactivated, since p53 may have a 
role in guarding the cell against maintaining extra-chromosomal DNA (Park and 
Androphy, 2002).
The truncated E6 proteins (E6*) may have a modulatory role, as demonstrated by their 
ability to block full-length E6-driven degradation of p53 in vitro (Pirn et al., 1997). 
This type of modulation may be necessary as there is a fine balance between creating 
conditions perfect for viral growth and preventing transformation, which would result 
in abrogation of the virus life cycle.
Viruses that cannot degrade p53 but where the E6 still associates with p53, can also 
affect p53 activity, for example, by inhibiting p53 binding to DNA, thus affecting its 
normal transcription factor activites (Lechner and Laimins, 1994; Thomas et al., 1995).
1.13.1.2 Other cellular binding partners
Following the discovery that E6 binds p53 and E6-AP, several other cellular binding 
partners have been identified. The first was called E6-binding protein (E6BP), a 
homologue of ERC55, a calcium-binding protein (Chen et al., 1995a). The significance 
of the E6 :E6BP interaction is unknown, although E6 has been shown to inhibit 
calcium-dependent differentiation of keratinocytes (Sherman and Schlegel, 1996).
Another protein shown to interact with BPV1 E6 and HPV 16 E6 is paxillin (Tong and 
Howley, 1997). Paxillin transduces signals from the plasma membrane to focal 
adhesions and the actin cytoskeleton, and BPVI E6 was found to disrupt actin 
filaments, the effects of which could be important for pathogenesis or malignancy.
E6 proteins are also capable of binding many PDZ domain-containing proteins (PDZ 
stands for the three proteins in which the domain was first identified; PSD-95, Dig and 
ZO-1). The first interaction of this type to be recognised was the binding of high-risk 
E6 to hDlg (Kiyono et al., 1997) and the subsequent degradation of hDlg (Gardiol et
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al., 1999). Other PDZ-containing proteins found to bind E6 and be targeted for 
degradation by the ubiquitin-proteasome pathway, include, MAGI-1, (Glaunsinger et 
al., 2000) MUPP1 (Lee et al., 2000b) and hScrib (Nakagawa and Huibregtse, 2000). 
PDZ domains are considered to act as a ‘glue’ in protein complexes, particularly in 
signal transduction complexes, cell junctions and plasma membrane-cytoskeleton 
interfaces and have roles in cell-cell contact and epithelial cell polarity (Fanning and 
Anderson, 1999). Therefore, E6 targeting of these proteins may disrupt normal cellular 
controls, possibly contributing to a transformed phenotype.
Other proteins that E6 can bind and promote the degradation of, are c-myc (Gross- 
Mesilaty et al., 1998), bak (Thomas and Banks, 1998) and MCM7 (Kuhne and Banks,
1998). c-myc is a transcription factor that can have pro-apoptotic effects (Pelengaris 
and Khan, 2003), bak is a pro-apoptotic member of the Bcl-2 family (Korsmeyer et al., 
2000) and MCM7 has a role in licensing DNA replication once per cell cycle (Blow 
and Hodgson, 2002), so targeting these proteins would be advantageous for the survival 
and successful replication of HPV. E6 has also been shown to bind but not degrade 
p300/CBP, a p53 co-activator (Patel et al., 1999), and by doing so, may reduce 
p53/p300/CBP-dependent transcription. Transactivation by HPV E2 also appears to 
involve co-activation by p300/CBP (Lee et al., 2000a), so E6 may also inhibit E2- 
driven transactivation.
1.13.1.3 Effects on transcription of cellular proteins
E6 can activate telomerase (Klingelhutz et al., 1996), a ribonucleoprotein enzyme 
important for the maintenance of telomeric structures at the ends of chromosomes 
(Greider, 1996). Lack of telomeric activity leads to progressive erosion of the ends of 
chromosomes, leading to senescence, a normal cellular event to limit the cell’s life span 
and prevent genomic instability and mutations. The catalytic subunit of telomerase, 
hTERT, is upregulated in cells expressing E6. Possible mechanisms have been 
proposed, for example, E6/myc complexes targeting myc-resposive elements in the 
hTERT promoter (Veldman et al., 2003) and E6-AP-mediated transactivation, with E6 
recruiting E6-AP to the promoter (Liu et al., 2005).
E6 can also upregulate the transcription of vascular endothelial growth factor ( VEGF), 
and although the mechanism is unknown, it is dependent on the Sp-1 transcription 
factor binding sites in the VEGF promoter (Lopez-Ocejo et al., 2000).
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1.13.1.4 Effects on viral transcription
The presence of an E6-inducible enhancer in the URR was reported (along with two 
other enhancers) for HPV 18 (Gius et al., 1988). A subsequent report, however, 
described that full-length E6 repressed the HPV 16 early promoter, while the truncated 
E6, E6*I, transactivated this promoter (Shirasawa et al., 1994). It is also feasible that 
by E6 interacting with some cellular factors, viral transcription is affected, for example 
p300/CBP can transactivate the viral early promoter but E6 can inhibit this factor by 
binding it (Patel et al., 1999).
1.13.1.5 DNA binding
The DNA-binding motif, the zinc finger domain, has been proposed to be present in 
HPV E6 for some time (Barbosa et al., 1989), however it was not until recently that the 
DNA-binding properties of E6 have been fully investigated (Ristriani et al., 2000). The 
C-terminal zinc finger has been shown to recognise 4-way DNA junctions, in a DNA- 
structure specific manner (Ristriani et al., 2001). The significance is unclear, although, 
the recognition of DNA structures may be related to the E6-inducible enhancer 
described above.
1.13.1.6 Immune evasion
It has been shown that HPV 16 E6 can down-regulate cell surface E-cadherins, leading 
to a loss of Langerhan’s cells in the epithelium (Matthews et al., 2003). Langerhan’s 
cells are antigen presenting cells and are crucial in the immune response to HPV 
infection, so their loss contributes to immune evasion by HPV (Bedell et al., 1987; 
Tindle, 2002).
1.13.1.7 Association with E2
Recently, Grm et al. (2005) showed that E6 of HPV 16 and HPV 18 can bind to 16E2. 
E6 and E2 colocalise in cells preferentially forming discrete nuclear speckles, and it 
appears that E2 can stabilise E6 protein levels especially that of E6*I. Also, E2 inhibits 
the ability of E6 to cause degradation of the PDZ-containing proteins, MAGI-1 and 
MAGI-3, but does not affect the degradation of p53. This interaction also modulates 
the ability of E2 to affect viral replication and viral transcription (see 1.13.4.7).
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1.13.2 The E7 protein
E7 is a small acidic protein, with a zinc finger domain and an LXCXE motif, required 
for binding to pRB (Stacey et al., 1994; Vousden, 1993). It has sequence and 
functional similarities to other DNA tumour virus proteins, such as SV40 large tumor 
antigen (TAg) and adenovirus El A (Barbosa et al., 1990). E7 has a major role in 
cellular transformation (Bedell et al., 1987; Munger et al., 1989a).
1.13.2.1 Association with retinoblastoma family proteins
The abilty of E7 to bind to members of the retinoblastoma protein family (pRB, p i07, 
p i30) is the most characterised property of this viral protein (Davies et al., 1993; 
Dyson et al., 1989; Munger et al., 1989b). In a similar way to adenovirus El A (Ludlow 
et al., 1989) and SV40 TAg (Dyson et al., 1992), E7 was found to bind preferentially to 
hypophosphorylated retinoblastoma proteins.
The function of hypophosphorylated pRB is to bind transcription factors of the E2F 
family, preventing E2F activating S-phase specific genes. As cells go through the cell 
cycle from GO to G1 and S-phase, pRB gets progressively phosphorylated by cyclin- 
dependent kinases (CDKs), enabling E2F to be released and activate S-phase genes 
such as those involved in DNA synthesis (Dyson, 1998). By binding pRB, E7 can 
disrupt pRB-E2F complexes, leaving E2F free to activate genes that cause cell cycling. 
E7 from both low- and high-risk HP Vs can bind pRB but the binding affinity appears to 
be greater with high-risk types (Gage et al., 1990).
1.13.2.2 Effects on other cell cycle regulators
As a consequence of E2F activation, several cell cycle regulatory proteins are also 
affected by E7. One example is the upregulation of CDK2/cyclin E (Funk et al., 1997; 
Jones et al., 1997), a result of which is increased DNA synthesis and further 
inactivation of pRB by phosphorylation. CDK2 can be inhibited by the CDK
p r p  I f  IP
inhibitors, p21 and p27 , and reports of 16E7 binding these inhibitors, suggest
another mechanism by which CDK2/cyclin E is activated by 16E7 (Funk et al., 1997; 
Jones et al., 1997). Once again, E7 is comparable to adenovirus El A, since El A has
If TPbeen shown to inhibit p27 (Mai et al., 1996). 16E7 has also been shown to directly 
interact with CDK2/cyclin A in vitro and increase the kinase activity of the complex 
(He et al., 2003). CDK2/cyclin E but not CDKl/cyclin B kinase activity was also 
increased by addition of 16E7. This supported the finding in a previous study where
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CDK2 and cyclin A coimmunoprecipitated with E7 extracted from HPV 16-transformed 
cervical cells (Tommasino et al., 1993).
1.13.2.3 Other cellular binding partners
E7 can associate with histone deacetylase (e.g. HDAC-1) complexes indirectly through 
the Mi2j3 protein (Brehm et al., 1999). Histone deacetylation is associated with 
chromatin taking on a ‘closed’ conformation, thus resulting in transcription repression 
(Pazin and Kadonaga, 1997). pRB can associate with HDAC-1 and both proteins 
cooperate to repress E2F-regulated promoters (Brehm et al., 1998), so E7 may interfere 
with formation of the pRB/HDAC-1 complex.
E7 can also bind members of the AP-1 transcription factor family, such as c-jun and c- 
fos, enhancing their transactivating properties (Antinore et al., 1996). AP-1 
transcription factors promote cell proliferation and regulate differentiation (Weiss and 
Bohmann, 2004), so this activity of E7 causes cell cycle progression. Conversly, E7 
can also inhibit c-jun activity. The c-jun promoter itself, contains AP-1 binding sites, 
and can normally be regulated by c-jun complexes. One such complex has been 
shown to be pRB/c-jun (Nead et al., 1998) and E7 can disrupt this complex and 
therefore affect c-jun activity in a negative manner. This positive or negative effect of 
E7 on c-jun may reflect the need to promote cell progression at one time and deregulate 
keratinocyte differentiation at another time (Chakrabarti and Krishna, 2003).
Other targets are members of the cellular basal transcription machinery, TATA binding 
protein (TBP; Massimi et al., 1996) and TBP-associated factor-110 (TAF-110) 
(Mazzarelli et al., 1995). The significance is unknown, but hints at E7’s ability to 
cause global effects on transcription.
Similarly to HPV E6 and adenovirus El A (Shuen et al., 2003), HPV E7 can also bind 
p300/CBP leading to repression of the co-transactivating role of p300/CBP (Bernat et 
al., 2003). As discussed for E6, this event may reduce transactivation by HPV E2.
A novel binding partner of E7 is the cellular phosphatase, PP2A (Pirn et al., 2005). E7 
expression was found to upregulate PKB/Akt signalling, which triggers a pro-survival 
pathway. PP2A can inactivate PKB by dephosphorylation, but E7 binding is able to 
inhibit this, thus prolonging the PKB signal.
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1.13.2.4 Association with E2
Recently, Gammoh et al. (2006) observed that HPV 16 E2 could inhibit the 
transforming activity of E7 (when expressed with an activated ras oncogene) without 
lowering E7 transcription. Further investigation showed that E7 and E2 can interact in 
vitro and in cells. The region of E7 involved in E2 binding is the same as that occupied 
by some cellular binding partners, such as and Mi2|3 and TBP. E2 may interfere with 
E7 binding of these cellular proteins, so this could be the mechanism of the reduced 
transforming activity. In addition, E2 can increase the half-life of E7 and cause the 
relocation of E7 to mitotic chromosomes, an event that does not occur when E7 is 
expressed alone. This association with chromosomes could be important in the ability 
of E7 to cause genomic instability (Duensing and Munger, 2004).
1.13.3 The El protein
The El protein is the largest papillomavirus protein and is well-conserved. El proteins 
are generally acidic and they have a nuclear localisation signal (NLS), DNA binding 
domain and ATP-dependent helicase activity (Wilson et al., 2002).
1.13.3.1 Necessary for papillomavirus replication
After sequencing of HPV la  and BP VI El ORFs, a role for papillomavirus El in 
replication was predicted, given its homology with the SV40 large T antigen, already 
known for replication initiation (Clertant and Seif, 1984). Consistent with this, it was 
shown that the El ORF is necessary for maintenance of the viral genome as an episome 
(Lusky and Botchan, 1985; Sarver et al., 1984). Subsequently, both HPV El and E2 
were found to be necessary and sufficient for the replication of plasmids containing the 
ori (Kuo et al., 1994; Yang et al., 1991). El can also drive replication independently of 
E2, but only when expressed at high levels (Bonne-Andrea et al., 1995; Seo et al.,
1993).
1.13.3.2 Helicase activity
Conserved motifs, typical of nucleoside triphosphate-binding proteins were identified 
in the C-terminal half of El (Gorbalenya et al., 1990). E l of BPVI was found to bind 
ATP (Sun et al., 1990) and similarly, HPV 16 El was shown to have ATP-binding and 
ATPase activity (Raj and Stanley, 1995). Helicase activity was subsequently shown for
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BPV El (Yang et al., 1993) and HPV El (Hughes and Romanos, 1993); El was found 
to be a 3’ to 5’ helicase that can unwind linear dsDNA fragments, circular dsDNA and 
ssDNA with a partially double-stranded region.
The ATPase and helicase activities are associated with the hexameric form of the 
protein (Fouts et al., 1999; Sedman and Stenlund, 1998). The formation of the final 
hexameric complex is stepwise and dependent on E2- and ori-binding (Chen and 
Stenlund, 2001; Sanders and Stenlund, 2000).
1.13.3.3 E l assembly on the origin of replication
E2 binding of El is how El is targeted to the ori (Blitz and Laimins, 1991; Mohr et al.,
1990). Although El can initiate replication independently of E2 when expressed at 
high levels, this is believed to occur through non-specific DNA binding (Dixon et al., 
2000). In vivo, El is thought to be expressed at low levels (Seedorf et al., 1987), so E2 
is needed to improve the efficiency of ori binding.
The DNA binding domain of El is in its N-terminal region and has been structurally 
analysed (Chen and Stenlund, 1998; Enemark et al., 2000). The region of El important 
for interacting with the transactivating domain (TAD) of E2, lies in the C- 
terminus/ATP-binding area (Titolo et al., 1999).
The El binding sites in the ori (ElBSs) were identified when BPV1 El was shown to 
bind preferentially to a hexanucleotide sequence, 5’-ATTGTT-3’, in an E2-dependent 
manner (Chen and Stenlund, 2001). The ori of papillomaviruses have two copies of 
this E1BS and 4-5 copies of related hexanucleotide sequences, overlapping with each 
other in a 24 bp region of the ori. A stepwise mechanism for El loading onto ori has 
been proposed by Chen and Stenlund (2001). A complex involving two El molecules, 
two E2 molecules and ori first forms on a pair of ElBSs. Another complex of EH-E22- 
ori forms using another pair of ElBSs, but on the opposite face of the DNA helix (Chen 
and Stenlund, 2002). As a result, DNA at the ori is distorted and bent, ready for 
unwinding by the helicase (Gillette et al., 1994). The helicase activity does not initiate 
until E2 is displaced by ATP binding to El (Sanders and Stenlund, 1998) and El has 
oligomerised via its C-terminal to form two El hexamers (Chen and Stenlund, 2002; 
Sanders and Stenlund, 2000).
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1.13.3.4 Cellular binding partners
Several cellular factors are involved in the replication of papillomaviruses (Melendy et 
al., 1995), and since SV40 TAg has been shown to bind several host proteins of the 
replication complex (Melendy et al., 1995), the ability of HPV El to bind replication- 
related proteins was also investigated.
The El of BPV1 was found to bind the DNA polymerase a  primase subunit (Park et 
al., 1994), then the El of HPV 16 was also shown to have the same binding activity 
(Masterson et al., 1998). HPV11 El was found to interact with histone HI and was 
able to displace it, suggesting a need to disrupt nucleosomes and make the viral 
chromatin more accessible for replication (Swindle and Engler, 1998). Similarly, 
HPV 18 El associates with Inil/hSNF5 (Lee et al., 1999), a component of the SWI/SNF 
protein complex, which has chromatin remodelling abilities and usually serves to 
facilitate transcription (Peterson and Herskowitz, 1992). In this case, Inil/hSNF5 
binding appeared to be important for HPV DNA replication. Another El binding 
partner believed to be important in viral replication, is replication protein A (RPA), a 
ssDNA binding protein required in DNA replication (Iftode et al., 1999). HPV 11 El 
was shown to bind the largest subunit of RPA, thereby recruiting RPA to the site of 
viral DNA replication (Loo and Melendy, 2004).
In addition to binding replication proteins, El of HPV 11 can associate with the 
chaperone proteins, Hsp40 and Hsp70 (Liu et al., 1998). Chaperone proteins assist in 
the folding of proteins and the assembly of protein complexes (Hartl, 1996), and by 
EM, it was seen that the formation of El di-hexamers was facilitated by the interaction 
with Hsp40.
1.13.4 The E2 protein
The E2 protein possesses a transactivation domain (TAD) in its N-terminal region and a 
dimerisation and DNA-binding domains in its C-terminal (Giri and Yaniv, 1988). The 
N- and C-terminal domains are separated by a flexible hinge region and the protein 
exists as a dimer (Dostatni et al., 1988; Gauthier et al., 1991). mRNA encoding 
truncated E2 forms containing the C-terminal region (E2C), have also been detected 
(Doorbar et al., 1990; Lambert et al., 1987) and have proposed functions (Bouvard et
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al., 1994b; Liu et al., 1995).
1.13.4.1 DNA binding
E2 binds DNA via its C-terminal to the palindromic consensus site, ACCgNNNNcGGT 
(where bases in small case are preferred and N4 is the spacer between the two 
palindromic halves; Androphy et al., 1987; Hawley-Nelson et al., 1988). The spacer 
varies in its sequence but not in length, and different E2 proteins have different 
preferences for the sequence, for example, E2 of HPV 16 has greater affinity for the 
spacer sequence, AA(A/T)N (Hines et al., 1998). High-risk HPVs have four E2 
binding sites, E2BS#l-4, in their LCR (Figure 1.2). E2BS#1 is the most proximal to 
the early promoter and E2BS#4 is the most distal. E2 binds E2BS#4 with greatest 
affinity and E2BS#1 with lowest affinity, so E2BS#1 may only be occupied when E2 
levels are high (Sanders and Maitland, 1994).
1.13.4.2 Transcriptional activation
A major function of E2 is to transactivate papillomavirus genes from the early promoter 
and this activity has been assigned to its N-terminal TAD (Cripe et al., 1987; Hirochika 
et al., 1987; Phelps and Howley, 1987). Specifically, it is low level E2 that upregulates 
early promoter activity (Steger and Corbach, 1997). E2 is believed to achieve this role 
by interacting with and recruiting cellular transcription factors such as Spl (Li et al.,
1991) and p300/CBP (Lee et al., 2000a), to the promoter where they can aid 
transcription. p300/CBP is a transcriptional co-activator with histone acetylase 
transferase activity and therefore functions by remodelling the chromatin into an ‘open’ 
conformation, ready for transcription (Grunstein, 1997).
1.13.4.3 Transcriptional repression
As well as activation of transcription, E2 has the important ability to cause 
transcriptional repression, and is therefore a crucial regulator of viral gene expression 
(Bouvard et al., 1994b; Thierry and Yaniv, 1987).
Repression is thought to occur at higher E2 concentrations when E2 has occupied more 
E2BSs. A likely mechanism is by inhibition of TBP binding the TATA box by steric 
hindrance when E2 is occupying E2BS#1 (Dostatni et al., 1991). Binding of E2 to 
E2BS#2 and E2BS#3 may also cause repression by competing with binding of cellular 
transcription factors such as Spl (Demeret et al., 1997; Desaintes et al., 1999). Several
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truncated versions of HPV and BPV E2, still containing the C-terminal region, E2C, 
have been shown to also have transcription repression effects (Bouvard et al., 1994b; 
Lambert et al., 1987; Liu et al., 1995). The mechanism could either be through forming 
heterodimers with full-length E2 (Barsoum et al., 1992) or through competition with 
full-length E2 for E2BSs (Lim et al., 1998).
The importance of the ability of E2 to negatively regulate transcription of the viral 
oncogenes E6 and E7, is demonstrated by the frequent disruption of the E2 gene 
through integration in cancers (El Awady et al., 1987; Vernon et al., 1997).
1.13.4.4 Role in replication
As described in 1.13.3, E2 is important for viral DNA replication due to its role in 
recruiting El to the ori, forming the El-E2-ori complex and therefore initiating 
assembly of the active El helicase (Sedman and Stenlund, 1995). E2-E1 interactions 
are mediated through the N-terminal TAD of E2 (Benson and Howley, 1995).
However, mutagenesis studies suggest other methods of promoting replication, since a 
16E2 mutant that still retained full El-binding ability, showed reduced replication 
activity (Sakai et al., 1996). One way BPV-1 E2 may increase replication is to bind 
RPA, a mechanism also used by El (Li and Botchan, 1993). BPV-1 E2 binding to 
E2BSs has also been shown to upregulate replication of viral DNA that has been 
transcriptionally repressed through the addition of hi stones, so E2 can increase 
replication in vivo by overriding inhibitory effects of nucleosomes (Li and Botchan, 
1994).
Interestingly, p53 can inhibit HPV replication (Lepik et al., 1998) and E2 can bind p53, 
but a mutant p53 that cannot bind E2, no longer inhibits replication (Massimi et al.,
1999). This suggests a possible role for E2 in restricting the level of viral replication.
1.13.4.5 E2 and apoptosis
E2 has been associated with anti-proliferative and cell-cycle arrest effects (Goodwin et 
al., 1998; Hwang et al., 1996). The induction of apoptosis by expression of high-risk 
E2 in has also been well-documented (Blachon et al., 2005; Desaintes et al., 1997; 
Sanchez-Perez et al., 1997). Whether this apoptosis is p53 dependent or not has been
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controversial. p53 independence has been reported from experiments where 18E6 
overexpression lowered p53 levels but did not alter apoptosis (Desaintes et al., 1999). 
p53 dependence has also been reported as a result of inhibiton of 16E2-induced 
apoptosis when a dominant negative p53 was expressed (Webster et al., 2000). It has 
been shown that the TAD of E2 is important for apoptosis, but neither transactivation 
nor replication is necessary for E2-induced apoptosis (Demeret et al., 2003; Desaintes 
et al., 1999). The current thinking is that E2-mediated apoptosis can be p53 
independent and use the caspase pathway, as demonstrated by caspase 8 activation 
(Blachon et al., 2005; Demeret et al., 2003).
1.13.4.6 Role in viral DNA segregation
Another function of E2, is the ability to bind viral genomes to mitotic host 
chromosomes, thus ensuring the correct segregation of viral genomes into the daughter 
cells. This activity has been well characterised for BPV1 E2 (Lehman and Botchan, 
1998; Skiadopoulos and McBride, 1998) which appears to require binding to the 
cellular protein Brd4 in order to allow segregation (You et al., 2004). E2 of HPV11, 
16 and 18 have also been shown to colocalise to mitotic chromosomes (Van Tine et al.,
2004). This function of E2 is likely to contribute to viral genome maintenance and 
persistent viral infection. 16E2 has also been shown to bind 16E7 and recruit it to 
mitotic chromosomes at the telophase stage (Gammoh et al., 2006). The significance 
of this is unclear, but is interesting given the fact that E7 can cause abnormal host 
genome segregation.
1.13.4.7 Association with E6 and E7
E2 is able to interact directly with both E6 and E7 as described in 1.13.1.7 and 1.13.2.4. 
The C-terminus of 16E2 is involved in E6 binding (Grm et al., 2005), while the hinge 
region is important for E7 binding (Gammoh et al., 2006). E6 appears to inhibit the 
viral DNA replication activity of E2 but enhance viral transcription by E2 (Grm et al.,
2005). Most interestingly, E2 has been shown to negatively regulate E6 and E7 
independently of its transcriptional repression activity. It can reduce the PDZ- 
containing protein degradation by E6 (Grm et al., 2005) and can inhibit the 
transforming activity of E7 possibly by competing with E7 cellular binding partners 
(Gammoh et al., 2006).
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1.13.5 The E5 protein
E5 is a small hydrophobic protein that exists as a dimer in the endoplasmic reticulum 
(ER), golgi apparatus, plasma membrane and nuclear membrane (Burkhardt et al., 
1989; Conrad et al., 1993; Valle and Banks, 1995). The protein is predicted to have 
three membrane helices and short N- and C-termini (Ullman et al., 1994). In BPV 
infections, E5 is the major transforming protein (Burkhardt et al., 1987), while E5 of 
HPV may play a more subtle albeit important role in cancer progression.
1.13.5.1 Effects on extracellular mitogen signalling pathways
BPV1 E5 has been shown to directly bind and stimulate the epidermal growth factor 
receptor (EGFR) and p platelet-derived growth factor receptor (pPDGFR; Cohen et al., 
1993; Goldstein at al., 1994). The main consequence of signalling from these receptors 
is the activation of genes that cause proliferation, but cellular differentiation can also be 
triggered (Figure 1.4). HPV 16 E5 also enhances EGF-induced signalling 
(Leechanachai et al., 1992), but whether direct interaction with the EGFR is involved, 
is uncertain (Conrad et al., 1994; Hwang et al., 1995). One mechanism of increasing 
receptor signalling, reported for both BPV and HPV, is the association of E5 with a 
vacuolar H+ ATPase (Goldstein et al., 1992). This interaction affects the internalisation 
of the growth factor receptors, promoting recycling of receptors back to the plasma 
membrane, thus increasing receptor number and prolonging their signalling (Straight et 
al., 1993). However, the observation that EGFR-activating phosphorylation is also 
increased by HPV E5, suggests that increased numbers of EGFR due to increased 
recycling, cannot alone account for the increased signalling (Crusius et al., 1998).
A major signalling pathway activated by EGFRs is the MAPK pathway, and 16E5 has 
been shown to activate p42/p44MAPK (Crusius et al., 1997). E5-mediated MAPK 
activation was shown with both EGF and the phorbol ester, PMA, the EGF method 
being PKC-independent and the PMA method being PKC-dependent (Crusius et al., 
1997). E5 also had the ability to activate MAPK in the presence of sorbitol, a chemical 
that causes osmotic shock. The MAPK, p38, is normally associated with stress 
responses such as osmotic shock, however, E5 and sorbitol activated only 
p42/p44MAPK and not p38MAPK (Crusius et al., 2000).
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Figure 1.4 Signalling from the EGFR
Activation of the EGFR leads to several signalling cascades including the ras- 
MAPK pathway, the PLCy-PKC pathway and the PI3K-PKB pathway. Note that 
the MAPK pathway can be PKC-dependent or -independent. The PI3K-PKB 
pathway promotes cell survival and anti-apoptosis responses. The MAPK pathway 
leads to activation of nuclear transcription factors that promote cell divison, 
proliferation or differentiation.
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1.13.5.2 Apoptosis prevention
16E5 can protect cells from UV (3-induced apoptosis (Zhang et al., 2002) and from Fas 
ligand and TRAIL (tumour necrosis factor-related apoptosis-inducing ligand)-induced 
apoptosis (Kabsch and Alonso, 2002; Kabsch et al., 2004). The mechanism of 
apoptosis prevention appears to be through EGFR signalling, stimulating the pro­
survival pathways of p42/p44MAPK and PI3K-PKB (Zhang et al., 2002).
1.13.5.3 Immune evasion
Cell-mediated immunity is required to clear virally-infected cells, but persistent HPV 
infections suggest that the virus can evade normal immune responses. BPV and HPV 
E5 contributes to this immune evasion by downregulating surface expression of the 
major histocompatibilty class I (MHC I) complexes, which present viral peptides to 
cytotoxic T cells (Ashrafi et al., 2005; Ashrafi et al., 2002). E5 achieves this by 
causing retention of MHC I in the golgi and deregulating proteins involved in the 
maturation and transport of MHC I to the plasma membrane (Leykauf et al., 2004; 
Marchetti et al., 2002).
1.13.5.4 Role in gene expression and viral genome amplification
MAPK signalling can activate several cellular transcription factors, one example being 
the AP-1 family (Whitmarsh and Davis, 1996). As a result, E5 has been reported to 
affect some AP-1 transcription factors, for example, E5 expression upregulates c-jun, 
jun-B, jun-D and c-fos (Bouvard et al., 1994a; Chen et al., 1995b; Leechanachai et al.,
1992). These are all transcription factors that promote cell cycling and proliferation 
(Angel and Karin, 1991). There has also been one report of E5-dependent activation of 
c-jun causing a decrease in the CDK inhibitor, p21cip (Tsao et al., 1996).
Several AP-1 binding sites are found in the enhancer region of the viral LCR and AP-1 
binding is thought to activate viral gene expression (Chong et al., 1991). Indeed, E5 
expression has been shown to upregulate viral genes (Bouvard et al., 1994a), and an 
HPV31 E5-knockout in raft culture showed a reduction in viral transcripts from the late 
promoter and reduced levels of E1AE4 protein (Fehrmann et al., 2003).
As well as affecting viral gene expression, E5-knockouts appeared to affect viral 
genome amplification. An HPV31 E5-knockout in raft culture, had decreased viral 
genome amplification (Fehrmann et al., 2003). An HPV 16 E5-knockout in raft culture,
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had more subtle effects; ~2-fold decrease in cellular DNA synthesis in the suprabasal 
layer, but no observed difference in viral genome amplification (Genther et al., 2003).
1.13.6 The capsid proteins; LI and L2
LI is the major capsid protein present at 360 copies per virus, and L2 is the minor 
capsid protein present at -12 copies (Finnen et al., 2003). Both proteins have NLSs in 
their C-termini (Nelson et al., 2000; Sun et al., 1995).
1.13.6.1 Encapsidation of the viral genome
Viral DNA replication is thought to occur in nuclear compartments called NDlOs, and 
L2 functions by entering NDlOs, associating with the viral genome and recruiting LI to 
the site (Day et al., 1998; Florin et al., 2002b). As well as encapsidating the viral 
genome, L2 may also have a role in directing the viral genome to the nucleus upon viral 
entry, therefore encouraging viral transcription (Day et al., 2004). L2 appears to 
reorganise ND10 domains, for example it causes the release of an ND10 protein, 
S p l00, before LI is recruited (Florin et al., 2002b).
1.13.6.2 Assembly of the capsid
The major protein component of ND10 is the promyelocytic leukaemia protein (PML), 
and although this is considered to be important for papillomavirus infection (Day et al., 
2004), it appears that it is unnecessary for assembly of LI and L2 into VLPs (Becker et 
al., 2004). LI alone, or LI together with L2, can self-assemble into VLPs in vitro and 
in cells (Hagensee et al., 1993; Rose et al., 1993; Zhou et al., 1991). VLPs are well- 
documented, as a result of their use as prophylactic vaccines (see 1.8.3). LI molecules 
associate by disulphide bonding to form pentameric capsomeres, to which a single L2 
can bind through hydrophobic interactions involving sequences from its N- and C- 
termini (Finnen et al., 2003; Okun et al., 2001). Reducing conditions are required, 
although in non-reducing conditions, LI capsomere formation can be enhanced by the 
presence of L2 (Ishii et al., 2005).
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1.13.7 The E1AE4 protein
E1AE4 is translated from a spliced mRNA, with the first five amino acids of the protein 
being encoded by the El ORF, while the rest are encoded by the E4 ORF, hence the 
name ‘E1AE4’ (Doorbar et al., 1988; Doorbar et al., 1990; Nasseri et al., 1987). E1AE4 
proteins are small (for example 16E1AE4 is 10 kDa; Figure 1.5), unusually rich in 
proline and charged residues and many have a N-terminal conserved leucine cluster, for 
example LLKLL for 16E1AE4 and LLNLL 11E1AE4 (Doorbar and Myers, 1996). 
Generally, the protein sequence varies between different HPV types, but there is some 
degree of conservation in the C-terminal region within cutaneous types and within 
mucosal types. As a result, it has been proposed that E1AE4 may play a role in 
determining tissue specificity (Smith and Campo, 1985). There are exceptions, 
however, since HPV1 and HPV2 are predominantly cutaneous viruses (although HPV2 
is occassionally found in mucosal sites), but their E1AE4 sequences are not well- 
matched to sequences of other cutaneous types (Doorbar et al., 1989).
1.13.7.1 Oligomerisation and post-translational modificiations
The C-terminal region has been shown to be important for dimer and oligomer 
formation for 1E1AE4 (Ashmole, 1998), 11E1AE4 (Bryan et al., 1998) and 16E1AE4 
(Roberts et al., 1997; Wang et al., 2004). Full-length 16E1AE4 was shown to exist as 
monomers, dimers and hexamers, while a A87-92 16E1AE4 was only detected as a 
monomer (Wang et al., 2004). When SDS-PAGE is performed in non-reducing 
conditions, several high molecular weight species of 16E1AE4 are seen on the gel, 
however, the presence of reducing agents or the mutation of the two cysteines (C61 and 
C62) to alanines prevents this observation (Roberts et al., 1997; Wang et al., 2004). 
This suggests that the oligomers are stabilised by disuphide bonding.
E1AE4 proteins can be post-translationally modified by phosphorylation and by N- 
terminal proteolysis. E1AE4 proteins known to be phosphorylated are 1E1AE4 (Grand 
et al., 1989) and 11E1AE4 (Bryan et al., 2000) and there has been a report of a 
phosphorylated form of 16E1AE4 (Wang et al., 2004). The findings of these papers are 
further discussed in 1.15.5.
N-terminally cleaved forms of E1AE4 have been well-characterised for HPV1. In 
HPV1 lesions, full-length (17 kDa) E1AE4 is more abundant in the lower layers, while
E1 proline-rich
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Figure 1.5 16E1AE4 amino acid sequence and functional domains
16E1AE4 has 92 amino acids, the first five of which are encoded by the El ORF, while the remaining are encoded by the E4 ORF. The main 
functional domains identified so far include, the keratin binding motif, a proline-rich region important for cell cycle arrest, and a C-terminal 
domain involved in keratin collapse and oligomerisation.
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the truncated forms (16 kDa, 11 kDa and 10 kDa) are more abundant in the upper 
layers, suggesting that this proteolysis is differentiation-dependent (Breitburd et al., 
1987; Doorbar et al., 1988). Recently, different activities have been assigned to the 
different forms of 1E1AE4 (Knight et al., 2004: see 1.13.7.4).
An N-terminally truncated form of 16E1AE4 has also been proposed. 16E1AE4 staining 
with an antibody that recognises a central epitope, often reveals small perinuclear 
bundles correlating with E1AE4 and collapsed keratin filaments (see 1.14.7.3 and 
1.14.7.4), but when an N-terminal-specific antibody was used, only the periphery of the 
bundles were stained (Doorbar et al., 1997). This differential staining suggests that 
there is a form of 16E1AE4 lacking the N-terminus and that this may behave differently 
to the full-length protein.
1.13.7.2 E1AE4 expression patterns
In a productive infection E1AE4 is expressed at high levels, particularly in the 
intermediate and superficial layers (Crum et al., 1990; Doorbar et al., 1997; Middleton, 
4 2003; Stoler et al., 1989). In some infections, for example with HPV1, E1AE4 
constitutes up to 30 % of the total protein in the lesion (Doorbar et al., 1986). In 
malignancy, however, integration events frequently lead to disruption of the E1AE4 
ORF, resulting in reduction or complete loss of E1AE4 expression (Durst et al., 1992; 
Middleton, 2003). The high level expression requires activation of the differentiation- 
dependent promoter (Hummel et al., 1992), coincides with the onset of viral genome 
amplification (Breitburd et al., 1987; Doorbar et al., 1997; Peh et al., 2002) and occurs 
prior to LI expression (Doorbar et al., 1997; Middleton, 2003).
Although, E1AE4 levels per cell can become very high (as seen with immunostaining), 
the protein is apparent in only a subset of infected cells in both cell culture systems and 
rafts (Frattini et al., 1997; Genther et al., 2003) and in lesions (Doorbar et al., 1989; 
Nicholls et al., 2001). There is growing evidence for E1AE4 being present at low levels 
but perhaps difficult to detect by immunostaining, so there is the possibility that E1AE4 
is expressed at low level in many of these cells that appear E lAE4-negative. For 
example, E lAE4-encoding transcripts are detected in undifferentiated monolayer cells 
(Doorbar et al., 1990; Hummel et al., 1992) and even in the basal cells of an HPV6 
infection (Stoler et al., 1989). More recently, there have been reports on E1AE4 
disturbing keratinocyte differentiation and its role in viral DNA replication, suggesting
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that E1AE4 functions prior to activation of the differentiation-dependent promoter (see
1.13.7.6 and 1.13.7.7). Nakahara et al. (2005) also reported that by Western blotting, 
16E1AE4 could be detected in monolayer cells and rafts, whereas, by immunostaining, 
it was only detected in the terminally differentiated layers. In these rafts, effects of 
E1AE4, such as increased DNA synthesis, could be detected earlier (i.e. at lower 
layers), before E1AE4 itself could actually be detected (by immunostaining).
E1AE4 of HPVs are predominantly cytoplasmic. The E1AE4 of certain cutaneous types 
are often stained as cytoplasmic inclusion granules (Doorbar et al., 1989; Egawa,
1994), but filamentous E1AE4 (Roberts et al., 1993) and nuclear E1AE4 has been 
described for HPV1 (Roberts et al., 2003). Lesions caused by the animal 
papillomaviruses ROPV (rabbit oral papillomavirus) also have predominantly 
cytoplasmic E1AE4, whereas CRPV and COPV (canine oral papillomavirus) infections 
have cytoplasmic and nuclear E1AE4 (Peh et al., 2002).
Mucosal/anogenital HPV types typically have a filamentous pattern for E1AE4 due to 
their association with keratin (see 1.13.7.3; Doorbar, 1991; Sterling et al., 1993). As 
well as showing a filamentous phenotype, 16E1AE4 (Doorbar et al., 1991) and 
31E1AE4 (Pray and Laimins, 1995) but not 1E1AE4 (Roberts et al., 1993) appear to 
cause filament collapse and the E1AE4 localises as a perinuclear aggregate or bundle. 
11E1AE4 predominantly appears as perinuclear aggregates (Bryan et al., 1998) but a 
filamentous distribution has also been described (Bryan et al., 2000). In addition, 
11E1AE4 has been shown to associate with the cornified envelope of differentiated 
keratinocytes (Bryan et al., 1998).
1.13.7.3 Association with keratins
The filamentous pattern seen with HPV 16 E1AE4 can be attributed to its association 
with keratin filaments. Keratins 8 and 18 were co-purified with 16E1AE4 from cultured 
epithelial cells when an immunoprecipitation was carried out with an anti-16ElAE4 
antibody (Doorbar et al., 1991). Similarly, keratins 8 and 18, immunoprecipitated 
using anti-keratin 8/18 rabbit serum, were shown to bind bacterially expressed 
16E1AE4 (Wang et al., 2004). The association was shown to be direct by a far-Western 
experiment where SDS-PAGE-separated 16E1AE4 was transferred to a membrane and 
then shown to bind purified keratin 18. Also, when 16E1AE4 was incubated with
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purified keratins 8 and 18 that were loaded on a membrane, 16E1AE4 binding to keratin 
18 was easily detected, whereas binding to keratin 8 appeared to be weaker (Wang et 
al., 2004).
The binding of 16E1AE4 to keratin appears to affect normal keratin dynamics by 
keeping keratin in the insoluble fraction of the cell, despite phosphorylation of keratin 
which normally leads to its solubilisation (Wang et al., 2004). The 16ElAE4-mediated 
collapse or reorganisation of keratin filaments has also been described, both in cultured 
cells (Doorbar et al., 1991), and in vivo (Doorbar et al., 1997; Wang et al., 2004).
The N-terminal 16 residues of 16E1AE4 is sufficient to target green fluorescent protein 
(GFP) to keratin (Wang et al., 2004). However, mutation of the leucine cluster region, 
for example, LLGLL (residues 10-14) of 1E1AE4 or LLKLL (residues 12-16) of 
16E1AE4, can prevent colocalisation with keratin (Roberts et al., 1994a; Roberts et al., 
1997). The collapse of keratin requires the C-terminal region of E1AE4 (Roberts et al., 
1997) and as discussed in 1.13.7.1, this region is also important for oligomerisation. 
Interestingly, a A87-92 16E1AE4 oligomerisation mutant, colocalises partially with 
keratin (as seen with immunostaining) but is soluble and cannot inhibit keratin 
dynamics (Wang et al., 2004). A model of El AE4/keratin dynamics has therefore been 
proposed by Wang et al. (2004) whereby E1AE4 molecules are bound to keratin but 
also bound to other E1AE4 molecules through their C-termini, therefore cross-linking 
the keratins, preventing their solubilisation. The purpose of disrupting keratin 
dynamics or causing keratin collapse could be to weaken cell integrity and aid virus 
release (see 1.13.7.8).
1.13.7.4 Association with cyclins and cell cycle effects
16E1AE4, 11E1AE4 (Davy et al., 2002), 18E1AE4 (Nakahara et al., 2002) and 1E1AE4 
(Knight et al., 2004) have all been shown to cause cells to arrest in the G2 phase of the 
cell cycle. With 16E1AE4, when two threonines in the proline-rich region were 
mutated to alanines (T22A T23A) and expressed in mammalian cells, cell cycle arrest 
was abrogated (Davy et al., 2002). In the yeast, S pombe, a T23A mutant was 
expressed and this mutation was sufficient for blocking arrest. To investigate whether 
phosphorylation of this threonine was important for arrest (T23 is a putative CDK1 
phosphorylation site), it was replaced with aspartic or glutamic acid (T23D and T23E), 
both of which can mimic phosphate, however neither mimic caused G2 arrest (Davy et
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al., 2002). 16E1AE4 was subsequently found to colocalise with cyclin B/CDK1 and
sequester it in the cytoplasm and this association was absent in a T22A T23A 16E1AE4 
mutant (Davy et al., 2005). Active cyclin B/CDK1 is required to enter the nucleus to 
trigger mitosis (Smits and Medema, 2001), and it appears that the mechanism of 
16ElAE4-induced arrest is via the inhibition of cyclin B nuclear entry.
Interestingly, cell cycle arrest by HPV1 is mediated by the 16 kDa truncated protein 
and not the full-length 17 kDa protein, although coexpression of both did not inhibit the 
arrest (Knight et al., 2004). The G2 arrest is again dependent on a threonine residue in 
the proline-rich region (T13) and can be reversed by exogenous expression of cyclin B 
from a cytomegalovirus (CMV) promoter.
Recently, cyclin A/CDK2 has also been found to associate with 16E1AE4 (Davy et al.,
2006). The function of this interaction is also likely to be related to cell cycle arrest. 
The ability to cause cell cycle arrest could be the mechanism by which E1AE4 acts as 
an enhancer of viral DNA replication (see 1.14.7.6). This is because a HPV-infected 
cell arrested at G2 and expressing E7, would possess a sustained S-phase-like state,
allowing the virus to use the cellular DNA replication machinery for its own
replication.
1.13.7.5 Other cellular binding partners
A yeast-two hybrid screen of 16E1AE4 with an epithelial cell cDNA library identified a 
novel DEAD box protein as a E1AE4 binding partner (Doorbar et al., 2000a). Dead box 
proteins possess the motif, apartic acid-glutamic acid-alanine-aspartic acid, and have 
ATP and RNA binding sites. They play a role in RNA processing, stability and 
biogenesis of ribosomes (Tanner and Linder, 2001). This novel DEAD box protein was 
named E1AE4-DEAD box protein (E4-DBP). The association was found to require the 
C-terminal region of 16E1AE4. A putative role of 16E1AE4 in RNA 
stability/translation has therefore been proposed, and this could be important in light of 
the finding that 31E1AE4 is important for production of late viral transcripts (see 
1.13.7.8).
E1AE4 of HPV1 was found to bind zinc and this association was dependent on the 
histidine residues of the protein (Roberts et al., 1994b). Dimerisation and keratin
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colocalisation activities were not affected in a mutant unable to bind zinc, so the 
function of zinc binding is unknown.
1.13.7.6 Role in viral DNA amplification
Consistent with the observation that E1AE4 expression correlates with viral genome 
amplification, there have been several reports of E1AE4 being necessary for viral 
genome amplification. The first report was of CRPV that was mutated to abolish 
E1AE4 expression (Peh et al., 2004). In an infection with this mutant, papillomas were 
produced but viral genome amplification did not occur. More recently, HPV31 
(Wilson et al., 2005) and HPV 16 (Nakahara et al., 2005), both with mutated E1AE4, 
were grown in raft culture. Both mutants revealed a significant reduction in cellular 
DNA synthesis in the suprabasal layers and a reduction in viral genome amplification. 
For HPV 16, the LLKLL leucine cluster of E1AE4 was shown to be necessary for viral 
DNA replication (Nakahara et al., 2005).
1.13.7.7 Effects on keratinocyte differentiation
Keratinocyte differentiation is tightly regulated in the epithelium and aspects of the 
papillomavirus life cycle are dependent on this differentiation as previously discussed. 
The expression of E1AE4, however, appears to disturb normal differentiation as shown 
by the absence or reduction of some differentiation-specific cellular proteins. For 
example, filaggrin, loricrin, and keratins 1 and 10 expression is reduced in 1E1AE4- 
positive cells as compared to neighbouring E lAE4-negative cells (Doorbar et al., 1997). 
Similarly, 16E1AE4 expression correlated with lowered keratins 4 and 13 (Doorbar et 
al., 1997) and 11E1AE4 caused a reduction in loricrin and keratin 10 in the cornified 
cell envelope (Brown and Bryan, 2000). This phenomenon was also observed in raft 
cultures, where 16E1AE4 coincided with keratin 10-negative cells in the upper 
epithelial layers (Nakahara et al., 2005).
1.13.7.8 Role in virus production and release
There is now strong evidence that E1AE4 is necessary for virus production given its 
role in late viral events, such as viral genome amplification (Nakahara et al., 2005; 
Wilson et al., 2005). It also appears to be important for expression of late viral 
proteins, particularly in CRPV infections, where without E1AE4, LI was no longer 
expressed (Peh et al., 2004). Similarly, Wilson et al. (2005) reported a reduction in
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late viral transcripts when E1AE4 was absent in HPV31-containing differentiated 
keratinocytes.
In addition to aiding virus production, E1AE4 is thought to contribute to virus release 
by increasing the fragility of keratinocytes in the uppermost epithelial layers. This 
hypothesis arises from knowledge of the activities of E1AE4, for example, its ability to 
disrupt keratin dynamics (Wang et al., 2004) and contribute to the formation of 
abnormal cornified cell envelopes (Brown and Bryan, 2000). 16E1AE4 has also been 
shown to cause apoptosis when overexpressed in cells (Raj et al., 2004). The 
mechanism may be related to its association with mitochondria at late time points 
following keratin collapse. The association with mitochondria was found to be 
dependent on the leucine cluster sequence (LLKLL). The in vivo significance of 
apoptosis induction is unclear, however, apoptosis of epithelial cells may be another 
way to aid virus release and improve transmission.
1.14 Protein phosphorylation
Protein phosphorylation by protein kinases is one of the most frequent post- 
translational protein modifications and can have dramatic affects on protein function. 
The cell therefore uses phosphorylation (by kinases) and dephosphorylation (by 
phosphatases) to regulate many signalling pathways and other important cellular 
activities (Hardie, 1999). The most common form of phosphorylation is the formation 
of phosphate esters of the amino acids, serine, threonine and tyrosine (Pawson, 1994; 
Taylor et al., 1995). It is thought that at any time, 30 % of a cell’s proteins are 
phosphorylated, some at multiple sites (Zolnierowicz and Bollen, 2000).
The enzymatic transfer of phosphate to a protein was first discovered in 1954 when 
liver extract was found to phosphorylate casein (Burnett and Kennedy, 1954). A year 
later the first functional role of phosphorylation was discovered when phosphorylation 
was found to regulate the activity of the enzyme, glycogen phosphorylase (Fischer and 
Krebs, 1955; Sutherland and Wosilait, 1955). The importance of this work was later 
recognised when Fischer and Krebs were awarded the 1992 Nobel Prize in Physiology 
or Medicine for their ‘discoveries concerning reversible protein phosphorylation as a 
biological regulatory mechanism.’
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With the completion of the human genome project, it is now believed that around 1.7% 
of all human genes encode protein kinases, bringing the number to approximately 500 
protein kinases (Manning et al., 2002). Of these, 164 map to chromosomal loci 
associated with tumours and another 80 map to loci associated with other diseases. 
This emphasises the role of phosphorylation in regulating cellular activities, and reveals 
why kinases and phosphatases make attractive targets for therapeutics.
1.15 Phosphorylation of papillomavirus proteins
1.15.1 Phosphorylation of E6
PKA has been shown to phosphorylate E6 at a site within the PDZ binding domain 
(Kuhne et al., 2000). Interestingly, this has been shown to occur with only high-risk E6 
proteins and not low-risk ones. Phosphorylation inhibits the interaction of E6 with 
hDlg and prevents E6-mediated degradation of hDlg.
1.15.2 Phosphorylation of E7
E7 was shown to be labelled with P, however mutating serine 31 or serine 71 
appeared to decrease this (Storey et al., 1990). Subsequently, both serines 31 and 32 
were found to be phosphorylated by casein kinase II (CKII; Barbosa et al., 1990). 
Mutation of residues 31 and 32 to arginine and proline respectively, did not alter pRB 
binding, but did decrease anchorage independent growth of mouse fibroblasts. It was 
later shown that phosphorylation by CKII at serines 31 and 32 increases the affinity of 
E7 for TBP (Massimi et al., 1996). The original observation of serine 71 being a 
phosphorylation site was confirmed by Massimi and Banks (2000). It was found that 
E7 is differentially phosphorylated during the cell cycle, with serine 71 being 
phosphorylated at S-phase by a yet unknown kinase, and CKII phosphorylating serines 
31 and 32 at an earlier cell cycle stage (Massimi and Banks, 2000).
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1.15.3 Phosphorylation of E l
BPV1 El was identified as a phosphoprotein due to its incorporation of P (Sun et al.,
1990). Several phosphorylation sites in BPV1 El have since been described. The first 
to be identified was threonine 102 which was shown to be phosphorylated by CDK1 
(Lentz et al., 1993). Also, serine 109 was found to be phosphorylated in vivo and then 
shown to be phosphorylated in vitro by protein kinase A (PKA) and protein kinase C 
(PKC; Zanardi et al., 1997). Mutation of serine 109 to alanine causes an improvement 
in viral DNA replication and ori binding, while mutating to glutamic acid to mimic 
phosphorylation decreases replication. Another phosphorylation event, at serine 48 
was found to affect replication activity positively (McShan and Wilson, 2000). Serine 
48 was identified as a phosphorylation site of CKII and mutating to glycine lead to a 
loss in replication activity, while mutating to aspartic or glutamic acid restored activity. 
Finally, serine 584, a residue conserved in many El proteins, was identified as a 
phosphorylation site of casein kinase I and II (CKI and CKII) although the function is 
unclear (Lentz, 2002).
A role for El phosphorylation in HPV has also been investigated. Mutation of 
candidate CDK phosphorylation sites of HPV 11 El was shown to impair viral 
replication (Ma et al., 1999). It was later found that CDK (probably CDK2) 
phosphorylation can inhibit the export of El from the nucleus (Deng et al., 2004). 
Mutating either of the target serines (S89, 93, 107) to alanine, inhibited nuclear 
localisation and also reduced replication.
1.15.4 Phosphorylation of E2
The major phosphorylation sites of BPV1 E2 have been mapped to serines 298 and 301 
(McBride et al., 1989) and mutation of serine 301 to alanine causes ~20-fold increase 
in viral DNA plasmid copy number (McBride and Howley, 1991). This may relect the 
preference of El to bind non- or under-phosphorylated E2 (Lusky and Fontane, 1991) 
or the fact that serine 301 phosphorylation increases ubiquitination and degradation of 
E2 (Penrose and McBride, 2000). Phosphorylation of BPV1 E2 may also affect its 
ability to segregate viral genomes by binding to mitotic chromosomes. Additional 
phosphorylated serines were identified and it was found that a phosphorylation mutant 
with four serines mutated (serines 235, 290, 298 and 301; all in the central hinge
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region) could no longer bind mitotic chromosomes (Lehman and Botchan, 1998). In 
this case, serine 235 was considered critical, as a mutant with just the other three 
serines mutated still retained the ability to colocalise with chromosomes and segregate 
viral DNA.
1.15.5 Phosphorylation of E1AE4
Phosphorylation of E1AE4 was first reported by Breitburd et al. (1987). HPV1 E1AE4 
proteins (full-length and truncated) from warts were analysed by two-dimensional gel 
electrophoresis (2D SDS-PAGE). Each E1AE4 protein had several isoelectric variants 
meaning the variants were differentially charged, and interestingly, the most superficial 
wart layer had more acidic variants than the deeper layers did. The more acidic 
variants of the 16 kDa and 17 kDa become more intensely labelled with 32P than the 
more basic variants. Taken together, the results suggest that 1E1AE4 is phosphorylated 
in vivo and phosphorylation increases as the protein reaches more superficial layers. 
1E1AE4 phosphorylation was further analysed by Grand et al. (1989). The 16kD and 
17kD isoforms were subsequently shown to be phosphorylated in vitro by PKA (Grand 
et al., 1989).
11E1AE4 phosphorylation has also been described and some phosphorylation sites 
mapped (Bryan et al., 2000). When HPV11-infected human genital tissue was grown 
as a xenograft in a mouse and radiolabelled with 32P, the E1AE4 became labelled. In 
vitro kinase assays also demonstrated that 11E1AE4 can be phosphorylated by 
p42MAPK at threonine 53 (within a variant of the MAPK consensus site) and by PKA 
at threonine 36 (within a PKA consensus site) and serine 44 (within a variant of the 
PKA consensus site; Figure 1.6). Bryan et al. (2000) also made phosphorylation site- 
mutant 11E1aE4s and reported that the MAPK site-deficient E1AE4 had a reduced 
filamentous distribution as compared to wild type E1AE4. Wild type 11E1AE4 has 
been shown to oligomerise (Bryan et al., 1998) but this MAPK mutant E1AE4 did not 
colocalise with wild type E1AE4. The PKA mutant 11E1AE4 had similar cellular 
distribution to the wild type and also colocalised with wild type E1AE4, suggesting it 
still retained the ability to oligomerise.
16E1AE4 phosphorylation has been reported by Wang et al. (2004) but not discussed in
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Figure 1.6 Phosphorylation sites of 11E1AE4
The HPV11 E1AE4 amino acid sequence is shown together with phosphorylation 
sites (red) reported by Bryan et al. (2000).
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any detail. Considering that other E1AE4 types are phosphorylated and functional roles 
for HPV protein phosphorylation have been found, it was decided to focus further on 
16E1AE4 phosphorylation.
The aim of this study was to investigate 16E1AE4 phosphorylation. The main
objectives were to confirm that 16E1AE4 can be phosphorylated, to map the 
phosphorylation site(s) and to find the biological effects of phosphorylation.
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2.1 Suppliers of reagents
Except where specified, including below, reagents were obtained from Sigma-Aldrich 
Company Ltd. (UK), BDH Laboratory Supplies (UK) or Fisher Scientific (UK).
Suppliers of commonly used reagents are listed below:
Agarose, ammonium persulfate (APS), ethidium bromide, sodium dodecyl sulfate 
(SDS) and N,N,N,N’-tetra-methyl-ethylenediamine (TEMED) were obtained from Bio- 
Rad (UK). Ultra Pure ProtoGel Acrylamide was obtained from National Diagnostics 
(UK). Benzonase® was obtained from Novagen, Merck (UK). Complete Protease 
Inhibitor Cocktail Tablets were obtained from Roche (UK). Marvel was obtained from 
Premier International Foods (UK). Fetal calf serum (FCS) was obtained from Perbio 
Science Ltd. (UK). Dulbecco’s modified Eagle’s medium (DMEM) was obtained from 
Invitrogen (UK). All primers were produced by Sigma-Genosys (UK).
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2.2 Components of commonly used buffers and reagents
Commonly used buffers were prepared according to Table 2.1.
Table 2.1 Buffers and reagents
2 x Laemmli’s buffer 4 % (w/v) SDS, 20 % (v/v) glycerol, 0.1 
M DTT, 0.12 M Tris, pH 6.8, containing 
a trace of bromophenol blue
10 x loading buffer 50 % (v/v) glycerol, 0.5 % (w/v) 
bromophenol blue, 0.4 % (w/v) xylene 
cyanol
LB broth 1 % (w/v) tryptone, 0.5 % (w/v) yeast 
extract, 86 mM NaCl
LB agar LB broth + 2 % (w/v) Bacto agar
PBS 0.17 M NaCl, 3.3 mM KC1, 10 mM 
Na2H P04, 1.8 mM KH2P 0 4, pH 7.4
TBE 0.1 M Tris base, 0.62 % (w/v) boric acid, 
5 mM EDTA, pH 8.0
TBS 0.15 M NaCl, 10 mM Tris pH 7.5
trypsin-versene 0.14 M NaCl, 2.7 mM KC1, 8.5 mM 
Na2H P04, 1.5 mM KH2P 0 4, 0.27 mM 
EDTA, 0.13 % (w/v) trypsin, 0.001 % 
(w/v) phenol red, pH 7.6-7.8
pen/strep stock (cell culture antibiotics) 0.6 % (v/v) penicillin, 1 % (v/v) 
streptomycin
SDS electrophoresis buffer 25 mM Tris base, 192 mM glycine, 0.1 % 
(w/v) SDS
transfer buffer 30 mM Tris base, 240 mM glycine, 20 % 
(v/v) methanol
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2.3 Cell culture methods
2.3.1 Cell lines
SiHa cells were used for most of the cell culture experiments. These cells are an 
adherent cervical carcinoma cell line containing integrated HPV16 DNA (Friedl et al., 
1970). SiHa cells constitutively express E6/E7 but lack E1AE4 expression due to loss 
of the E4 ORF. This cell type gives high efficiency infection with recombinant 
adenoviruses (rAds). C33A, NIKS and COS-7 cell lines were also used. C33A cells 
are a cervical epithelial carcinoma cell line that is not HPV-transformed. C33A cells 
lack a functional p53 gene due to an inactivating mutation at codon 273 (Scheffner et 
al., 1991). NIKS are a HPV-negative spontaneously immortalised human keratinocyte 
cell line (Allen-Hoffmann et al., 2000) and COS-7 cells are a simian virus 40 (SV40) 
transformed, African green monkey kidney cell line (Gluzman, 1981).
2.3.2 Maintenance of cells
Cells were maintained in 75 cm2 Corning flasks in 10 ml of DMEM (Dulbecco’s 
modified Eagle’s Medium) supplemented with 10 % (v/v) fetal calf serum (FCS) and 1 
% (v/v) antibiotics stock (pen/strep). In this study, the concentrations of FCS and 
pen/strep were kept constant at 10 % and 1 % respectively, unless otherwise stated, and 
DMEM supplemented with these reagents is termed ‘complete DMEM’. Cells were 
incubated at 37 °C in a 5 % CO2 environment. When the cells reached confluency, 
they were passaged by seeding 10 % of them into a new flask (approximately twice a 
week). To detach the adherent cells from the flask, they were washed with phosphate 
buffered saline (PBS), incubated for 5 min at 37 °C with trypsin-versene until they 
detached from the bottom of the flask and then suspended in more complete DMEM. 
When cells were required to be seeded at a particular density, the cells in suspension 
were counted on a haemocytometer, using a phase contrast light microscope (Nikon 
Eclipse TS100, Surrey, UK) to estimate the cell concentration.
2.3.3 Long-term storage of cells
Cells were cultured until confluent and then a suspension of ~ lx l0 6 cells was prepared
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as above (using trypsin-versene). They were then pelleted (2500 g, 5 min) and then 
resuspended in 1 ml of freezing medium (90 % (v/v) FCS, 10 % (v/v) dimethyl 
sulphoxide (DMSO)) and transferred to a cryogenic vial. This was stored at -80 °C 
overnight, wrapped in 12-15 layers of tissue paper to slow down the freezing of the 
cells, before being transferred to liquid nitrogen. When required, the cells were rapidly 
defrosted at 37 °C and added to 10 ml of complete DMEM. The cells were pelleted as
'y
above, resuspended in 10 ml of complete DMEM and transferred to a 75 cm flask.
2.3.4 TVG402 monoclonal antibody production
TVG402 was produced from a hybridoma cell line (Doorbar et al., 1992), which was 
maintained in complete DMEM. Following the recovery of the TVG402 hybridoma 
cell line from long-term storage, the cells were passaged at least six times before being 
used for antibody production. The cells were then grown until they were over- 
confluent (-4-7 days after confluence was reached). Subsequently, the supernatant 
containing -20-50 pg/ml of antibody was collected and then centrifuged to remove cell 
debris (1000 g, 10 min). The cell culture supernatant was then filtered through a 0.2 
pm filter, sodium azide added to 0.02 % (v/v), and then the antibody stock was stored 
at 4 °C.
2.3.5 Infection with recombinant adenovirus (rAd)
Recombinant adenovirus preparations were produced by Dr Deb Jackson (NIMR). 
SiHa cells were seeded in 90 mm Nunc culture dishes in 5 ml of complete DMEM at a 
concentration of 5x105 cells per dish. After 24 h, 16ElAE4-expressing adenovirus 
(rAdElAE4) or pGAL-expressing adenovirus (rAdpGAL) was added to the media at a 
100 MOI (multiplicity of infection) for each 90 mm dish. Cells were harvested after 24 
h of incubation with the rAds unless otherwise stated.
2.3.6 Transient transfections
Plasmid DNA purified with the HiSpeed Maxi Kit (Qiagen, UK), was used for
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transfection of cultured cells. Transfection was performed using the Effectene® 
Transfection Kit (Qiagen, UK) according to the manufacturer’s protocol. Cells were 
seeded at the densities shown in Table 2.2, 24 h prior to transfection. Medium 
containing the transfection reagent was removed from the dishes/wells 6 h following 
transfection and replaced with fresh complete DMEM. Cells were harvested 24 h post­
transfection (18 h following renewal of the medium) unless otherwise stated.
Table 2.2 Cell seeding densities for transfections
Culture format Number of cells to seed
24-well plate 3 x 104 per well
6-well plate 2 x 105 per well
60 mm dish 3 x 105 per dish
2.3.7 Stable transfection of an HP VI6 E5-expressing vector
SiHa cells were stably transfected with an E5-expressing vector by Dr Qian Wang 
(NIMR). Briefly, cells were co-transfected with the HPV16 E5-expressing vector, 
pMT3H16E5KC (a kind gift from Dr Dan DiMiao, Department of Genetics, Yale 
University School of Medicine, CT, USA) and pBabe-puro (Morgenstern and Land, 
1990) using Effectene®. After selection by G418, HPV 16 E5-positive clones were 
detected by RT-PCR (see 2.5.11).
2.3.8 Okadaic acid (OA) experiments
OA was dissolved in ethanol to make a 50 pg/ml stock for storage at -20 °C. It was 
either added to the cell culture media 1 h before harvesting the cells or included in the 
SDS cell lysis buffer, at a concentration of 1 p,g/ml.
2.3.9 MAPK inhibitor experiment
SiHa cells were grown in 90 mm dishes and infected with rA dElAE4 (see 2.3.5). Six h
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post-infection, the cell culture medium was removed and replaced with 5 ml of 
complete DMEM. MAPK inhibitors dissolved in DMSO or 10 pi DMSO (as the 
negative control) were then added to the media. The inhibitors used were, the 
p38MAPK inhibitor, SB 203580 (Calbiochem, UK) at a concentration of 5 pM, and the 
MEK inhibitors, PD 98059 (Calbiochem, UK) at a concentration of 50 pM and U 1026 
(Calbiochem, UK) at a concentration of 5 pM. The cells were harvested after 18 h 
incubation.
2.3.10 CDK1/2 inhibitor experiment
SiHa cells were grown in 90 mm dishes and infected with rA dElAE4 (see 2.3.5). Six 
hours post-infection, the virus-containing medium was removed and replaced with 5 ml 
of complete DMEM. The CDK 1/2 inhibitor, Roscovitine (dissolved in DMSO), was 
then added to a final concentration of 30 pM and for the negative control, 10 pi of 
DMSO was added. The cells were harvested after 18 h incubation.
2.3.11 Harvesting cells for protein analysis
Cultured cells growing in plates/dishes (90 mm dishes, 60 mm dishes or 6-well plates) 
were washed with PBS, then 1.5 ml of PBS containing 1 mM EDTA was added (per 
well/dish) and left for 5 min at R/T. The cells were then scraped using Corning cell 
scrapers, collected into 1.5 ml microfuge tubes and centriguged at 1000 g for 5 min to 
pellet the cells. The supernatant was carefully pipetted and discarded and the cell pellet 
used immediately or frozen at -80 ° C.
2.3.12 Fixing and blocking cells for immunostaining
When cells were cultured for immunostaining, they were grown on glass coverslips (13 
mm diameter) in dishes/plates. When ready to be fixed, the cell culture medium was 
removed and the cells washed three times with PBS. The cells were then fixed with 
ice-cold methanol for 2 min. Following this, the cells were washed twice with PBS 
then incubated at 4 °C overnight with 2 % (w/v) bovine serum albumin (BSA) in PBS
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containing 0.01 % (v/v) sodium azide. The cells were stored for longer periods at 4 °C 
in this blocking solution if necessary.
2.4 Cell staining and analysis
2.4.1 Immunostaining
Table 2.3 shows a list of primary antibodies used in immunostaining. Cells previously 
treated with a solution of BSA (see 2.3.12) were incubated with primary unconjugated 
antibodies diluted in 0.1 % (w/v) FCS in PBS, at 37 °C for 1 h. They were then washed 
five times in PBS at 5 min intervals. Following this, the cells were incubated with 
Alexa Fluor® 488- or Alexa Fluor® 594-conjugated secondary antibodies (Molecular 
Probes, UK; diluted 1:200) and 1 p-g/ml of 4’,6-diamino-2-phenylindole (DAPI) diluted 
in 0.1 % (v/v) FCS in PBS, at 37 °C in the dark for 1 hr. When Alexa Fluor® 488- 
conjugated TVG405, a mouse anti-16ElAE4 antibody, was used, it was added to the 
cells at the same time as the secondary antibodies and DAPI. Finally, the coverslips 
were washed five times in PBS as above, rinsed briefly with ddF^O then inverted onto 4 
\.il of citifluor (Agar Scientific, UK) on a microscope slide.
Table 2.3 Primary antibodies for immunostaining
Target Protein/ Epitope Primary Antibody Dilution Source/ 
Reference
16E1AE4
epitopes recognised: 
PKPSPWAP 
KPSPWAPK 
PSPWAPKK 
SPWAPKKH 
PWAPKKHR
Alexa Fluor® 488- 
conjugated 
TVG405 (human 
Fab)
1:75 (Doorbar et al., 
1997)
Keratin anti-pan-keratin, 
c2562 (mouse 
monoclonal)
1:200 Sigma, UK
Cyclin A 6E6 (mouse 
monoclonal)
1:400 Novocastra, UK
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2.4.2 Microscopy
Cells were observed on a fluorescent Labophot II microscope (Nikon, Kingston upon- 
Thames, UK). Digital images were captured with a SenSys monochrome camera and 
IP Lab imaging software (Roper Scientific, Marlow, UK). Fluorescent signals were 
overlaid by computer assistance.
2.5 DNA methods
2.5.1 DNA constructs used
Bacterially-expressed wild-type C-terminus hexa-histidine tagged 16E1AE4 with a 
‘leucine, glutamic acid’ linker (WT His-E1AE4) was produced from the pET-28(b)+ 
expression vector (Novagen, UK). The construct was produced by Dr Pauline 
McIntosh (NIMR). The forward primer was GGG CCC TCG GTT TCC AjTG GCT 
GAT CCT GCA GCA GCA21 (the Ncol site is underlined and nucleotides 1 to 21 
correspond to the E1AE4 sequence). The reverse primer was TAT AT A ACT CTC 
GAG T279GG GTG TAG TGT TAC TAT TAC258 (the Xhol site is underlined and 
nucleotides 279 to 258 correspond to the E1AE4 sequence). Recombinant protein 
expression from pET-28(b)+ constructs are regulated by T7 RNA polymerase which is 
under the control of the lacUVS promoter, thus IPTG was required to induce 
expression. In cell culture, WT 16E1AE4 was expressed by transfection of the 
pMVl 1.16E1AE4 construct (Davy et al., 2002) and by infection of recombinant 
adenovirus containing the rA dl6E lAE4 construct (Doorbar et al., 2000b). pGAL was 
expressed by infection of recombinant adenovirus containing the rAdpGAL construct 
(Fournier et al., 1999). HPV 16 E5 was expressed from the vector, pMT3H16E5KC (a 
kind gift from Dr Dan DiMiao, Department of Genetics, Yale University School of 
Medicine, CT, USA).
2.5.2 E.coli strains used
XL 1-Blue supercompetent cells (Stratagene, UK) were used in the mutagenesis 
protocol and for when new plasmid DNA preps were required. The strain is 
recombination deficient, endonuclease deficient, and has a mutation in the hsdR
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endonuclease system so that cleavage of cloned DNA is reduced. BL21 Star™ (DE3) 
One Shot® cells (Invitrogen, UK) were used to express His-E1AE4 from the pET- 
28(b)+ vector. The strain was chosen for optimal E1AE4 production because it does not 
express the Lon or the OmpT proteases and is deficient in its ability to degrade mRNA 
because of a truncated RNase E enzyme.
2.5.3 Growing E.coli cultures
Cells were grown in LB medium containing appropriate antibiotics to select for 
plasmid maintenance. The antibiotics used were ampicillin (100 pg/ml) for pM Vll 
and kanamycin (50 pg/ml) for pET-28(b)+. Cultures were incubated at 37 °C, in LB 
broth with shaking (220 rpm) or LB agar.
2.5.4 Transformation of E.coli with DNA
The chemical competent E.coli cells, XL 1-Blue supercompetent cells or BL21 Star™ 
(DE3) cells, were used in transformations. One pi of plasmid miniprep or maxiprep 
DNA (0.1-50 ng of DNA) was added to 50 pi of cells in a pre-chilled 15 ml Falcon 
2059 polypropylene tube. The tube was incubated on ice for 30 min then heat-pulsed 
in a 42 °C water bath for 45 sec. After cooling the tube on ice for 2 min, 1 ml of SOC 
medium (Invitrogen, UK) was added, then the tube incubated at 37 °C for 1 h with 
shaking at 220 rpm. The culture (-250 pi) was spread on an LB agar plate (containing 
50 pg/ml kanamycin or 100 pg/ml ampicillin) using aseptic technique and the plate 
incubated overnight at 37 °C. Cultures of any resultant E. coli clones were prepared the 
following day by transferring bacteria from the plate to LB broth using a sterile pipette 
tip and aseptic technique.
2.5.5 Glycerol stocks
E.coli clones were stored at -80 °C as a ‘glycerol stock’. A glycerol stock was 
prepared by transferring 0.5 ml of a fresh mid-log culture (in LB broth) to a cryogenic 
vial and adding 0.5 ml of glycerol. This was mixed and immediately stored at -80 °C.
Chapter 2: Materials and Methods 66
2.5.6 Purifying plasmid DNA
2.5.6.1 Minipreps
Two ml of plasmid-containing Ecoli cultures (in LB broth with 50 pg/ml kanamycin or 
100 pg/ml ampicillin) were grown overnight at 37 °C with shaking at 220 rpm. 
Plasmid minipreps were prepared using the Quantum Prep® Plasmid Miniprep Kit 
(Bio-Rad, UK) using the manufacturer’s protocol. DNA was eluted using 50 pi of 
deionised H2O.
2.5.6.2 Maxipreps
A 5 ml plasmid-containing E. coli culture was grown during the day (for ~ 6 h) in LB 
broth containing 50 pg/ml kanamycin or 100 pg/ml ampicillin (at 37 °C with shaking at 
220 rpm). Then, 150-250 ml of LB broth (containing antibiotic) was inoculated with 
the 5 ml culture, and was incubated overnight at 37 °C with shaking at 220 rpm. The 
HiSpeed Maxi Kit (Qiagen, UK) was used to produce plasmid DNA maxipreps 
according to the manufacturer’s protocol. DNA was eluted using 1 ml of deionised 
H20 .
2.5.7 Quantitation of DNA
DNA concentrations were assayed using a 1201 UV-visible spectrophotometer 
(Shimadzu, UK). DNA solutions were diluted 1:100-1:500 and their absorbance at 260 
nm measured in quartz cuvettes. DNA concentrations were calculated assuming an 
A260 of 1 is equivalent to 50 pg/ml of double-stranded DNA.
2.5.8 TBE agarose gel electrophoresis
To check for the presence or quantity of DNA (for example, mutagenesis PCR 
products, miniprep DNA and RT-PCR products), the DNA was separated on a 1 % 
agarose gel, buffered with TBE, containing 1 pg/ml ethidium bromide. Samples were 
mixed with 10 x loading buffer, loaded into the gel, and electrophoresis was carried out 
at a constant voltage of 70 V, limiting to 200 mA. DNA bands were visualized by 
trans-UV illumination and compared to DNA markers (Invitrogen, UK) of known
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molecular mass. Digital images were captured with a Kodak Image Station 440 and 
Digital Science ID software (Perkin Elmer Life Sciences Ltd., UK).
2.5.9 Site-directed mutagenesis of 16E1AE4
Site-directed mutagenesis was performed using the QuickChange® Site-Directed 
Mutagenesis kit (Stratagene, UK) according to the manufacturer’s protocol. The 
primers used to make the 16E1AE4 mutants are shown in Table 2.4. They were 
designed to have the mutation in the middle of the sequence, a melting temperature 
(Tm) equal to or greater than 78 °C (Tm = 81.5 + 0.41 (% GC) -  675/N where N is the 
number of bases) and a minimum GC content of 40 %. The plasmid in which the 
mutation was desired was used as the template DNA for a PCR reaction and the 
relevant pair of primers was added. To make the T54/57A and T51/54/57A mutants, 
the T57A mutant plasmid was used as the template DNA. The mutagenesis PCR 
reactions were cycled using Thermal Cycler 200 (GRI, UK) and the programmes used 
are shown in Table 2.5.
Table 2.4 Primers for mutagenesis
Mutation Forward primer Reverse primer
S32A ccataccaaagccggcgccttgggcac
eg
cggtgcccaaggcgccggctttggtat
gg
S43A S44A cgaagaaacacagacgactagccgcc
gaccaagatcagagccag
ctggctctgatcttggtcggcggctagt
cgtctgtgtttcttcg
S49A ccagcgaccaagatcaggcccagaca
ccggaaacccc
ggggtttccggtgtctgggcctgatctt
ggtcgctgg
T51A caagatcagagccaggcaccggaaac
ccctg
caggggtttccggtgcctggctctgat
cttg
T54A ccagacaccggaagcccctgccacac
c
ggtgtggcaggggcttccggtgtctgg
T57A cggaaacccctgccgcaccactaagtt
gttg
caacaacttagtggtgcggcaggggtt
tccg
T54/57A ccagacaccggaagcccctgccgcac
ca
tggtgcggcaggggcttccggtgtctg
g
T51/54/5 7A cagagccaggcaccggaagcccctgc
egea
tgcggcaggggcttccggtgcctggc
tctg
T57D gacaccggaaacccctgccgacccact
aagttgttgcacag
ctgtgcaacaacttagtgggtcggcag
gggtttccggtgtc
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Table 2.5 PCR programmes for mutagenesis
pM V ll pET-28(b)+
1) 95 °C, 30 sec 1) 95 °C, 30 sec
2) 95 °C, 30 sec 2) 95 °C, 30 sec
3) 55 °C, 1 min 3) 55 °C, 1 min
4) 68 °C, 4 min 4) 68 °C, 6 min
Repeat steps 2-4 16 times Repeat steps 2-4 16 times
Following the PCR reaction, the template plasmid DNA was removed by digestion 
using 10 U of Dpn I (part of the kit), leaving only the PCR product. Then XL 1-Blue 
supercompetent cells were transformed by heat shock using 1 pi of this PCR product 
(see 2.5.4). The cells were incubated on ice for 2 min then mixed with 1 ml of SOC 
medium and shaken at 220 rpm for 1 h at 37 °C. They were then spread on LB agar 
plates (containing kanamycin for pET-28(b)+ mutagenesis or ampicillin for pM V ll 
mutagenesis). The resultant colonies were sequenced to check for correct mutagenesis 
(see 2.5.10).
2.5.10 Sequencing of 16E1AE4
When 16E1AE4 sequence-containing plasmids were required to be sequenced, 
minipreps of the DNA were prepared using the Quantum Prep® Plasmid Miniprep kit 
(Bio-Rad, UK). The sequencing PCR reaction was performed using the Big Dye® 
Terminator v l.l  Sequencing kit (Applied Biosystems, UK), using 200 ng of the 
miniprep DNA and 3.2 pmol of primer. Each reaction was performed in duplicate 
using the forward primer, cttgatcatatggctgatcctgcagcagcaac. The PCR reaction was 
cycled using Thermal Cycler 200 (GRI, UK). Following the reaction, the DNA was 
precipitated by adding 2 pi of 3 M sodium acetate (pH 4.6) and 50 pi of ice-cold 95 % 
ethanol, vortexing briefly, incubating on ice for 10 min and centrifuging at 9000 g for 
15 min. The supernatant was carefully removed, the DNA pellet washed with 70 % 
ethanol and then air-dried for 1 h. Capillary sequencing was performed using 
MegaBACE™ (GE Healthcare, UK).
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2.5.11 Reverse transcription-polymerase chain reaction (RT-PCR) of HPV16 E5
To check for the presence of E5 mRNA in the stably-transfected SiHa cells described 
in 2.3.7, RT-PCR was performed. The cells were grown to confluency in a 90 mm dish 
and the total RNA extracted using the RNase-Easy® Mini Kit (Qiagen, UK) and eluted 
into 50 pi of RNase-free H2O (part of the kit). One pi of the extracted RNA was added 
to 25 pmoles of Oligi dT 12-18 mer primer (Invitrogen, UK), 0.5 pi of 10 mM dNTP 
and ddH20, and incubated at 65 °C for 5 min followed by 1 min on ice. Reverse 
transcription to produce cDNA was then carried out by adding 2 pi of First Strand 
Buffer (Invitrogen, UK), 0.5 pi of 0.1 M DTT, 0.5 pi of RNasin® (Promega, UK) and 
0.5 pi of Superscript™ III reverse transcriptase (Invitrogen, UK) and incubating at 50 
°C for 90 min. The reaction was then inactivated by incubation at 70 °C for 15 min. A 
20 pi PCR reaction mixture was made using 2 pi of the cDNA sample, 2 pi of 
Thermoprime Plus DNA polymerase buffer (Abgene®, UK), 2 pi of 25 mM MgCE, 1 
pi of 10 mM dNTP, 0.5 pi of Thermoprime Plus DNA polymerase (Abgene®, UK) and 
10 pmoles of each E5 primer shown below.
forward: CG AT GG AT CC ACC AT G AC AAAT CTT GAT ACT GC AT C 
reverse: GCT AG A ATT CTT AT GT A ATT AA A A AGCGT GC
The PCR programme used is outlined below:
Step 1: 94 °C 3 min 
Step 2: 94 °C 45 sec 
Step 3: 55 °C 45 sec 
Step 4: 72 °C 30 sec 
Repeat steps 2-4, 29 times.
The PCR reaction was cycled using Thermal Cycler 200 (GRI, UK).
2.6 Protein methods
2.6.1 SDS-PAGE
SDS-PAGE was used to separate proteins according to molecular mass. It was 
performed using Mini Protean II apparatus (Bio-Rad, UK). 1.5 mm spacers were used 
and 15 % acrylamide resolving gels were made unless otherwise stated. The
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components for preparing 12 % and 15 % resolving gels are shown in Table 2.6. The 
resolving gel solution was prepared, ensuring that the APS and TEMED were added 
just before use. This solution was poured into the caster to 3 cm below the top, 
overlaid with water-saturated butanol and allowed to polymerise for 20 min. Once the 
resolving gel was set, the butanol was rinsed away with ddH20  and the stacking gel 
solution prepared using the components shown in Table 2.6 (the APS and TEMED 
were added just before use). The stacking gel was poured on top of the resolving gel 
and a gel comb inserted into the stacking gel solution. After 20 min the comb was 
removed and the gel positioned in the electrophoresis tank. The tank was filled with 
SDS electrophoresis buffer and the sample wells rinsed with this buffer.
Table 2.6 Components of the resolving and stacking gels
Stock solutions 10 ml resolving solution 5 ml stacking solution
ddH20 3.3 ml (12 %), 2.3 ml (15 
%)
3.4 ml
30 % acrylamide 4 ml (12%), 5 ml (15%) 0.83 ml
1.5 M Tris pH 8.8 2.5 ml 0 ml
1 M Tris pH 6.8 0 ml 0.63 ml
10 % (w/v) SDS 0.1 ml 0.05 ml
10 % (w/v) APS 0.1 ml 0.05 ml
TEMED 0.004 ml 0.005 ml
Protein samples were then prepared for loading by mixing with an equal volume of 2 x 
Laemmli’s buffer and denaturing by incubating at 95 °C for 2 min. To prepare 
harvested cell pellets (see 2.3.11) for loading, the pellets were lysed on ice with 2 % 
SDS in PBS, unless otherwise stated. After lysis, 1 pi of Benzonase® was added to 
each sample to reduce viscosity caused by DNA and RNA. The cell extract samples 
were also denatured with Laemmli’s buffer as described above. Samples and protein 
standards (rainbow protein standards (GE Healthcare, UK) or silver stain protein 
standards (Bio-Rad, UK)) were loaded into the wells of the gel. The gel was then run 
at a constant voltage of 150 V until the desired separation of the protein-standards was 
achieved.
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2.6.2 Two dimensional (2D) SDS-PAGE
2.6.2.1 Sample preparation
To prepare SiHa cell extracts for 2D SDS-PAGE followed by Western blotting, cells 
were harvested (see section 2.3.11) and lysed on ice with 2 % SDS in PBS (100 pi per 
90 mm dish or 50 pi per 60 mm dish of cells) in the presence of 1 pi Benzonase®. 
This lysate was diluted 1:3 in ddH20 (cell extracts that were treated with X phosphatase 
(see 2.7.2) were also diluted 1:3 and subsequent steps were identical). This dilution 
step is to ensure that the SDS concentration is not high enough to interfere with 
isoelectric focusing (IEF; or in other terms, ‘the first dimension’). Thirty pi of the 
diluted lysate was then mixed with 470 pi of urea-thiourea (U-T) buffer (5 M urea 
(PlusOne, GE Healthcare, UK), 2 M thiourea (Fluka, Sigma-Aldrich, UK), 2 % 
CHAPS, 2 % SB 3-10 (Fluka, Sigma-Aldrich, UK), 65 mM DTT (SigmaUltra, Sigma- 
Aldrich, UK), 20 mM Tris pH 9.5, 0.1 mM EDTA). The sample was spun at 100000 g 
for 50 min at 16 °C in an TLA-100 ultracentrifuge (Beckman, USA). The supernatant 
was transferred to a clean 1.5 ml microfuge tube and stored at -80 °C. Prior to using 
the sample for IEF, the sample was thawed and mixed with immobilised pH gradient 
(IPG) buffer (GE Healthcare, UK) to make a final IPG buffer concentration of 0.8 % 
(v/v) and spun in a microcon filter tube (0.22 pm pore; Millipore, UK) at 9000 g for 3 
min.
When SiHa cells were prepared for 2D SDS-PAGE followed by silver staining, ten 90 
mm dishes were harvested for each IEF run and the cells were lysed directly into 100 pi 
of U-T buffer. 2 pi of Benzonase® was added and the sample sheared using a 1 ml 
syringe fitted with a 23 gauge needle. The ultracentrifugation step and all subsequent 
steps were the same as described above.
2.6.2.2 Performing isoelectric focusing (IEF; the first dimension)
7 cm IPG strips of pH 6-11 or pH 3-10 (GE Healthcare, UK) were rehydrated overnight 
with 125 pi of U-T buffer in an Immobiline DryStrip Reswelling Tray (GE Healthcare, 
UK). All strips were overlaid with IPG cover fluid (GE Healthcare, UK) and the tray 
covered with Saran Wrap® (The Dow Chemical Company, USA).
IEF was performed the following day using the Multiphor II system (GE Healthcare, 
UK; Figure 2.1). The Immobiline DryStrip tray (GE Healthcare, UK) and DryStrip
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aligner (GE Healthcare, UK) were correctly positioned and then the rehydrated IPG 
strips were positioned gel-side-up on the aligner. The acidic ends of the strips were 
near the anode whilst the basic ends were near the cathode. Two electrode strips (GE 
Healthcare, UK) were moistened with ddH20  and placed over the acidic and basic ends 
of the strips, perpendicular to the strips. The anode bar (GE Healthcare, UK) was fitted 
over the electrode strip at the acidic end and the cathode bar (GE Heatlthcare, UK) was 
fitted over the electrode strip at the basic end. Sample cups (GE Healthcare, UK) were 
positioned over the acidic end of the gel using a sample cup bar (GE Healthcare, UK), 
and the tray was filled with 230 ml cover fluid. One hundred pi of sample (containing 
a trace of bromophenol blue powder) was applied into each sample cup by pipetting 
under the surface of the cover fluid. The samples were now ready to run. A 
MultiTemp III thermostatic circulator (GE Healthcare, UK) was used to set the 
temperature to 20 °C. An EPS 3501 XL power supply (GE Healthcare, UK) was 
programmed to run seven phases in the order shown in Table 2.7. When the IEF was 
complete, the second dimension was either performed straight away, or the IPG strips 
were stored at -80 °C until required.
Table 2.7 IEF programme
Phase Voltage (V) Current
(mA)
Resistance
(Ohms)
Time
(h:min)
Volthours
1 150 2 5 0:30 75
2 300 2 5 2:30 750
3 700 2 5 0:30 350
4 1500 2 5 0:30 750
5 2000 2 5 0:30 1000
6 3000 2 5 0:30 1500
7 3500 2 5 16:00 56000
(a)
(b)
electrode
bar
M ulitem p III M ultiphor II EPS3501XL
sample cup bar sample cup
DryStrip tray 
DryStrip aligner
IPG strip
(c)
(d)
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Figure 2.1 IEF apparatus and pH gradient
(a) Image of the Multiphor II IEF system (GE Healthcare), (b) Loading of samples using sample cups, (c and d) Graphs provided by GE Healthcare 
(cat no 18-1140-60) showing pH as a function of distance along the IPG strip, were used to calculate the pH at which proteins focused in (c) pH6-l 1 
IPG strips and (d) pH3-10 IPG strips.
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2.6.2.3 SDS-PAGE (the second dimension)
The second dimension runs were carried out using Mini Protean II gel electrophoresis 
apparatus. Fifteen % acrylamide gels were made using 1.5 mm gel spacers and the 
resolving gel components described in Table 2.6. The casters were filled with the 
resolving gel solution to 5-10 mm below the top and the gels overlaid with water- 
saturated butanol. The gels were allowed to polymerise for 20 min.
While the gels were setting, the IPG strips were equilibrated in the reswelling tray with 
gentle shaking. Each strip was bathed in 3 ml of equilibration buffer (50 mM Tris pH 
8.8, 6 M urea, 30 % (v/v) glycerol, 2 % (v/v) SDS) containing 2 % (w/v) DTT 
(SigmaUltra, Sigma-Aldrich, UK) for 15 min, followed by another 15 min in 
equilibration buffer with 2.5 % (w/v) iodoacetamide (SigmaUltra, Sigma-Aldrich, UK) 
and a trace of bromophenol blue.
Once the resolving gels were set, the surface of the gels were rinsed with ddH20. An 
equilibrated IPG strip was placed on the surface of each gel, avoiding air bubbles 
between the two gel surfaces. The strips were set in place with 1 % agarose. Rainbow 
protein standards were loaded by creating a well in the agarose using a strip of 1 mm 
thick card. Each gel was run in SDS electrophoresis buffer at a constant voltage of 150 
V. The gels were run until sufficient separation of the rainbow markers was achieved.
When analysing the results, the pH at different points of the IPG strip was calculated 
using the charts in Figure 2.1 (catalogue no 18114060, GE Healthcare, UK).
2.6.3 Staining of electrophoresed proteins
2.6.3.1 Silver staining
Gels to be silver stained were fixed for 1 h in 50 % (v/v) methanol. Then they were 
incubated for 1 min in 50 ml of ddH20  containing 85 pi of 10 % (w/v) sodium 
thiosulphate and then rinsed three times for 5 sec with ddH20 . The gels were stained 
for 8 min with 50 ml of H20  containing 650 pi of 20 % (w/v) silver nitrate and 500 pi 
of 37 % formaldehyde. The gels were rinsed three times more with ddH20  then the 
stain developed with 50 ml of ddH20  containing 21 pi of 37 % formaldehyde, 21 pi of 
10 % sodium thiosulphate and lg of sodium carbonate. When the protein stain became
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apparent, the reaction was stopped with 1 % (v/v) acetic acid.
2.6.3.2 Coomassie staining
Gels were stained using the Colloidal Blue Staining kit (Invitrogen, UK). After 
electrophoresis, gels were fixed for 10 min in 50 % (v/v) methanol and 10 % (v/v) 
acetic acid. A solution containing Colloidal Coomassie was prepared according to the 
manufacturer’s protocol and gels incubated in this solution overnight. Gels were 
destained for at least 7 h with deionised H2O.
2.6.4 Western blotting
Western blotting was performed to detect proteins that have been electrophoretically 
separated. The protein sample was first run in a denaturing gel (either 1D or 2D SDS- 
PAGE; see 2.6.1 or 2.6.2 respectively). The separated proteins were then transferred 
from the gel to a PVDF membrane, Immobilon™ (Millipore, UK). This was achieved 
using a wet transfer system, Mini Transfer Blot (Bio-Rad, UK; filled with transfer 
buffer), at a constant voltage of 150 V for 90 min. For detecting active p42/p44 
MAPK, a nitrocellulose membrane, Protran® (Schleicher and Schuell Bioscience, 
Geneflow Ltd., UK), was used instead of Immobilon™.
The membrane was incubated in blocking solution for 1 h at R/T with gentle shaking. 
For most Western blots, the membrane was blocked in PBS containing 5 % (w/v) 
Marvel (Premier Brands UK, Ltd., UK) and 0.1 % (v/v) Tween20. When detecting 
phosphotyrosine, Marvel was replaced with BSA and PBS was replaced with Tris 
buffered saline (TBS). When detecting active p42/p44MAPK, the membrane was 
blocked with 2 % (w/v) BSA in TBS.
For most Western blots, the membrane was incubated with primary antibody (see 
Table 2.8 for a list of antibodies and their working dilutions) for 2 h at R/T with gentle 
shaking, in PBS, 5 % (w/v) Marvel and 0.1 % (v/v) Tween20. When detecting 
phosphotyrosine, Marvel was replaced with BSA and PBS was replaced with TBS. 
When detecting active p42/p44MAPK, the antibody was diluted in TBS containing 0.1 
% (w/v) BSA and 0.05 % (v/v) Tween20.
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Table 2.8 Primary antibodies used for Western blotting
Target Protein/ 
Epitope
Primary Antibody Dilution Source/
Reference
16E1AE4
epitopes recognised: 
PWAPKKHR 
WAPKKHRR 
APKKHRRL 
PKKHRRLS 
KKHRRLSS
TVG402, hybridoma 
supernatant (mouse 
monoclonal)
1:10 (Doorbar et 
al., 1992)
16E1AE4 N-terminus 
MADPAAATKYPL
Anti-N-terminus (rabbit 
polyclonal)
1:800 (Doorbar et 
al., 1997)
Phosphotyrosine anti- phosphotyrosine, clone 
PY20 (mouse monoclonal)
1:300 Neomarkers,
UK
Keratin anti-keratin 18/8, 8592 (rabbit 
polyclonal)
1:1000 Dr Bishr
Omary
(Stanford
University,
USA)
Active
p42/p44MAPK
anti-ACTIVE® MAPK 
(rabbit polyclonal)
1:5000 Promega,
UK
GAPDH anti-GAPDH, MAB374 
(mouse monoclonal)
1:800 Chemicon 
Europe Ltd., 
UK
For most Western blots, the membrane was then washed in PBS with 0.1 % (v/v) 
Tween20 three times at 15 min intervals. When detecting phosphotyrosine, the PBS 
was replaced with TBS. When detecting active p42/p44MAPK, the membrane was 
washed in TBS with 0.05 % (v/v) Tween20.
For most Western blots, the membrane was then incubated for 1 h at R/T with gentle 
shaking in PBS with 5 % (w/v) Marvel and 0.1 % (v/v) Tween20, containing HRP- 
conjugated anti-mouse or HRP-conjugated anti-rabbit IgG (GE Healthcare, UK) diluted 
to 1:3000. When detecting phosphotyrosine, Marvel was replaced with BSA and PBS 
was replaced with TBS. When detecting active p42/p44MAPK, the anti-rabbit 
antibody was diluted in TBS containing 0.1 % (w/v) BSA and 0.05 % (v/v) Tween20. 
Following this, the membranes were washed three times as described above.
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Binding of HRP-conjugated antibody was visualized by Enhanced Chemiluminescence 
(ECL; GE Healthcare, UK), with blots being exposed to Kodak MXB X-ray film (X- 
ograph imaging systems, UK). Films were developed using a Fujifilm FPM-3800A 
processor (UK).
2.6.5 Expression, purification and refolding of His-E1AE4
C-terminus hexa-histidine tagged E1AE4 with a ‘leucine, glutamic acid’ linker (His- 
E1AE4) was expressed from a pET-28(b)+ construct (Novagen, UK) in BL21 Star™ 
cells (Invitrogen, UK). The cloning of this construct and optimisation of the following 
expression and purification steps, was done by Dr Pauline McIntosh (NIMR). The 
glycerol stock of this construct (in BL21 Star™ (DE3)) was streaked onto an LB agar 
plate (containing 50 pg/ml kanamycin) and the plate incubated overnight at 37 °C. A 
colony was scraped and transferred to 10 ml of LB broth (containing kanamycin) and 
this culture grown overnight at 37 °C with shaking. The following morning, the culture 
was diluted in 1000 ml of LB broth (containing kanamycin) and grown at 37 °C with 
shaking. When the culture had an OD of 0.6 at wavelength 600 nm, the bacteria were 
induced to express His-E1AE4 by addition of 0.2 mM IPTG and the temperature 
reduced to 30 °C. Three h after induction, the culture was centrifuged at 3000 g for 15 
min at 4 °C to pellet the bacteria. The pellet was resuspended in 100 ml of pH 7 urea 
buffer (8 M urea, 0.01 M Tris, 0.1 M NaH2P04) containing 25 mM Complete Protease 
Inhibitor. The resuspension was sonicated (at 34 Watts, with a 15 sec pulse followed 
by a 15 sec pause repeated sixteen times) by a Branson Digital Sonifier®, then 
centrifuged at 15000 g for 30 min at 4 °C. The supernatant was clarified bacterial 
lysate. One ml of Talon Metal Affinity Resin (BD Biosciences, UK) was added to an 
Econo-Pac column (Bio-Rad, UK) and equilibrated by washing with 10 ml of the pH 7 
urea buffer. The lysate was added to the column and allowed to flow through. The 
column was washed five times with 10 ml of the pH 7 urea buffer. The His-E1AE4 was 
eluted into five 1 ml aliquots using a pH 4.3 urea buffer (8 M urea, 0.01 M Tris, 0.1 M 
NaH2P04). The third 1 ml elution was generally the purest and the most concentrated 
sample, and was used in experiments. The protein samples were refolded for 
experiments (unless otherwise stated) by dialysing into PBS (containing 2 mM DTT) 
overnight at 4 °C using Slide-A-Lyzer Mini Dialysis Units with a 5000 Da cut-off 
(Pierce, UK).
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2.6.6 Quantitation of protein
2.6.6.1 Quantitation by spectrometry
Protein concentrations were assayed against a blank using a 1201 UV-visible 
spectrophotometer (Shimadzu, UK). Protein concentrations were calculated using the 
formula below. The extinction coefficient of WT His-El AE4 and His-El AE4 with point 
mutations is 18470 (calculated by the ProtParam Tool, ExPASy, 
http://ca.expasy.org/cgi-bin/protparam). The molecular mass (also calculated by 
ExPASy) of WT His-El AE4 and His-El AE4 with point mutations, is 11, 100 Da (to the 
nearest 0 .1k Da.
pg/^1 = O D 2 8 0  -  O D 3 2 0
Extinction
Coefficient
X mass in daltons
2.6.6.2 Quantitation with a protein assay
When a protein assay was performed, the Bio-Rad Protein Assay Dye Reagent 
Concentrate was used and the manufacturer’s protocol followed. BSA standards 
ranging from 0.1 to 1.0 mg/ml were used to make a standard curve.
2.6.7 Mass spectrometry (MS)
2.6.7.1 Sample preparation
ID or 2D SDS-PAGE was performed (see 2.6.1 or 2.6.2 respectively) using the protein 
sample to be analysed by MS. The gels were stained using Colloidal Blue (Invitrogen, 
UK) as described in the manufacturer’s protocol. The gels were destained overnight in 
deionised water. The following sample preparation steps were conducted in a sterile 
tissue culture hood (as keratin contamination is a common problem with MS).
The stained bands of interest were excised, cut into 2 mm x 1 mm pieces and placed in 
0.5 ml non-coloured low adhesion siliconised tubes (Eppendorf, UK) (that have been 
pre-rinsed with Buffer A (200 mM ammonium bicarbonate (Merck, UK), 50 % (v/v) 
acetonitrile (Rathburn Chemicals Ltd, Scotland, UK)). The SDS and Coomassie were 
extracted from the gel pieces by 30 min incubations in 500 \il of Buffer A until the
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Coomassie stain was no longer apparent. The protein was reduced by incubating the 
gel pieces in 200 p,l Buffer A containing 20 mM DTT (SigmaUltra, Sigma-Aldrich, 
UK) for 1 h. The DTT was then removed by washing with Buffer A and the cysteine 
residues alkylated by incubating the sample with 200 \i\ of Buffer A containing 5 mM 
iodoacetamide (SigmaUltra, Sigma-Aldrich, UK) for 20 min (in the dark). The gel 
pieces were then rinsed twice with 500 \x\ of Buffer B (20 mM ammonium bicarbonate, 
50 % acetonitrile) and 500 \i\ of neat acetonitrile added for 15 min. Following this, all 
liquid was removed by pipetting and the gel pieces left to air-dry for 1 h. The sample 
was then stored at -20 0 C.
Before performing MS, each gel piece was incubated overnight (in a 32 0 C oven) in a 
small volume (just enough to fully immerse the gel piece) of 2 p,g/ml sequencing grade 
chymotrypsin (Roche, UK) in 5 mM ammonium bicarbonate. The MS steps described 
below were performed by Dr Steve Howell (NIMR). Results were analysed by Dr 
Steve Howell using software obtained as part of the mass spectrometer package.
2.6.7.2 MALDI MS
The digested protein was acidified with 1/10 volume of 2 % trifluoroacetic acid. A 
Reflex II MALDI TOF mass spectrometer (Bruker Daltonik GmbH, Bremen, 
Germany) equipped with a nitrogen laser and a Scout-384 probe was used for MS. 
Thin layer matrix surfaces of a-cyano-4-hydroxycinnamic acid mixed with 
nitrocellulose were prepared. A small volume (0.4 p,l) of the acidified supernatant was 
deposited onto the thin layer and allowed to dry prior to rinsing with water. An 
accelerating voltage of 26 kV was used with detector bias gating set to 2 kV.
2.6.7.3 Nanospray MS
The digested protein was acidified with 1/10 volume of 2 % trifluoroacetic acid. The 
supernatant was loaded onto a 2 mm x 0.8 mm C l8 microcolumn (LC Packings, 
Amsterdam, Netherlands), washed and step eluted with 60 % methanol, 0.1 % formic 
acid directly into an Econo 12 nanospray needle (New Objective Inc, Cambridge MA). 
Nanospray mass spectra were acquired on an LCQ Quadruple ion trap mass 
spectrometer (ThermoQuest Corporation, Austin, TX) equipped with a nano spray 
source (Protana, Odense, Denmark) operated at a spray voltage of 800 V and a 
capillary temperature of 150 °C. For collision-induced fragmentation, mass spectra
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were acquired at a collision energy of 30 % and a parent ion isolation width of 3 Da.
2.7 Other molecular biology and biochemistry methods
2.7.1 In Vitro kinase assays
Radioactive in vitro kinase assays were carried out using protein substrates, y- P-ATP 
and recombinant kinases. All kinases used were commercially available and these are 
listed in Table 2.9, accompanied by the 10 x reaction buffer components. His-ElAE4, 
myelin basic protein, a-casein or GSK-3 fusion protein (Cell Signalling Technology, 
UK) were used as substrates. The reaction mixture consisted of 1 pg of substrate, 2.5 
pi of 10 x reaction buffer, 2.5 pi of 10 mM 32P-ATP (100-500 pCi/pmol; GE 
Healthcare, UK), 1 pi of kinase (CKII, CDK1, CDK2, p42MAPK, PKA, PKB or 
PKCa) and ddH20 to make the total volume 25 pi. CaMKII was activated by 
autophosphorylation prior to substrate phosphorylation, by incubating 1 pi of the kinase 
for 10 min at 30 °C in a 20 pi reaction containing 2.5 pi of 10 x reaction buffer, 2 mM 
CaCb, 1.2 pM calmodulin, 100 pM ATP (non-radioactive) and ddH20. One pg of 
substrate, 10 mM y-32P-ATP (100-500 pCi/pmol) and d d ^ O  were then added to the 
mixture to make the total volume 25 pi. Substrate and kinase reaction mixtures were 
incubated for 30 min at 30 °C unless otherwise stated, and the reactions stopped by 
addition of 25 pi of 2 x Laemmli’s buffer and heating at 95 °C for 3 min.
SDS-PAGE was carried out on the samples ensuring that the dye front was run-off (to 
remove free ATP). The acrylamide gel was then fixed for 20 min in 40 % (v/v) 
methanol, 10 % (v/v) acetic acid and 1 % (v/v) glycerol. The gel was dried, exposed to 
a light-blanked Phosphorlmager plate overnight and then analysed using a Storm860 
Phosphorlmager (GE Healthcare, UK) and ImageQuant 5.0 software.
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Table 2.9 Protein kinases used and their reaction buffer components
kinase 10 X reaction buffer
CaMKII (New England 
Biolabs, UK)
0.5 M Tris, 0.1 M MgCl2,20 mM DTT, 1 mM Na2 EDTA, 
pH 7.5
CDKl/cyclin B (New 
England Biolabs, UK)
0.5 M Tris, 0.1 M MgCl2, 10 mM EGTA, 20 mM DTT, 0.1 
% (v/v) Brij 35, pH 7.5
CDK2/cyclin A (New 
England Biolabs, UK)
0.5 M Tris, 0.1 M MgC12, 10 mM EGTA, 20 mM DTT, 
0.1 % Brij 35, pH 7.5
CKII (New England 
Biolabs, UK)
0.2 M Tris, 0.5 M KC1, 0.1 M MgCl2, pH 7.5
p42MAPK (New England 
Biolabs, UK)
0.5 M Tris, 0.1 M MgCl2, 10 mM EGTA, 20 mM DTT, 
0.1 % (v/v) Brij 35, pH 7.5
PKA (Promega, UK) 0.4 M Tris, 0.2 M magnesium acetate, pH 7.4
PKB (Cell Signaling 
Tecnology, UK)
0.25 M Tris, 50 mM J3-glycerolphosphate, 20 mM DTT, 1 
mM Na3V 0 4, 0.1 M MgCl2;pH 7.5
PKCcx (Calbiochem, UK) 100 mM HEPES, 1 M MgCl2, CaCl2, 50 mM DTT, 10 
mM EGTA, 0.1 % (v/v) Triton X-100, 0.1 % (w/v) 
phosphatidylserine (Avanti® Polar Lipids, Inc., USA), 0.1 
% (w/v) diacylglycerol (Avanti® Polar Lipids, Inc., USA), 
pH 7.4
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When protein phosphorylation was required for MS, kinase reactions were carried out 
as described above but non-radioactive ATP was used.
2.7.2 lambda (X) phosphatase experiments
A 90 mm plate of rAdElAE4-infected SiHa cells was harvested and the cells lysed in 
50 pi of 0.8 % (v/v) Empigen. Twenty pi of the lysate was incubated with 1 x X 
phosphatase buffer (New England Biolabs, UK), 2 mM MnCb (New England Biolabs, 
UK) and 1 pi of A. phosphatase (New England Biolabs, UK) for 30 min at 30 °C to 
allow protein dephosphorylation. A X phosphatase-negative sample was always 
included, where the phosphatase was replaced by 1 pi of ddfUO.
2.7.3 Immunoprecipitation of 16E1AE4
Three 90 mm plates of rAdElAE4-infected SiHa cells were harvested 24 h post­
infection. The cells were resuspended in 500 pi of 0.8 % (v/v) Empigen in PBS then 
incubated on ice for 30 min. The immunoprecipitation in this study was carried out for 
detection of potential phosphotyrosine, so the cells were lysed in the presence of lmM 
sodium vanadate, an inhibitor of tyrosine phosphatases (Lau et al., 1989). The lysate 
was centrifuged for 5 min at 9000 g, then 50pl of the supernatant transferred to a clean
1.5 ml microfuge tube. Nine hundred and forty pi of PBS (containing 1 % (v/v) NP40, 
100 pg/ml BSA and 25 mM Complete Protease Inhibitor) and 10 pi of anti- 
MBP16E1AE4 rabbit polyclonal IgG (Doorbar et al., 1997) was added and the mixture 
rotated at 4 °C for 1 h. A 50 pi slurry (50 % (v/v)) of Protein G sepharose beads (GE 
Healthcare, UK; pre-washed with PBS to remove ethanol) was then added and the 
mixture rotated for a further 1 h. The 1.5 ml tube was centrifuged at 1000 g for 1 min, 
the supernatant removed and the beads washed three times with PBS (by centrifuging at 
1000 g for 30 sec and carefully pipetting the liquid out with a glass pipette). The beads 
were then resuspended in 50 pi of 2 x Laemmli’s buffer and incubated at 96 °C for 5 
min. The sample was then analysed by SDS-PAGE and Western blotting.
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2.7.4 Immunoprecipitation of keratin followed by incubation with His-El AE4
SiHa cells (3 X 106 cells) were harvested and the pellet resuspended in 500 pi of 
Empigen buffer (1 % Empigen (v/v) and 25 mM Complete Protease Inhibitor in PBS). 
This was incubated on ice for 30 min and then centrifuged at 9000 g for 10 min. Fifty 
pi of the supernatant was added to 150 pi of Empigen buffer and 2 pi of the anti-keratin 
8/18 mouse monoclonal, L2A1 (a kind gift from Dr Bishr Omary, Palo Alto VA 
Medical Center and Stanford University School of Medicine, CA, USA). The sample 
was mixed and incubated on ice for 1 h. For negative controls, the cell extract (keratin) 
or L2A1 were omitted. A 50 pi slurry (50 % (v/v)) of Protein G sepharose beads (GE 
Healthcare, UK; pre-washed with PBS to remove ethanol) was then added and the 
mixture rotated at 4 °C for 1 h. The beads were then washed three times (by 
centrifuging at 1000 g for 30 sec and carefully pipetting the liquid out with a glass 
pipette) with 400 pi of Empigen buffer and then once with 400 pi of NP40 buffer (0.5 
% (v/v) NP40, 0.125 % (w/v) gelatin, 25 mM Complete Protease Inhibitor, in PBS). 
Four hundred pi of NP40 buffer containing 0.4 pg of refolded His-ElAE4 (see section 
2.6.5) was added to the beads and the sample rotated at 4 °C for 2 h. The beads were 
then washed four times with NP40 buffer and resuspended in 25 pi of 2 x Laemmli’s 
buffer. The sample was heated for 5 min at 96 °C, centrifuged at 1000 g for 1 min, and 
analysed by Western blotting.
2.7.5 Solubility fractionation
SiHa cells were grown in 60 mm Nunc dishes, transfected and harvested 24 h post­
transfection (unless otherwise stated). The pellets were resuspended in 80 pl/dish of 
NP40 lysis buffer (0.5 % (v/v) NP40 in PBS with 25 mM Complete Protease Inhibitor). 
Each sample was then rotated at 4 °C for 30 min. The sample was subsequently 
pelleted by centrifugation (10000 g, 10 min, 4 °C). The supernatant was transferred to 
a 1.5 ml microcentrifuge tube and stored on ice. This was called the ‘NP40-soluble 
fraction’. The resultant pellet was resuspended in 80 pl/dish of 0.8 % (v/v) Empigen in 
PBS with 25 mM complete Protease Inhibitor cocktail, using a 1 ml syringe fitted with 
a 23 gauge needle, and then rotated at 4 °C for 30 min. The extract was centrifuged 
and the supernatant stored on ice and this was called the ‘Empigen-soluble fraction’. 
The remaining pellet was resuspended in 80 pl/plate of 9 M urea in PBS and
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subsequently stored on ice, and this was termed the ‘insoluble fraction’ or the ‘urea- 
soluble fraction’. The fractions were analysed by SDS-PAGE and Western blotting.
2.7.6 Antibody production
Phosphorylated and unphosphorylated 16E1AE4 peptides were produced, conjugated to 
a carrier protein and injected into rabbits in order to produce polyclonal 
phosphospecific antibodies.
2.7.6.1 Peptide conjugation to carrier protein
Peptide sequences of 16E1AE4 (10-13 amino acids long) containing the target amino 
acid (phosphorylated or unphosphorylated) in the middle of the sequence were 
synthesised by Peter Fletcher (NIMR). The FastMoc solid phase peptide synthesis 
method was used, the peptides purified using reverse-phase high performance liquid 
chromatography (HPLC) and then freeze-dried (Tiburu et al., 2003). A cysteine group 
was included at the end of each sequence to enable conjugation with a maleimide- 
containing carrier protein via the cysteine’s free sulfhydryl (-SH) group (Figure 2.2). 
The carrier protein used was mariculture keyhole limpet haemocyanin (mcKLH) pre­
activated to contain maleimide groups, and the conjugation was performed using the 
Imject® Maleimide Activated mcKLH Kit (Pierce, UK). KLH was used because it 
induces a strong antibody response due to its large mass (> 106 kDa) and it has the 
advantage of being a non-mammalian protein. The manufacturer’s protocol was 
followed; 2 mg of peptide was dissolved in 300 pi of the kit’s conjugation buffer and 
allowed to mix with the pre-activated KLH for 2 h at R/T. Cysteine assays were 
performed to ensure that conjugation was efficient (see 2.6.6.2).
After conjugation, the peptide-KLH sample (the antigen) was dialysed into PBS by 
loading the sample into a Slide-A-Lyzer® cassette with a MW cut off of 10,000 Da 
(Pierce, UK) and then immersing the cassette into PBS, stirring overnight at 4 °C. 
After dialysis the protein concentration was measured using a protein assay (see 
2.6.6.2). A concentration of 0.1 -  0.2 mg/ml of antigen was used in this study. The 
antigen was filter-sterilised through a 0.2 pM filter and twelve 0.5 ml aliquots prepared 
for sending to Harlan Sera-Lab (Loughbourgh, UK).
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Figure 2.2 Outline of peptide-carrier protein coupling
mcKLH, pre-activated to contain maleimide groups, was coupled to a cysteine- 
containing peptide. The complex was then used to immunise rabbits to 
produce an antibody response against the peptide.
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2.7.6.2 Cysteine assay
Cysteine assays were performed using Ellman’s reagent (Pierce, UK), also known as 
DTNB (5,5’ -dithio-bis-(2-nitrobenzoic acid). A solution of Ellman’s reagent produces 
a measurable yellow-coloured product when it reacts with free -SH  (sulfhydryl) 
groups, so when peptide-conjugation has been successful, the level of free -SH groups 
should be lowered by at least 25 %. Four mg of Ellman’s reagent was dissolved in 1 ml 
of reaction buffer (0.1 M sodium phosphate pH 8.0, 1 mM EDTA) to produce Ellman’s 
reagent solution. A set of cysteine standards at concentrations ranging from 0 to 1.5 
mM were prepared in reaction buffer. Fifty pi of the Ellman’s reagent solution and 2.5 
ml of reaction buffer was added to 250 pi of each cysteine standard, mixed and left at 
R/T for 15 min. The absorbance at 412 nm was measured for each sample using a 1201 
UV-visible spectrophotometer (Shimadzu, UK) and the values plotted to obtain a 
standard curve. To perform the cysteine assay for peptide-KLH conjugation, 25 pi of 
solution was taken immediately following mixture of the peptide with the KLH (section
2.6.6.1) and immediately mixed with 2.725 ml of reaction buffer and 50 pi of Ellman’s 
reagent solution. After 15 min at R/T, the absorbance at 412 nm was recorded. 
Similarly, a 25 pi aliquot was taken after 2 h of peptide and KLH mixing, and a 
cysteine assay performed in the same way.
2.7.6.3 Immunisation of rabbits
For polyclonal antibody production, two New Zealand White rabbits were injected for 
each antigen by Harlan Sera-Lab (Loughbourgh, UK). Immunisations and boosts were 
delivered subcutaneously at four sites, using a total volume of 1 ml (0.5 ml antigen and 
0.5 ml of Freunds complete/incomplete adjuvant) for the immunisation and for each 
boost. The programme followed is shown below in Table 2.10.
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Table 2.10 Immunisation programme for polyclonal antibody production in 
rabbits
Day No. Action
0 Pre-bleed + Immunisation 
(Freunds Complete Adjuvant)
14 Boost 1 (Freunds Incomplete Adjuvant)
28 Boost 2 (Freunds Incomplete Adjuvant)
35 Test bleed 1
42 Boost 3 (Freunds Incomplete Adjuvant)
49 Test bleed 2
56 Boost 4 (Freunds Incomplete Adjuvant)
63 Test bleed
70 Boost 5 (Freunds Incomplete Adjuvant)
77 Terminal bleed
2.8 Statistical analysis
Means and standard deviations were calculated using Microsoft Excel. Where bar 
graphs were used to display the data, the mean values were shown and error bars used 
to represent the standard deviation. The unpaired T-test with Welch’s correction was 
performed using GraphPad InStat version 3.06 (Welch’s correction does not assume 
equal standard deviations).
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Chapter 3: Analysis o f 16E1AE4 In Vitro Phosphorylation  
Sites
3.1 Introduction
A phosphorylated form of 16E1AE4 has been reported but not characterised in any 
detail (Wang et al., 2004). To initiate a study on the phosphorylation of 16E1AE4, the 
first aim was to map the phosphorylation site(s). 16E1AE4 was phosphorylated in vitro 
and then the phosphorylation site(s) investigated using mass spectrometry (MS). This 
approach for phosphorylation studies was also used for 11E1AE4 (Bryan et al., 2000). 
The E1AE4 used was bacterially-expressed histidine-tagged 16E1AE4 (His-ElAE4) as 
this was easy to produce and purify. The kinases used were recombinant, commercially 
available protein kinases, selected based on the presence of their consensus sequence 
within 16E1AE4 (further discussed in this chapter). Some of these kinases have 
previously been reported to phosphorylate other E1AE4 proteins, so it was important to 
test for their ability to phosphorylate 16E1AE4. MS was used as the method for 
phosphorylation site mapping, for its ease, safety and ability to provide results with low 
protein levels, as compared to other mapping techniques discussed in 3.1.1.1.
3.1.1 Phosphorylation site mapping
3.1.1.1 Traditional techniques
Traditional techniques for phosphoprotein analysis involve incorporating 32P into 
cellular proteins by incubating cells with radiolabelled phosphorus (Haystead and 
Garrison, 1999; Van der Geer et al., 1999). The phosphoproteins are then detected (e.g. 
by isoelectric focusing (IEF) or high-performance liquid chromatography (HPLC)). 
The phosphoamino acid content can be determined by complete hydrolysis of the 
protein into amino acids and two-dimensional thin-layer chromatography, a technique 
allowing separation of phospho-serine, -threonine and -tyrosine. The site(s) of 
phosphorylation can be determined by proteolytic digestion of the radiolabeled protein, 
separation of the peptides (e.g. by two-dimensional thin-layer chromatography) 
followed by peptide sequencing using Edman degradation.
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3.1.1.2 Mass spectrometry (MS,)
The traditional methods of phosphorylation mapping require significant levels of 
radioactive protein, therefore in recent years they have been superseded by MS 
techniques (Mann et al., 2001; Mann et al., 2002; McLachlin and Chait, 2001). The 
basic components of MS were pioneered early in the last century by JJ Thompson 
(Thompson, 1913). MS instruments can ionise molecules in the ‘ionisation source’ and 
then sort them according to mass/charge (m/z) ratio in the ‘analyzer’ to produce a 
spectrum displaying m/z in the x-axis and relative intensity in ‘arbitrary units’ in the y- 
axis (Figure 3.1). In many cases the charge is equal to +1, so the m/z value is equal to 
the molecular mass in Daltons. Addition of a phosphate group will increase the m/z 
value by 80 units (HPO3' = 80 Da). The relative intensity is often a loose correlation 
with the actual relative amount as it may depend on how easily a molecule is ionised 
and not just on its abundance. Phosphopeptides are not easily ionisable so their peaks 
are often weak in intensity even if they are present at high levels.
For mapping phosphorylation sites of 16E1AE4, in-gel proteolyitic digestion of the 
protein was followed by analysis of the resultant peptides using matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI TOF) MS or nanospray quadrupole ion 
trap MS. In MALDI, the sample to be analysed is dissolved in a matrix and allowed to 
crystallise (Karas and Hillenkamp, 1988). Laser pulses are then used to generate 
gaseous ions for MS. TOF refers to the system used to analyse the ions (Wiley and 
McLaren, 1955). With TOF, the ions are accelerated to a fixed amount of kinetic 
energy so smaller ions have a higher velocity (or a lower time-of-flight) and are 
detected before larger ions. Nanospray MS generates ions by allowing the liquid 
sample to flow through a needle at high voltage and electrostatically disperse or 
‘electrospray’ (Wilm and Mann, 1996). The quadrupole ion trap is a different type of 
analyser to TOF. Ions are trapped between electrodes by use of radio frequency 
electric fields. Ions with increasing m/z can be sequentially ejected from the trap by 
varying the applied voltage, thus allowing a spectrum to be generated. Data from 
MALDI and from nanospray MS can therefore allow identification of phosphopeptides.
Nanospray quadrupole ion trap MS coupled with collision-induced fragmentation can 
assist in more precise mapping of phosphorylation sites (Marina et al., 1999; Ogueta et 
al., 2000). With this technique, any ion suspected to be a phosphopeptide can be
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Figure 3.1 Outline of mass spectrometry
The basic functional components of a mass spectrometer is shown in this block 
diagram (www.asms.org/whatisms/p4.html). The sample enters the vacuum 
chamber and is transformed into the gas phase and ionised. The mass analyser 
sorts the gas phase ions according to their mass/charge ratio (m/z). The ions are 
collected by a detector where they are converted into an electrical current. The 
data output shows the magnitude of the electrical signals as a function of m/z and 
this is the mass spectrum.
Chapter 3: Analysis of 16E1AE4 In Vitro Phosphorylation Sites 91
isolated within the ion trap. The ion can be bombarded with atoms of an inert gas (e.g. 
helium) causing dissociation of the ion to produce smaller ions. This fragmentation 
step can be described as ‘MS2’. An ion produced by MS2 can also be selected for the 
ion trap and subjected to even further fragmentation and this process is described as 
MS3. MS2 and if necessary, MS3, can help to narrow down the phosphorylation site or 
even identify the exact residue.
3.2 Predicted phosphorylation events for 16E1AE4
To predict phosphorylation sites for 16E1AE4, the NetPhos 2.0 Server 
(http://www.cbs.dtu.dk/services/NetPhos/) was used. NetPhos is an artificial neural 
network-based method for predicting potential phosphorylation sites at serine, 
threonine or tyrosine residues in protein sequences (Blom et al., 1999).
Crystallisation studies have suggested that —7-12 residues surrounding the phosphate 
acceptor are in contact with the kinase active site (Songyang et al., 1994), so NetPhos 
was designed to search for common patterns in the surrounding residues based on 
studies of a large set of verified phosphorylation sites. Examples of common features 
include the fact that tryptophan and cysteine rarely surround phosphorylated serines 
and basic residues are commonly found at positions -2  and -3 of phosphorylated 
threonines. Using these patterns, NetPhos predicts a score (i.e. probability) of each 
serine, threonine and tyrosine in a protein sequence, being phosphorylated. For 
16E1AE4, the amino acids with a score above 0.5 were, threonine 21, serine 32, serine 
43, serine 44, serine 49 and threonine 51, with serines 32, 43 and 44 having scores 
above 0.8 (Figure 3.2a).
Another prediction tool used was ScanProsite (http://ca.expasy.org/tools/scanprosite). 
ScanProsite scans the query protein sequence against the Prosite database (Falquet et 
al., 2002) of protein families and domains, which includes the phosphorylation site 
consensus for a few well-characterised kinases; PKA and cGMP-dependent protein 
kinases (PKG), tyrosine kinase, receptor tyrosine kinase and CKII. For 16E1AE4, the 
phosphorylation consensus sites recognized by ScanProsite, were for PKA at serine 43
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and for CKII at serine 44 (Figure 3.2b). These kinases were therefore included in the 
list of kinases to test for the ability to phosphorylate 16E1AE4 in vitro.
To decide which other protein kinases to test, the high NetPhos-scoring (>0.5) residues 
were analysed to see which (if any) protein kinase consensus sites they fit (Figure 3.3). 
It was recognized that threonine 23 falls in both the CDK consensus site (Moreno and 
Nurse, 1990; Stevenson-Lindert et al., 2003) and a MAPK consensus site (Gonzalez et 
al., 1991), serine 32 falls in a PKC consensus site (Pearson and Kemp, 1991) and a 
MAPK consensus site, serine 43 falls in the PKA (Kennelly and Krebs, 1991; 
Zetterqvist et al., 1976), PKC and calmodulin kinase II (CaMKII; Payne et al., 1983) 
consensus sites, serine 44 falls in the CaMKII, PKC and CKII (Russo et al., 1992) 
consensus sites and threonine 51 falls in the MAPK consensus site. PKA has been 
previously been shown to phosphorylate 1E1AE4 (Grand et al., 1989) and both PKA 
and p42MAPK have been reported to phosphorylate 11E1AE4 (Bryan et al., 2000).
Importantly, several of these kinases are involved in cell proliferation, growth and 
differentiation of keratinocytes in the epithelium, for example, MAPK (Mitev et al., 
1995; Seo et al., 2004), CaMKII (Praskova et al., 2002) and in particular, PKCcx 
(Bollag et al., 1993; Tibudan et al., 2002; Yang et al., 2003). PKB (also known as Akt) 
is also involved in keratinocyte survival and differentiation (Calautti et al., 2005; Janes 
et al., 2004) and although its consensus sequence, R-X-R-X-X-S/T (Alessi et al., 1996), 
is not present in 16E1AE4, it was also tested for its ability to phosphorylate His-El AE4.
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Figure 3.2 NetPhos and ScanProsite phosphorylation predictions for 16E1AE4
(a) Phosphorylation predictions by NetPhos (http://www.cbs.dtu.dk/services/NetPhos/) 
for each serine (blue), threonine (green) and tyrosine (red) are shown graphically and in 
a tabular form. The predictions are given as a probability (or maximum score of 1). 
The threshold used by NetPhos for describing a high probability is a score above 0.5. 
Residues with scores above 0.5 are serines 32, 43, 44, 49 and 73 and threonines 8, 23 
and 51. (b) ScanProsite (http://ca.expasy.org/tools/scanprosite) was used to scan 
16E1AE4 against the Prosite database. This recognised a PKA phosphorylation 
consensus site at residues 40-43 and a CKII phosphorylation consensus site at residues 
44-47.
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3.3 His-El AE4 is phosphorylated in vitro by CDK1, CDK2, p42MAPK, 
PKA and PKCa
In vitro kinase assays were performed using 1 pg of His-El AE4 as the substrate (Figure 
3.4a) and a range of commercially available recombinant protein kinases; CDK1, 
CDK2, CKII, CaMKII, p42MAPK, PKA, PKB and PKCa. Radioactive ATP (v 32P- 
ATP) was incorporated into the reaction, allowing detection of any 16E1AE4 
phosphorylation. SDS-PAGE was performed to separate 16E1AE4 and kinase and the 
dye front was run off to ensure that free 32P-ATP was removed from the gel. The gel 
was dried and a Phosphorlmager used to detect, phosphorylated protein. 
Phosphorylated 16E1AE4 was seen with CDK1, CDK2, p42MAPK, PKA and PKCa 
kinase assays (Figure 3.4b). Interestingly, p42MAPK phosphorylation caused a gel- 
shift from 14.3 kDa to approximately 16 kDa that was clearly visibly in a 15 % 
acrylamide gel (Figure 3.4b and c). Note that in this study, all gels showing 16E1AE4 
are 15 % gels since the gel-shift is difficult to visualise in a lower percentage gel. Non- 
16E1AE4 bands were seen with CKII and PKCa kinase assays with apparent molecular 
weights of 40 kDa and 80 kDa respectively (Figure 3.4b). These represented 
autophosphorylated CKII (Litchfield et al., 1991; Palen and Traugh, 1991) and PKCa 
(Liu and Heckman, 1998; Newton, 1995) respectively.
To ensure that CaMKII, CKII and PKB can phosphorylate substrates under these kinase 
assay conditions, they were tested for their ability to phosphorylate 1 pg of their known 
substrates in vitro. Bovine myelin basic protein (apparent molecular mass -20 kDa) 
was phosphorylated by CaMKII, bovine a  casein (apparent molecular mass -30 kDa) 
was phosphorylated by CKII and a glycogen synthase kinase-3 (GSK-3) fusion protein 
(apparent molecular mass -30 kDa) was phosphorylated by PKB (Figure 3.4d). This 
confirmed that these kinases are functional in these conditions, therefore 16E1AE4 must 
be a poor substrate for them.
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Figure 3.3 Protein kinase consensus sites in 16E1AE4
The 16E1AE4 amino acid sequence is shown and serines/threonines that fall in 
a protein kinase consensus site are underlined by a coloured line. Each colour 
corresponds to a different kinase; the key is shown in the table above. The 
table also shows the full consensus site for each kinase. The amino acid 
number (in the context of the 16E1AE4 sequence) for each underlined amino 
acid is indicated as a subscript. All the amino acids with a NetPhos score 
above 0.5 are indicated with their NetPhos scores aligned above them.
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Figure 3.4 In vitro phosphorylation of His-E1AE4
(a) Silver stain following SDS-PAGE of purified unphosphorylated His-E1AE4. (b) 
Autoradiograph of samples separated by SDS-PAGE following in vitro kinase assays 
with y 32P-ATP. His-E1AE4 (1 jig) was used as the substrate in CDK1, CDK2, 
p42MAPK, PKA and PKCa kinase assays, (c) Silver stain following SDS-PAGE of 
His-E1AE4 that had been subjected to kinase assay conditions in the presence (+) and 
absence (-) of p42MAPK. (d) Autoradiograph following SDS-PAGE of kinase assay 
samples; reactions were performed to confirm that CaMKII, CKII and PKB can 
phosphorylate their known substrates in vitro. The substrates used for CaMKII, CKII 
and PKB were 1 pg bovine myelin basic protein, bovine a  casein and a 
GSK-3 fusion protein respectively.
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3.4 MS mapping of phosphorylation sites
To perform mapping by MS, the protein of interest must first be digested to produce 
smaller ions/peptides that can be detected in the mass spectrometer. For His-E1AE4, 
chymotrypsin was chosen because the fragments it produced gave greater coverage of 
the protein than those produced by trypsin, when the protein was analysed post­
digestion by MALDI-TOF MS. The main sites cut by chymotrypsin are the C-terminal 
sides of phenylalanine (F), tyrosine (Y), tryptophan (W), leucine (L) and methionine 
(M) unless the next residue is proline (P). These are the cut sites considered by the 
software used to analyse the MS data, but chymotrypsin can occasionally cut at other 
sites such as alanine (A), aspartic acid (D) and glutamic acid (E). The peptides 
detected that corresponded to unphosphorylated His-E1AE4 were of m/z 2002 
(GSTWPTTPPRPIPKPSPW, residues 17-34,) and m/z 2789 (APKKHRRLSS 
DQDQSQTPETPATPL, residues 35-59; Figure 3.5). Other fragments generated by 
chymotrypsin digestion may have been too small or difficult to ionise and therefore 
undetected by MALDI. Unidentified peaks in the spectrum may correspond to 
16E1AE4 peptides produced by chymotrypsin cleavage at a non-typical site.
Addition of a phosphate group (HPO3') leads to a mass increase of 80 Da, so by 
repeating MALDI using phosphorylated His-E1AE4, phosphorylation could be detected 
when it occurred within residues 17-34 or 35-59. Although, MALDI does not cover the 
entire protein, it does cover the kinase consensus sites described earlier (Figure 3.3). 
Phosphorylation may of course occur in non-consensus sites.
His-E1AE4 was used in kinase assays with those kinases shown to phosphorylate the 
protein (CDK1, CDK2, p42MAPK, PKA and PKCa), but this time non-radioactive 
ATP was used. The resultant phosphorylated protein was isolated following 
electrophoresis by colloidal Coomassie staining and excision of the band. In-gel 
chymotrypsin digestion was performed to fragment the phosphorylated 16E1AE4 into 
peptides which were then analysed by MS. Phosphorylation by CDK1 or CDK2 gave 
an ion of m/z -2082, corresponding to addition of one phosphate to the peptide 
GSTWPTTPPRPIPKPSPW (Figure 3.6a). PKA, PKCa or p42MAPK phosphorylation 
resulted in the ion of m/z -2868, corresponding to addition of one phosphate to the 
peptide APKKHRRLSSDQDQSQTPETPATPL (Figure 3.6b). The presence of more
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Figure 3.5 MALDI of His-El AE4
Purified bacterially-expressed His-El AE4 was cleaved with chymotrypsin by in-gel 
digestion. The sample was analysed by MALDI-TOF MS and the resulting 
spectrum is shown. Ions of m/z 2002 and 2789, corresponding to E1AE4 peptides, 
are indicated (the residue numbers are also shown).
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Figure 3.6 MALDI of phosphorylated His-El AE4
Purified His-ElAE4 was phosphorylated in vitro by (a) CDK1 and CDK2, and (b) 
p42MAPK, PKA and PKCa. The phosphorylated H is-E lAE4 was digested by 
chymotrypsin and analysed by MALDI. E1AE4 ions are indicated in each MALDI 
spectrum.
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than one phosphorylation site within these ions with any single kinase assay was never 
detected by MALDI.
Nanospray coupled with collision-induced fragmentation was used to map the exact 
residues phosphorylated by the kinases. This approach was a success with His-El AE4 
phosphorylated by CDK1 and by PKA. The phosphopeptides obtained by 
phosphorylation by CDK2, p42MAPK and PKCa were too weak to be detected by 
nanospray.
His-El AE4 was phosphorylated in vitro and samples prepared for MS and digested with 
chymotrypsin. The full-scan nanospray spectrum of CDK1-phosphorylated His-ElAE4 
indicated an ion of m/z 1041.6. This corresponded to the mono-phosphorylated 
peptide, GSTWPTTPPRPIPKPSPW (residues 17-34), with a mass of 2082 Da but with 
a charge of +2, hence a m/z of 1041.6 (Figure 3.7). This ion was selected for the ion 
trap where it was further fragmented (a process called MS2). Fragmentation occurs 
along the peptide backbone, each amino acid successively fragmenting off, both in the 
N- to C-terminus direction to leave ‘y ions’ and in the C- to N-terminus direction to 
leave ‘b ions’. After ion 1041.6 was subjected to MS2 several b and y ions were 
detected (Figure 3.8).
The ions of significance included the bn ion (the subscript is the number of amino 
acids in the ion) of m/z 1516.9 corresponding to the unphosphorylated fragment, 
GSTWPTTPPRPIPK, and the ion of m/z 566.1 corresponding to the phosphorylated 
peptide, PSPW. This revealed that serine 32 is phosphorylated by CDK1. Another 
indication that 1041.6 contained a phosphate is the loss of phosphoric acid (H3PO4; 98 
Da) during fragmentation. The +2 charged ion of m/z 1041.6 lost phosphoric acid to 
leave the +1 charged ion at m/z 993. To confirm that serine 32 is the phosphorylation 
site, the y4 ion (m/z 566.1) was further fragmented (MS3). This produced a y ion of 
m/z 469.1 corresponding to the phosphorylated fragment, SPW and an ion at m/z 468.1 
corresponding to loss of phosphoric acid from PSPW (Figure 3.9).
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Figure 3.7 Nanospray of CDKl-phosphorylated His-El AE4
Purified His-ElAE4 was phosphorylated in vitro by CDK1, separated by SDS-PAGE 
and in-gel digested with chymotrypsin. The sample was analysed by nanospray MS. 
A peak at m/z 1041.6 corresponding to an El AE4 peptide is indicated. This ion was 
then selected for collision-induced fragmentation in the ion trap.
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Figure 3.8 Fragmentation of the CDKl-phosphorylated ion of m/z 1041.6
Following nanospray of CDKl-phosphorylated His-El AE4, a phosphorylated ion of 
m/z 1041.6 was detected and this was fragmented in the ion trap. The spectrum shows 
the b and y ions detected after fragmentation. Above the spectrum is a diagram of the 
peptide sequence fragmented with the corresponding b and y ions aligned. The b and y 
ions revealed that serine 32 (indicated in a box) was phosphorylated by CDK1. Also 
indicated is an ion of m/z 993 corresponding to the +2 ion of m/z 1041.6 losing a 98 Da 
phosphoric acid.
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Figure 3.9 Fragmentation of the CDKl-phosphorylated ion of m/z 566.1
Following nanospray of CDKl-phosphorylated His-El AE4, a phosphorylated ion of m/z 1041.6 was detected. This was fragmented in the ion trap 
and subsequently, an ion of m/z 566.1 was detected and suspected to contain a phosphate group. To verify this, the ion of m/z 566.1 was selected 
for the ion trap and further fragmented and the resultant spectrum is shown. Fragmentation caused loss of phosphoric acid (98 Da) leaving an ion 
of m/z 468.1. Also a y ion of m/z 469.1 was detected, corresponding to phosphorylation within the fragment, SPW (residues 32-34), showing that ! 
serine 32 w as
o
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The full-scan nanospray spectrum of PKA-phosphorylated His-ElAE4 showed an ion of 
m/z 1154.6 which corresponded to the +2 form of the mono-phosphorylated peptide, 
RRLSSDQDQSQTPETPATPL (Figure 3.10). This was selected for the ion trap for 
MS2. The significant ions detected post-fragmentation include the b4 ion of m/z 593.2 
corresponding to phosphorylation within the fragment, RRLS, and the yi6 ion of m/z 
1715.8 corresponding to the unphosphorylated peptide, SDQDQSQTPETPATPL 
(Figure 3.11). This indicated that serine 43 but not serine 44 is phosphorylated by 
PKA.
3.5 Further mapping using mutagenesis
The p42MAPK phosphorylation site had been narrowed down by MALDI to the 
peptide APKKHRRLSSDQDQSQTPETPATPL (residues 35-59). To find the exact 
amino acid phosphorylated, each serine and threonine within this region of the full- 
length protein, were mutated to an alanine, to give the His-ElAE4 mutants, S43/44A, 
S49A, T51A, T54A and T57A. Each mutant was used as the substrate in non­
radioactive p42MAPK assays (Figure 3.12). This experiment showed that T57 had no 
detectable gel-shift following p42MAPK treatment, whereas the other mutants did, 
suggesting that T57 is the phosphorylation site.
To confirm that the in vitro phosphorylation sites identified by MS are correct, site- 
directed mutagenesis was carried out to remove the identified phosphorylation sites and 
kinase assays repeated with the mutants to check for abrogation of phosphorylation. 
Serine 32 was confirmed as the CDK1 phosphorylation site so was changed to alanine 
to produce S32A His-ElAE4. A CDK1 assay and a CDK2 assay were performed using 
this mutant as substrates (Figure 3.13a). Phosphorylation by CDK1 was abolished, 
confirming that S32 is the CDK1 phosphorylation site. Phosphorylation by CDK2 was 
clearly reduced but not abolished, suggesting that S32 is phosphorylated by CDK2 but 
either there is more than one phosphorylation site, or in the absence of S32, another 
amino acid is targeted. By MS, serine 43 was found to be the PKA phosphorylation 
site, so this residue was mutated to alanine to produce S43A His-ElAE4. This mutant 
was used in a PKA assay which showed that phosphorylation was reduced but not
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Figure 3.10 Nanospray of PKA-phosphorylated His-El AE4
Purified His-ElAE4 was phosphorylated in vitro by PKA, separated by SDS-PAGE 
and in-gel digested with chymotrypsin. The sample was analysed by nanospray MS. 
An ion corresponding to the +2 form of mono-phosphorylated RRLSSDQDQSQ 
TPETPATPL was detected at m/z 1154.6. This was selected for fragmentation in the 
ion trap.
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Figure 3.11 Fragmentation of the PKA-phosphorylated ion of m/z 1154.6
Nanospray of PKA-phosphorylated His-El AE4 allowed detection of a phosphorylated 
+2 ion of m/z 1154.6 which was then fragmented in the ion trap. The spectrum shows 
the b and y ions detected after fragmentation. Above the spectrum is a diagram of the 
peptide sequence that was fragmented with the corresponding b and y ions aligned. 
The b and y ions indicated that serine 43 (shown in a box) was phosphorylated by 
PKA and no other phosphorylated residues were detected.
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Figure 3.12 p42MAPK assays using His-El AE4 mutants
Following p42MAPK phosphorylation of His-El AE4, MALDI MS identified 
a phosphopeptide spanning residues 35-59 (shown above). To map the exact 
phosphorylation site, each serine and threonine within this sequence was 
mutated to alanine to make a series of His-ElAE4 mutants. Each mutant was 
subjected to a p42MAPK assay and analysed for a gel-shift by SDS-PAGE, 
followed by silver staining.
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Figure 3.13 In vitro phosphorylation of His-El AE4 mutants
(a) Autoradiograph of CDK1, CDK2, p42MAPK and PKA in vitro kinase 
assays using WT and mutant His-ElAE4 proteins. The mutant proteins had 
the phosphorylation sites (as detected by MALDI / mutagenesis) mutated by 
replacing the serine/threonine with an alanine. (b) Further sites were 
mutated in an attempt to abolish phosphorylation by p42MAPK and PKA; 
autoradiograph following kinase assays is shown. PKC consensus site 
mutants (S32A and S43/44A) were also tested in PKCa kinase assays.
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abolished (Figure 3.13a). Similarly, the T57A mutant that previously showed no 
p42MAPK-induced gel-shift (Figure 3.12), did incorporate some ATP in a radioactive 
kinase assay suggesting that there is infact some degree of in vitro phosphorylation in 
the absence of T57 (Figure 3.13a).
The reason for the reduced but residual phosphorylation with these kinase assays was 
predicted to be because of neighbouring amino acids that may act as phosphate 
acceptors in the absence of the preferred site. Therefore, for the PKA assay, the serine 
residue that neighbours S43 was also changed to alanine, to give a double mutant, 
S43/44A. When this mutant was used in a PKA assay, there was no longer any 
phosphorylation, in agreement with the prediction (Figure 3.13b). Similarly, threonines 
51 and 54 were also changed to alanines to give the mutants T54/57A and T51/54/57A, 
as these threonines fall in MAPK consensus regions (Figure 3.3) so may be 
phosphorylated in the absence of T57. When T54/57A was used in a p42MAPK assay,
'X'ythe P signal was abolished (Figure 3.13b), showing that T54 had caused the low level 
phosphorylation of T57A.
A PKCa phosphorylation site had been mapped to the peptide APKKHRRLSSDQD 
QSQTPETPATPL (residues 35-59) by MALDI. 16E1AE4 has three consensus sites for 
PKC, at serine 32, serine 43 and serine 43, so the latter two fall within this peptide. 
The S32A mutant and S43/44A mutant were tested in PKCa assays, however both 
retained wild-type levels of phosphorylation (Figure 3.13b). PKCa may therefore 
target all consensus sites, or another site within this peptide.
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3.6 Discussion
This study has demonstrated that 16E1AE4 has several candidate phosphorylation sites 
and CDK1, CDK2, PKA, PKCa and p42MAPK can phosphorylate bacterially- 
expressed 16E1AE4 in vitro. Interestingly, phosphorylation by p42MAPK causes a gel- 
shift of His-El AE4, suggesting a structural change. The in vitro phosphorylation sites 
have been mapped for some of these kinases. CDK1 and CDK2 phosphorylate at 
serine 32, PKA phosphorylates at serine 43 and p42MAPK phosphorylates at threonine 
57. It has been shown, however, that if these sites are mutated the corresponding 
kinase can phosphorylate other sites in vitro. This must be considered when producing 
phosphorylation mutants for functional analysis, for example, to ensure total abrogation 
of PKA phosphorylation, both serines 43 and 44 should be mutated, since serine 44 
appears to be phosphorylated in the absence of serine 43.
The phosphorylation sites of PKA and p42MAPK fit the classical consensus sites for 
these kinases, but the CDK1 and CDK2 phosphorylation site at serine 32 does not fit 
the S/T-P-X-R/K consensus as it lacks the R/K residue. Surprisingly, there was no 
detection of phosphorylation at threonine 23 by CDK1 even though this falls in the 
only CDK consensus site present. This is supported by the absence of phosphorylation 
in the peptide of residues 17-30 (m/z 1516.9) after collision-induced fragmentation of 
the phosphorylated peptide (residues 17-34, m/z 1041.6). Threonine 23 was shown to 
be required for E lAE4-induced G2 arrest in S.pombe since a mutation to alanine 
abolished arrest, however, mutating to the phosphate mimics, glutamic or aspartic acid, 
did not rescue arrest (Davy et al., 2002). This also suggests that threonine 23 
phosphorylation may not be important.
Phosphorylation by CDK at a non-consensus site is not uncommon and has been 
reported for several proteins, for example poly (A) polymerase (Colgan et al., 1998), 
ribosomal S6 kinase 1 (Shah et al., 2003) and cytoplasmic polyadenylation-element- 
binding protein (CPEB; Thom et al., 2003). CDK substrate interaction is believed to 
depend on bipartite motif recognition of the substrate; a cyclin-binding motif and the 
phosphorylation site (Takeda et al., 2001). The existence of two types of substrate have 
been proposed; the first is a high turnover substrate that has a consensus 
phosphorylation site but binds weakly to cyclin/CDK, the second is a low turnover
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substrate which binds tightly to cyclin/CDK but has a non-consensus phosphorylation 
site (Murray, 2004). 16E1AE4 may prove to be in the latter group.
The MS method for phosphorylation mapping is frequently used, however, it is difficult 
to achieve total coverage of the protein. In this case, only residues 17-59 were covered 
out of the 92 amino acids of 16E1AE4. The low level phosphorylation of the S32A 
mutant by CDK2 and the phosphorylation of the S32A and S43/44A mutants by PKC 
could therefore also be explained by an additional phosphorylation site in a region not 
covered by MALDI. The existence of phosphorylation sites outside these regions was 
disproved for CDK1, PKA and p42MAPK because mutagenesis within these regions 
abolished phosphorylation by these kinases. The other problem with MS is that 
phosphorylated ions rarely give intense peaks, as phosphorylation makes peptides 
negatively charged causing weak ionisation in the positive mode in the mass 
spectrometer. The absence of strong peaks for some of the phosphorylation events 
prevented successful phosphorylation mapping by nanospray coupled with collision- 
induced fragmentation.
The phosphorylation events described in this chapter are of great interest and value, 
however, these events occured in vitro where the conditions are perhaps more 
favourable for phosphorylation than they are in vivo. For example, the kinase 
concentrations were high and phosphatases or any other inhibitory factors were absent. 
It is therefore important to analyse 16E1AE4 phosphorylation in mammalian cell 
culture or in vivo. The next chapter describes phosphorylation events of 16E1AE4 
when it is expressed in SiHa cells.
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Chapter 4: Analysis of 16E1AE4 Phosphorylation Sites in Cell 
Culture
4.1 Introduction
Following the mapping of in vitro phosphorylation sites of 16E1AE4 in Chapter 3, it 
was important to determine the in vivo phosphorylation sites. The extraction and 
analysis of 16E1AE4 from infected lesions is difficult especially if the tissue has been 
formalin- fixed. Instead, the protein was expressed and analysed in cell culture. The 
main aim was to determine which (if any) of the in vitro phosphorylation sites are 
phosphorylated when the protein is expressed in cultured cells. The 16E1AE4 protein 
was expressed in SiHa cells using recombinant adenovirus (rAd) infection or plasmid 
transfection. SiHa cells are a cervical cancer cell line, containing integrated HPV16 
DNA and expressing E6 and E7 but not E1AE4. Being an HPV-transformed cell line, 
SiHa cells are a good choice of cell type to analyse E1AE4 post-translational 
modifications and activities.
The approaches used to investigate 16E1AE4 phosphorylation in cells included the use 
of lambda (X) phosphatase, the phosphatase inhibitor, okadaic acid (OA) and protein 
kinase inhibitors. Detection of phosphorylated 16E1AE4 was attempted using 
phosphotyrosine-, phosphoserine- and phosphothreonine-specific antibodies. The use 
of such antibodies is potentially a much simpler method for phosphoamino acid 
analysis compared to traditional techniques involving amino acid hydrolysis (see
3.1.1.1). Isoelectric focusing (IEF; see 4.1.1) was a technique used to separate 
differentially phosphorylated forms of 16E1AE4 and was found to be useful for 
purification of the protein for phosphorylation mapping by MALDI. In addition, site- 
directed mutagenesis was used to remove phosphorylation sites proposed in Chapter 3 
from the in vitro kinase assays. The mutant 16E1AE4 proteins were then analysed for 
their ability to be phosphorylated in cells.
4.1.1 IEF (isoelectric focusing) and isoelectric point (pi)
IEF is a useful tool for analysing the phospho-status of proteins since it allows the 
isoelectric point (pi) of a protein to be determined. The pi of a protein is the pH at 
which the protein has no overall charge, and addition of a phosphate group will lower
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the pi as phosphates are negatively charged (Hardie, 1999). The theoretical pi can be 
calculated from the protein sequence. Ionisable groups include the N-terminal residue, 
lysine, arginine and histidine, which have the potential to be positively charged, and the 
C-terminal residue, aspartic acid and glutamic acid, which can become negatively 
charged. The number of each of these ionisable groups must be known to calculate the 
pi (Bjellqvist et al., 1993). The effect of phosphorylation on the pi can also be 
estimated. The calculated pi can be inaccurate however, because it considers each 
ionisable residue in isolation and does not take into account the influence of 
neighbouring residues on the charge. Table 4.1 shows the theoretical pis of 
unphosphorylated and phosphorylated forms of 16E1AE4 as calculated by Scansite 
(http://scansite.mit.edu/calc_mw_pi.html; Obenauer et al., 2003).
Table 4.1 Scansite pi prediction
Theoretical pis of unphosphorylated and phosphorylated forms of 16E1AE4 as 
calculated by Scansite (http://scansite.mit.edu/calc_mw_pi.html).
Number of phosphorylation 
events
0 1 2 3 4
pi 9.14 8.02 7.03 6.57 6.22
IEF was first introduced in 1975 (Klose, 1975; O'Farrell, 1975). It involves the 
production of a pH gradient in which proteins can be separated electrophoretically 
according to pi. The original method for creating a gel with a pH gradient used carrier 
ampholytes (small organic molecules with various isoelectric points and high buffering 
capacities). When a voltage is applied across an ampholyte mixture, they migrate in 
the gel until they reach their isoelectric point, thus a pH gradient is produced. Due to 
some limitations of carrier ampholytes (e.g. the poor reproducibility due to drift of 
ampholytes towards the cathode), the immobilised pH gradient (IPG) was later 
introduced (Bjellqvist et al., 1982). An IPG gradient is formed by covalently 
incorporating acidic and basic buffering groups into the acrylamide matrix at the time 
the gel is cast. Gels with immobilised pH gradients are commercially available. The 
IPG system was used for all IEF experiments described in this study. Following IEF, 
proteins are generally separated according to molecular mass by SDS-PAGE. The IEF
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step is termed the ‘first dimension’ and the SDS-PAGE step is termed the ‘second 
dimension,’ and the overall technique referred to as two-dimensional SDS-PAGE (2D 
SDS-PAGE; Figure 4.1).
4.2 16E1AE4 expressed in cell culture separates into different 
migratory forms by SDS-PAGE
16E1AE4 was expressed in SiHa, NIKS and C33A cells from the CMV promoter of a 
recombinant adenovirus vector (rAdElAE4). More than one migratory form was seen 
after SDS-PAGE with a 15 % acrylamide gel and Western blotting with the anti- 
16E1AE4 mouse monoclonal, TVG402 (Figure 4.2a). The protein migrated as a 13 kDa 
band and a 14 kDa band in all three cell lines. However, in C33A cells, the 14 kDa 
appeared weaker and there was an additional band at -10  kDa. Probing with an anti-N- 
terminus antibody failed to detect the 10 kDa form although this antibody detected the 
13 kDa band (Figure 4.2b). This suggests that N-terminal cleavage can occur in cell 
culture, particularly in C33A cells. When monitoring 16E1AE4 expressed in SiHa cells 
over a 24 h period, Western blotting with TVG402 showed that the 13 kDa band was 
detected first, followed by the gradual appearance of the 14 kDa band (Figure 4.2c).
4.3 The upper band (14 kDa) of 16E1AE4 is a phosphorylated form
SiHa cells were infected with rAdElAE4 for 24 h before harvest. The cells were lysed 
with Empigen and the cell extract treated with/without X phosphatase. X phosphatase is 
a serine/threonine/tyrosine phosphatase from bacteriophage X (Cohen and Cohen, 
1989). The proteins in the cell extract were then separated by SDS-PAGE and 
16E1AE4 detected by Western blotting with TVG402 (Figure 4.3a). The Western blot 
showed that the upper band (14 kDa band) was removed by X phosphatase. This result 
suggests that the upper band corresponds to a gel-shift produced as a result of serine, 
threonine or tyrosine phosphorylation. Interestingly, this gel-shift is similar to that seen 
following in vitro phosphorylation by p42MAPK (Figure 3.4b and c).
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Figure 4.1 Outline of 2D SDS-PAGE
The diagrams below represent the main steps of the 2D SDS-PAGE protocol used in 
this study, (a) The sample is applied at the acidic end (anode) of a gel strip 
containing an immobilised pH gradient (IPG), (b) A voltage is applied across the 
gel. All proteins (basic shown as blue and acidic as red) migrate until they reach the 
pH at which they have no charge (i.e. their isoelectric point), then isoelectric 
focusing (IEF) or the first dimension is complete, (c) The second dimension uses 
SDS-PAGE to separate all the proteins according to size.
(a) Sam ple application
11 10 9
pH
8 7 6
(b) IEF I First Dim ension
(c) Second  Dim ension
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Figure 4.2 Expression of E1AE4 in cultured cells
(a) SiHa cells, NIKS and C33A cells were infected with rAdElAE4 for 24 h, then 
the cell extracts analysed by SDS-PAGE and Western blotting using the anti- 
El AE4 antibody, TVG402. (b) E1AE4 was expressed in C33A cells using
rAdElAE4, separated by SDS-PAGE and Western blotting performed, first with an 
antibody that detects the N-terminus of 16E1AE4, then with TGV402 which 
recognises a central epitope of 16E1AE4. (c) SiHa cells were infected with
rAdElAE4 and harvested at timepoints ranging between 6 and 24 h post-infection.
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SiHa cells were again infected with rAdElAE4 for 24 h but treated with OA dissolved 
in ethanol or ethanol alone (as a negative control) for 1 h before harvesting. OA is a 
marine toxin that accumulates in filter feeding organisms such as shellfish and the 
sponge, Halichondria okadai, from which its name derives. It is a potent inhibitor of 
the mammalian serine/threonine phosphatases, protein phosphatase 1 and protein 
phosphatase 2 (PP1 and PP2 respectively; Bialojan and Takai, 1988). 16E1AE4 was 
detected once again by Western blotting, revealing that the upper band appeared 
stronger after OA treatment (Figure 4.3b). This suggests that the upper band contains 
phosphorylated serine or threonine or both. This also suggests that PP1/PP2 normally 
dephosphorylate 16E1AE4 in SiHa cells or that they negatively regulate the kinase that 
acts on 16E1AE4.
4.4 Use of phosphospecific antibodies
Phosphoserines and phosphothreonines are more abundant in cells than 
phosphotyrosines (Galski et al., 1983) however there is a greater choice of good 
phosphotyrosine-speciflc antibodies commercially available compared to antibodies for 
phosphoserine and phosphothreonine. The PY20 clone of mouse monoclonal anti- 
phosphotyrosine was used to try to detect phosphotyrosine in immunoprecipitated 
16E1AE4. Tyrosine 10 is the only tyrosine residue in the 16E1AE4 sequence. Although 
its NetPhos score for phosphorylation is low (0.218; Figure 3.1a), the detection of 
phosphotyrosine was attempted. 16E1AE4 was expressed in SiHa cells using rAd and 
was successfully immunoprecipitated as shown by Western blotting with TVG402 
(Figure 4.4a). When probed with PY20, however, no band corresponding to E1AE4 
was detected (long exposure of the blot led to detection of the light chain of the 
antibody used for the immunoprecipitation, probably due to non-specific interaction 
with the anti-mouse secondary antibody) although PY20 did detect active recombinant 
p42MAPK phosphorylated at tyrosine 185 (Figure 4.4b). Similar experiments were 
attempted with the mouse monoclonal anti-phosphoserine antibody, clone PSR-45, and 
the mouse monoclonal anti-phosphothreonine antibody, clone IE 11, however, even 
after several attempts, the background signal after Western blotting was very high 
indeed and no conclusions could be made (data not shown).
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Figure 4.3 Effect of 1 phosphatase and okadaic acid on E1AE4
(a) Western blot of E1AE4 expressed using rAd in SiHa cells. The cell extracts were 
treated with (+) or without (-) X phosphatase prior to SDS-PAGE. (b) Western blot 
of E1AE4 expressed using rAd in SiHa cells. The cells were treated with (+) or 
without (-) okadaic acid (OA; a phosphatase inhibitor) for 1 h before harvest.
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Figure 4.4 Immunoprecipitation of E1AE4 and Western blot with an anti- 
phosphotyrosine antibody
(a) E1AE4 was expressed in SiHa cells using rAd, then immunoprecipitated using an 
anti-MBPElAE4 rabbit polyclonal. Immunoprecipitated E1AE4 was detected by 
Western blotting using the mouse monoclonal, TVG402. The same membrane was 
probed with the anti-phosphotyrosine antibody, PY20. (b) Bacterially expressed 
recombinant p42MAPK containing phosphotyrosine was run in a separate lane and 
detected by PY20.
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4.5 There are two main phosphorylation events of 16E1AE4 in SiHa 
cells
Phosphorylation is known to alter the pi of proteins, thus changing the way a protein 
migrates in IEF. Unphosphorylated 16E1AE4 is predicted to have a basic pi of 9.14 
(Table 4.1), so IPG strips ranging from pH 6 to pH 11 were used to obtain good 
resolution. The pi of 16E1AE4 with up to four phosphates is predicted to fall within 
this pH range (Table 4.1). Extracts from rAdElAE4-infected SiHa cells were treated 
with/without X phosphatase and prepared for IEF. Following 2D SDS-PAGE, 
16E1AE4 was detected by Western blotting. Without X phosphatase, 16E1AE4 had 
three isoelectric variants since three spots were observed (pi values ~9.2, 8 and 6.7; 
Figure 4.5a). With X phosphatase, only the most basic spot of pi -9.2 was seen (Figure 
4.5a), suggesting that the other spots corresponded to phosphorylated forms. Indeed, 
the spots observed at pH 8 and pH 6.7 are close to the predicted pis for mono- and di- 
phosphorylated E1AE4, although the latter is about 0.3 pH units out (Table 4.1). The 
existence of more than two phosphorylation sites is possible, but these forms (16E1AE4 
with three or four phosphates) are predicted to appear within the pH 6-11 range but 
were not detected by Western blotting with TVG402. Attempts were made to separate 
the X phosphatase-negative sample in pH 3-10 IPG strips in order to identify any acidic 
forms (Figure 4.5b). However, the focusing was very poor and the phosphorylated 
forms seen with pH 6-11 were now difficult to visualise. IEF of basic proteins is 
notoriously difficult because of problems with the reducing agent, DTT, migrating 
towards the acidic end, leaving basic proteins vulnerable to disulphide bonding and 
desolubilisation (Bae et al., 2003). This may explain the poor focusing in the pH 3-10 
gradient compared with the focusing in pH 6-11 gradients.
4.6 Expression of phosphorylation mutants of 16E1AE4 in SiHa cells
To investigate the role of 16E1AE4 phosphorylation, the in vitro phosphorylation sites 
mapped in Chapter 3 were mutated to alanines to produce phosphorylation mutants for 
expression in SiHa cells. The pMVl 1.16E1AE4 construct, which contains a CMV 
promoter, was used as the template to perform site-directed mutagenesis to produce the 
mutants. A S32A mutant was produced to remove potential CDK1/2 phosphorylation,
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Figure 4.5 2D SDS-PAGE of E1AE4 expressed using rAd
(a) 2D SDS-PAGE of E1AE4 expressed in SiHa cells using rAd. A pH gradient of pH 
6-11 was used, and Western blotting with TVG402 performed to detect E1AE4. The 
cell extracts had been treated with (+) or without (-) X phosphatase, (b) Western blot 
to detect E1AE4 from the X phosphatase-negative sample separated by 2D 
SDS-PAGE in a pH 3-10 gradient.
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a S43/44A mutant produced to remove the potential PKA phosphorylation site, and two 
mutants, T57A and T54/57A, produced to remove potential p42MAPK 
phosphorylation. In addition, a phosphorylation mimic, T57D, was also produced to 
mimic constitutive phosphorylation of threonine 57. These constructs were expressed 
by transient transfection to investigate the effects of the mutations.
4.6.1 Expression of T57A and T57D
In vitro, p42MAPK phosphorylation causes a gel shift (3.5b and c) and WT 16E1AE4 
from mammalian cells shows an upper band following SDS-PAGE, corresponding to a 
phosphorylated form (Figure 4.3). Changing threonine 57 to alanine was sufficient to 
remove the upper band seen with WT 16E1AE4 in SiHa cells indicating that this residue 
alone is responsible for the phosphorylation-induced gel-shift in SiHa cells (Figure 
4.6a). The T54/57A mutant also lacked the upper band (data not shown) but the T57A 
mutant was used in experiments as this protein sequence was closer to WT. A mutant 
16E1AE4 with threonine 57 changed to aspartic acid (D) was also produced. Aspartic 
acid or glutamic acid are frequently chosen to replace phosphorylated serines, 
threonines or tyrosines to mimic constitutive phosphorylation. Examples include the 
mimicking of phosphorylated HPV16 E7 using aspartic acid (Massimi et al., 1996) and 
phosphorylated BPV1 El using aspartic acid or glutamic acid (McShan and Wilson, 
2000). These amino acids are chosen because they can become negatively charged to 
resemble residues with a negative phosphate group (Figure 4.6b). As expected, the 
T57D mutant migrated slower in SDS-PAGE, similar to the phosphorylated upper band 
of WT 16E1AE4 (Figure 4.6a). This is a good indication that this mutant can mimic 
phosphorylation.
4.6.2 Solubility fractionation of WT and mutant 16E1AE4
WT and mutant 16E1AE4 were expressed by transfection in SiHa cells. At 24 h post­
transfection, the cells were harvested and fractionated. The cells were lysed in 0.5 % 
NP40 and then centrifuged to obtain the supernatant which was the NP40-soluble 
fraction. The remaining cell extract (the pellet) was suspended in 0.8 % Empigen to 
obtain the Empigen-soluble fraction and the residual pellet was suspended in 9 M urea 
to obtain the insoluble fraction. NP40 is a non-ionic detergent useful for extracting
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Figure 4.6 Mutating threonine 57 to alanine and aspartic acid
(a) Western blot of T57A, WT and T57D E1AE4 expressed in SiHa cells by
transfection, (b) Structures of threonine, phosphorylated threonine and the amino
acids used to replace threonine 57, alanine (A) and aspartic acid (D).
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membrane proteins, while Empigen is a zwitterionic detergent useful for solubilising 
keratins. Detergents can solubilise proteins by interaction of the hydrocarbon tail of the 
detergent with the hydrophobic region of the protein to form a suspension of detergent- 
protein complexes (http ://www. merckbi osciences. co. uk/Sharedlmages/T echni cal 
Literature/l_Detbooklet_2001.pdf). Urea is a powerful protein denaturant that forms 
strong hydrogen-bonds with proteins thus interfering with the usual hydrogen-bonds 
between proteins and water molecules (Tobi et al., 2003).
Following fractionation, the 16E1AE4 was detected by Western blotting. The S32A 
and S43/44A mutants had an upper band and appeared similar to WT (Figure 4.7a). 
Interestingly, the upper band appeared predominantly in the insoluble (urea) fraction. 
As expected, the T57A and T57D mutants appeared as single bands. Overall, a similar 
distribution was observed for WT and mutant forms between the different fractions, 
with most of the 16E1AE4 protein appearing in the Empigen and insoluble (urea) 
fractions.
4.6.3 Immunostaining of WT and mutants
The typical staining patterns for 16E1AE4 involve colocalisation with keratin, either in 
a filamentous pattern or in aggregates corresponding to 16ElAE4-induced keratin 
collapse. To decipher any variations in cellular distribution resulting from the 
mutations, the S32A, S43/44A, T57A and T57D mutants together with the WT, were 
also analysed by fluorescent immunostaining at 24 h post-transfection. 16E1AE4 was 
detected with the antibody, TGV405, and keratin was detected using an anti-pan­
keratin antibody. The staining patterns were divided into four categories: i) keratin and 
16E1AE4 colocalisation and no keratin collapse, ii) keratin colocalisation and partial 
keratin collapse, iii) keratin colocalisation and full keratin collapse or iv) no keratin 
colocalisation (Figure 4.7b). No keratin colocalisation could mean colocalisation with 
mitochondria, but mitochondria were not stained in this experiment, or it could mean 
16E1AE4 has already caused keratin collapse and the keratin has been degraded 
(personal communication, Peter Laskey). Low-level 16E1AE4 that was diffuse (i.e. did 
not form filamentous or collapsed structures) and difficult to detect by immunostaining, 
was not included in the analysis.
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16ElAE4-positive cells were counted and classed into one of the four categories. The 
experiments were performed in triplicate, using 300 cells in total for each type of 
16E1AE4 tested. The means were plotted and the standard deviations indicated (Figure 
4.7b). The results showed that the vast majority of cells (about 70 %) had 16E1AE4 
and keratin colocalisation without keratin collapse and there were no significant 
differences in 16ElAE4/keratin patterns between the WT and mutants. Of course, there 
was likely to have been a sub-population of cells with low-level 16E1AE4 which could 
not be analysed.
4.7 Identification of 16E1AE4 phosphorylation sites in SiHa cells
The requirement for T57 for the occurrence of the gel-shift is clear, since the T57A 
mutant lacks the upper band that the WT protein shows. However, whether the absence 
of the gel-shift with T57A is actually due to lack of phosphorylation or a structural 
effect of alanine replacing threonine, needed to be determined. It was also necessary to 
investigate whether S32 or S43/44 are actually phosphorylated in SiHa cells. It was 
decided to analyse each mutant by 2D SDS-PAGE to compare the number of 
phosphorylated forms to that of WT. The WT and mutant proteins were expressed by 
transfection of pM V ll constructs. When WT 16E1AE4 was separated by 2D SDS- 
PAGE and Western blotted, only the spots at pH 9.2 and 8 were easily seen and a third 
spot at pH 6.7 observed only after overnight exposure (Figure 4.8a). This is different to 
the rAd-expressed 16E1AE4 that gave three clear spots, suggesting that rAd infection 
may enhance the level of phosphorylation.
In order to compare phosphorylation of the mutants with the WT, however, conditions 
permitting optimal phosphorylation levels were required. WT 16E1AE4 was expressed 
by transfection, the cells incubated with the phosphatase inhibitor, OA, for one hour 
before harvest (cells were harvested at 24 h post-transfection). OA was also added 
during lysis of the cells. 2D SDS-PAGE and Western blotting were performed to 
detect the WT 16E1AE4, and this time, spots at -pH  8 and -pH  6.7 were seen, 
corresponding to mono- and di-phosphorylated 16E1AE4 respectively (Figure 4.8b). 
OA treatment therefore resulted in complete 16E1AE4 phosphorylation as the
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Figure 4.7 Fractionation and immunostaining of phosphorylation mutants
(a) Western blots using TVG402 to detect WT and mutant E lAE4s following 
solubility fractionation using NP40, Empigen and urea solutions. (b) SiHa cells 
were immunostained for E1AE4 and keratin at 24 h post-transfection of WT and 
mutant E1AE4 constructs. The staining patterns were classed into four categories: 
‘keratin and E1AE4 colocalisation and no keratin collapse’, ‘keratin colocalisation 
and partial collapse’, ‘keratin colocalisation and full collapse’ or ‘no keratin 
colocalisation’. An example of each category is indicated showing E1AE4 in green 
and keratin in red. The percentage of cells in each category were recorded and mean 
values represented in a bar graph. The error bars indicate the standard deviation.
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unphosphorylated form at pH 9.2 was not detected. As this method provided a way to 
enhance 16E1AE4 phosphorylation in transfected SiHa cells, it was repeated with the 
mutants. After OA treatment and 2D SDS-PAGE of the mutant proteins, it was shown 
that the S43/44A mutant had a similar degree of phosphorylation to WT, but the S32A 
and T57A mutants had less phosphorylation, demonstrated by absence of a spot at pH 
6.7 and presence of a spot at pH 9.2 (Figure 4.8b). This supports the fact that T57 is 
phosphorylated in SiHa cells and suggests that S32 is also phosphorylated.
Another approach to map 16E1AE4 phosphorylation sites in cell culture is to purify 
16E1AE4 from the cells and analyse it by MS. This is the ideal approach, but 
technically difficult as the level of protein required must be high enough to be stained 
by Coomassie. Immunoprecipitation of 16E1AE4 was attempted but to achieve 
sufficiently high levels of 16E1AE4, the amount of antibody used was very high and 
only peptides corresponding to antibody fragments were detected by MALDI (data not 
shown). As an alternative to immunoprecipitation, an IEF approach was used as a 
method to separate 16E1AE4 from cellular proteins and use for MS. 16E1AE4 was 
expressed in SiHa cells using rAdElAE4 and separated by SDS-PAGE in triplicate, but 
the IEF protocol was bulked-up ten-fold for each IEF run. A negative control sample 
was also prepared using rAdpGAL-infected SiHa cells. The pGAL gel and one of the 
16E1AE4 gels were silver stained. By Western blotting another 16E1AE4 gel to detect 
16E1AE4 and comparing both silver stained gels, a silver stained spot corresponding to 
mono-phosphorylated 16E1AE4 could be detected (Figure 4.9a). The third 16E1AE4 
gel was stained with colloidal Coomassie (not shown) and this spot was excised for 
MALDI analysis. Interestingly, in this experiment, it appeared that the mono- 
phosphorylated form of 16E1AE4 was more abundant than the unphosphorylated or di- 
phosphorylated forms, as only this spot could be detected by silver stain. 
Chymotrypsin digestion and MALDI revealed an ion of m/z 2066 corresponding to the 
unphosphorylated, oxidated (+ 2CE) peptide GSTWPTTPPRPIPKPSPW (amino acids 
17-34) and an ion of m/z 2868 corresponding to the presence of one phosphate in the 
peptide APKKHRRLSSDQDQSQTPETPATPL (amino acids 35-59; Figure 4.9b). 
Exact mapping by collision-induced fragmentation was not possible as the protein level 
was too low. However, the MALDI result does support the existence of
phosphorylation at T57 and suggests that S32 phosphorylation does not occur in the 
mono-phosphorylated form. It is tempting to speculate that T57 phosphorylation may
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Figure 4.8 2D SDS-PAGE of phosphorylation mutants
(a) WT E1AE4 expressed by transfection (with a pM Vll 
construct) and WT E1AE4 expressed using rAd, were compared by 2D SDS- 
PAGE. Western blotting with TVG402 was used to detect E1AE4. An overnight 
exposure of the Western blot of the transfection sample, is also shown, (b) E1AE4 
was expressed by transfection and WT E1AE4 treated with (+) or without (-) OA. 
Mutant E1AE4 samples were treated with OA. All samples were compared by 2D 
SDS-PAGE and Western blotting.
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Figure 4.9 MALDI of El AE4 expressed in SiHa cells
(a) SiHa cells were infected with rAdElAE4 and the extracts separated by 2D SDS- 
PAGE in triplicate. SiHa cells were also infected with rAdpGAL, the sample used for 
a single 2D SDS-PAGE run, and used as the negative control (i.e. E lAE4-negative). 
One E lAE4-positive gel was used for Western blotting with TVG402, the second gel 
used for silver staining and the third used for colloidal Coomassie (third gel not 
shown). The E lAE4-negative (pGAL-containing) gel was silver stained and compared 
with the E lAE4-positive gels, in order to allow identification of any spots 
corresponding to E1AE4. (b) The E1AE4 spot at pH 8 was excised from the colloidal 
Coomassie-stained gel, chymotrypsin digested and analysed by MALDI. The MALDI 
spectrum is shown and the E1AE4 ions of m/z 2066 and m/z 2868 are indicated.
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occur before S32 phosphorylation.
4.8 MEK inhibitors reduce 16E1AE4 phosphorylation in SiHa cells
Kinase inhibitors were used to find whether a MAPK pathway is involved in the 
phosphorylation of 16E1AE4 in SiHa cells. The inhibitors, SB203580, PD98059 and 
U0126 or DMSO (negative control) were added to the cell culture media 6 h following 
infection of the SiHa cells with rAdElAE4. The cells were harvested after incubation 
with the inhibitors for 18 h. SB203580 inhibits p38MAPK by blocking its ATP 
binding site and PD98059 and U0126 bind MEK1 and MEK2 in a non-ATP 
competitive manner preventing them from activating p42 or p44MAPK (English and 
Cobb, 2002; Figure 4.10a). After the cell extracts were analysed by Western blotting to 
detect 16E1AE4, it was seen that the upper band was reduced in the samples treated 
with MEK inhibitors but not in the sample treated with the p38 inhibitor or in the 
negative control (Figure 4.10b). This suggests that downstream effectors of MEK 
cause the phosphorylation-induced gel-shift of 16E1AE4. MEK activates p42 and 
p44MAPK (Figure 1.4) so one or both of these MAPKs are likely to phosphorylate 
16E1AE4 to produce the upper band.
4.9 A CDK1/2 inhibitor reduces 16E1AE4 phosphorylation in SiHa 
cells
To test for a role for CDK1 or CDK2 in 16E1AE4 phosphorylation, the CDK1/2 
inhibitor, Roscovitine, was used (Figure 4.11a). Roscovitine inhibits CDK1/2 by 
competing with ATP but does not inhibit CDK4/cyclin D or CDK6/cyclin D complexes 
(Meijer et al., 1997). SiHa cells were infected with rA dElAE4 for 6 h, then 
Roscovitine or DMSO (as a negative control) was added to the cell culture media. The 
cells were harvested 16 h later and the extracts subjected to 2D SDS-PAGE. Following 
Western blotting with TVG402, it was seen that the Roscovitine-treated sample showed 
a significantly weaker spot at pH 6.7 compared with the Roscovitine-negative sample 
(Figure 4.1 lb). The spots at pH 9.2 and 8 were similar in both samples. The fact that 
the presence of Roscovitine lowered the degree of phosphorylation suggests that CDK1
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Figure 4.10 Treatment with MAPK inhibitors
(a) The structures of the MAPK inhibitors, SB 203580, PD 98059 and U 0126 
are illustrated and their IC50 values indicated (IC50 is the concentration of 
inhibitor needed to inhibit 50 % of the reaction), (b) Western blot of E1AE4 
expressed (using rAd) in SiHa cells, which were incubated with the different 
MAPK inhibitors. Each inhibitor was used alone and in conjunction with 
others.
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Figure 4.11 Treatment with Roscovitine
(a) The structure of the CDK1 and CDK2 inhibitor, Roscovitine and its IC50 value are 
shown, (b) Western blots of E1AE4 expressed using rAd in SiHa cells and separated 
by 2D SDS-PAGE (in pH 6-11). The rAd-infected cells had been treated with (+) or 
without (-) 30 pM Roscovitine.
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or CDK2 or both, can cause phosphorylation of 16E1AE4 in SiHa cells.
4.10 Discussion
4.10.1 16E1AE4 phosphorylation events in cell culture
16E1AE4 was expressed in cultured cells to reveal different migratory forms following 
SDS-PAGE. In all cells tested, a 14 kDa band and 13 kDa band were seen and in 
C33A cells, a 10 kDa form was detected. The upper band (14 kDa) was shown to 
correspond to a phosphorylated form while the 10 kDa band was an N-terminally 
truncated form. A phosphorylated form of 16E1AE4 that causes a gel-shift has not been 
previously reported in any detail, but N-terminally truncated forms of E1AE4 have been 
reported particularly for HPV1.
The phosphorylation status of 16E1AE4 expressed in SiHa cells was analysed to reveal 
that threonine 57 and serine 32 are phosphorylated. Threonine 57 phosphorylation is 
mediated by the MEK-p42/p44MAPK pathway and does not appear to involve 
p38MAPK. This phosphorylation event appears to cause a structural change since it 
causes a slower-migrating band in SDS-PAGE. Serine 32 is phosphorylated by 
CDKl/cyclin or CDK2/cyclin or both. Phosphorylation of tyrosine was not detected 
with an anti-phosphotyrosine antibody. Similarly, phosphoamino acid analysis of 
11E1AE4 from xenograft tissue did not detect phosphotyrosine (Bryan et al., 2000).
The evidence for these sites being phosphorylated comes from IEF experiments which 
suggest that phosphorylation is reduced in the T57A and S32A mutants. In addition, 
the T57A mutant loses the slower-migrating, phosphorylation-induced form that the 
WT possesses, whereas the T57D phosphorylation mimic appears as a slower- 
migrating band. Also, when WT 16E1AE4 was separated by IEF and analysed by 
MALDI, the mono-phosphorylated form was found to possess a phosphate within 
amino acids 35 to 59. Interestingly, no phosphorylation at serine 32 was detected by 
MALDI in this mono-phosphorylated form. This suggests that in rAd-infected SiHa 
cells, threonine 57 phosphorylation may take place before serine 32 phosphorylation. 
This may occur simply because the opportunity for threonine 57 phosphorylation is 
greater, for example if MAPK activity is particularly high in SiHa cells. Alternatively,
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serine 32 phosphorylation could be dependent on threonine 57 phosphorylation due to a 
change in protein conformation or location.
There is the possibility, however, that these sites are not normally phosphorylated, but 
mutating them alters the protein structure in such a way as to affect normal 
phosphorylation. However, the fact that in vitro phosphorylation data also involves 
these residues adds strong support to the prediction that these sites are phosphorylation 
sites in vivo.
There is no evidence for more than two phosphorylation events for 16E1AE4 in SiHa 
cells because only mono- and di-phosphorylated forms were detected by IEF, but other 
phosphorylation events may occur that are either minor events or not detected by the 
TGV402 antibody (see Table 2.8 for epitopes recognised). There may also be 
phosphorylation events that are cell cycle-dependent so may be undetected at the 
timepoint used in this study (24 h post-transfection or post-rAd infection). When the in 
vitro PKA site (serine 43) was mutated for expression in SiHa cells, the IEF profile 
indicated the same number of phosphorylation events as WT, suggesting that this site is 
not phosphorylated in SiHa cells. This may not be the case, however, as S43 could be 
phosphorylated in a cell cycle-dependent manner. In this experiment the mutant used 
was actually a S43/44A mutant since serine 44 is phosphorylated by PKA in vitro in the 
absence of serine 43. This S43/44A mutant may have a structural form that permits 
phosphorylation at a residue that is not normally phosphorylated in the WT thus 
masking the lack of S43 phosphorylation. Even if S43 is not phosphorylated in 
cultured SiHa cells, the possibility that it is an important functional target of kinases in 
HPV-infected epithelia should be considered in future projects. As well as 
phosphorylation by PKA, phosphorylation by PKC could occur in vivo especially 
considering the importance of PKC in epithelial growth and differentiation (Denning, 
2004; Yang et al., 2003).
The use of MEK inhibitors implicated p42 or p44 MAPK in 16E1AE4 phosphorylation 
in SiHa cells. Interestingly, the p42/p44MAPK pathway has been shown to be 
activated by high-risk HPV E6 proteins, including 16E6 (Chakrabarti et al., 2004), and 
SiHa cells express 16E6. HPV11 E1AE4 has also been shown to be phosphorylated by 
MAPK in vitro at threonine 53 and mass spectrometry data supported the
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phosphorylation of this site in vivo (Bryan et al., 2000). The p42 and p44 MAPKs are 
widely expressed and involved in the regulation of meiosis and mitosis and also have 
postmitotic functions in differentiated cells (Johnson and Lapadat, 2002). As well as 
phosphorylating nuclear transcription factors (Figure 1.4), p42/p44MAPK can 
phosphorylate other proteins such as the kinase, p90rsk/MAPKAP-Kl (Dalby et al., 
1998) and the microtubule-associated protein, tau (Illenberger et al., 1998). Although 
inhibiting p38MAPK did not appear to affect 16E1AE4 phosphorylation, other MAPK 
pathways (Figure 4.12) such as the jun N-terminal protein kinase (JNK) pathway (also 
known as stress-activated protein kinase/SAPK) may be involved and could be 
investigated in future experiments.
The use of Roscovitine implicated CDK1/2 in 16E1AE4 phosphorylation. CDK1 can 
associate with cyclin A or cyclin B and CDK2 can bind cyclin A or cyclin E and these 
complexes act to regulate cell cycle progression (Figure 4.12). CDK/cyclin A 
complexes control DNA replication, centrosome duplication and play a role in mitotic 
entry, and active CDK1/cyclin B is required for mitosis. Phosphorylation substrates of 
CDK/cyclin A include pRB which becomes further inactivated (Zarkowska and 
Mittnacht, 1997) and the transcription factor, upstream binding factor (UBF) which 
becomes activated and increases transcription of rRNA (Voit and Grummt, 2001). The 
targets of CDK1/cyclin B include the nuclear lamins, which become depolymerised 
leading to nuclear envelope breakdown in mitosis (Peter et al., 1990). The finding that 
CDK can phosphorylate 16E1AE4 is significant given that CDK1 /cyclin B (Davy et al., 
2005) and CDK2/cyclin A (Davy et al., 2006) can bind 16E1AE4 in cells. CDK 1/cyclin 
B binding is believed to be the mechanism for 16ElAE4-mediated G2 arrest, caused by 
16E1AE4 sequestering CDK1 from its normal substrates. The significance of 
CDK2/cyclin A association is uncertain, however, it is likely to affect normal 
CDK2/cyclin A activity. It would be interesting to test whether the S32A mutant, 
which is no longer phosphorylated in vitro by CDK 1 /cyclin B, retains the ability to 
bind cyclin B and cause G2 arrest.
Although the use of the inhibitors implicated these kinases in 16E1AE4 
phosphorylation, pharmacological inhibitors may have pleiotropic effects and not just 
block the kinase of interest. For example, the MEK inhibitors, PD98059 and U0126, 
can activate AMP-activated protein kinase (AMPK; Dokladda et al., 2005) and can
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Figure 4.12 Outline of the MAPK pathways and cell cycle 
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(a) Diagram of the main MAPK pathways. The p42/p44MAPK 
is involved in 16E1AE4 phosphorylation, (b) The stages of the cell 
cycle and associated CDK/cyclin complexes are indicated. 
16E1AE4 can associate with and be phosphorylated by 
CDK2/cyclinA and CDKl/cyclin B.
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inhibit kinase suppressor of ras (KSR-1), a kinase that can activate raf-1, so affect the 
MAPK pathway upstream of MEK (Wang and Studzinski, 2001).
Preliminary experiments were carried out to investigate the role of 16E1AE4 
phosphorylation. The WT and phosphorylation mutant proteins were expressed in 
SiHa cells and analysed for solubility by fractionation and also analysed by 
immunostaining. Following fractionation, the 14 kDa bands of the WT, S32A and 
S43/44A were found to only be in the urea fraction at 24 h post-transfection. This 
suggests a different activity, distribution or modification of the T57-phosphorylated 
form compared to the 13 kDa band which was found equally distributed between the 
Empigen and urea fractions and at very low levels in the NP40-soluble fraction. 
However, the phosphorylation mimic, T57D, also appeared at equal levels in the 
Empigen and urea fractions and at very low levels in the NP40 fraction.
This difference between the distribution of the upper band and T57D could be because 
in the latter, only the phosphorylation mimic form existed so its overall activities could 
be different to that of WT where both T57-phosphorylated and unphosphorylated forms 
existed. Protein phosphorylation is finely regulated by the cell, for example, during 
WT 16E1AE4 expression, the phosphorylated 14 kDa band appears gradually (Figure 
4.2c), whereas, when the T57D form is expressed, the phosphorylation mimic is present 
instantly. Therefore, it is not too surprising that the WT 14 kDa form and the T57D 
form may have differing activites when the proteins are expressed in this way.
The immunostaining patterns as determined with the anti-16ElAE4 antibody, TGV405, 
and the anti-pan-keratin antibody showed no differences between the WT and mutants, 
however, only cells with high-level 16E1AE4 could be detected and analysed. The 
phosphorylation mutants may behave differently to WT 16E1AE4 when protein levels 
are lower and below saturation. Differences may be more apparent in a system more 
similar to the in vivo situation, for example if the proteins are expressed from the HPV 
genome.
4.10.2 Abundance of 16E1AE4 phosphorylation in cell culture
The presence of di-phosphorylated 16E1AE4 in SiHa cells appears to be greater in rAd-
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infected cells compared to transfected cells. In this study, the di-phosphorylated form 
(IEF spot at pH 6.7) level could be greatly increased using okadaic acid treatment of 
transfected cells, without which, this form was difficult to detect. The difference in 
phosphorylation observed between transfected and infected cells could be due to 
transfection causing a decrease in cellular phosphorylation or adenovirus infection 
causing an increase in cellular phosphorylation or both. For example, Hela cells 
(HPV18-transformed cervical cancer cell line) have been shown to have altered cell 
cycling and increased apoptosis following transient transfection (Rodriguez and 
Flemington, 1999). It is therefore possible that these effects may also occur with 
transfected SiHa cells, thus affecting cell signalling and phosphorylation. In the 
adenovirus-infected cells, it is likely that the activity of the adenovirus proteins 
contributed to the increased phosphorylation, in particular, the activity of the 
adenovirus E4 ORFs.
The replication-defective adenoviruses used in this study lack the adenovirus El and 
E3 ORFs but retain E4 ORFs (see Appendix.4 for vector map). The E4 ORFs are 
known to have effects on transcription and cell signalling, and this may have 
implications for the use of adenoviruses as vectors (Weitzman, 2005). For example, 
E40RF4 interacts with and alters the substrate specificity of the c-src tyrosine kinase 
and E40RF6/7 binds to and increases activity of the E2F transcription factor 
(Weitzman, 2005). E2F-responsive genes include cyclins E and A, so adenovirus E4 
could increase HPV16 E1AE4 phosphorylation by CDK/cyclin. In a study where 
cellular genes induced by an adenovirus vector (lacking El but containing E4) were 
identified, one of the genes was found to be MEK5 (Ramalingam et al., 1999). MEK5 
is part of one of the MAPK pathways and can be activated by oxidative stress, 
mitogens or growth factors (Figure 4.12). It is upstream of ERK5 (also called MAPK7) 
and the MEK5/ERK5 pathway is essential for cardiac and vascular development and 
cell survival (Wang et al., 2005; Yan et al., 2003). Given that adenoviruses can affect 
this MAPK pathway, it is also possible that they may indirectly or directly affect 
p42/p44MAPK activity although there have been no such reports to date.
After okadaic acid treatment and 2D SDS-PAGE of 16E1AE4 expressed by 
transfection, the unphosphorylated form of 16E1AE4 was not detected, suggesting that 
the rate of phosphorylation is high and cellular phosphatases do lower 16E1AE4
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phosphorylation. Also, the finding that the mono-phosphorylated form of 16E1AE4 
was more abundant than the unphosphorylated form at 24 h post-rAd infection, 
indicates that most of the 16E1AE4 in cells (at least at that timepoint) is 
phosphorylated.
MALDI analysis suggested that the mono-phosphorylated form is the T57- 
phosphorylated form. When 16E1AE4 is detected by Western blotting following SDS- 
PAGE, the abundance of the upper band is at a maximum of 50 % of the total 
16E1AE4. The upper band is a result of T57 phosphorylation, so it was surprising that 
IEF found that the T57-phosphorylated form was more abundant than 
unphosphorylated 16E1AE4. An explanation could be that the T57 phosphorylation 
level is in fact high at 24 h, but the structural change that causes the slow-migration is 
partially lost during SDS-PAGE. It has been noticed that the upper band is reduced by 
freeze-thawing of the sample, so although the structural change is apparent by SDS- 
PAGE, it is somewhat sensitive to denaturation. A slower-migrating spot 
corresponding to the upper band is not visualised by IEF and this is likely to be because 
the protein is in denaturing conditions in the presence of urea and thiourea and is in a 
state where it has no overall charge, therefore charge-specific intra-molecular 
interactions may be disrupted.
Phosphorylation of 16E1AE4 does indeed appear to be abundant in cells so is likely to 
play a role in the virus life cycle. In addition to further work with phosphorylation 
mutants, an ideal method for detecting phosphorylated forms and finding 
phosphorylation effects in cell culture or in vivo is to use phospho-specific antibodies. 
The production of anti-16ElAE4 phospho-specific antibodies is in progression (see 
Appendix. 5) and will be valuable when complete.
Chapter 5: Further Analysis of 16E1AE4 Threonine 57 Phosphorylation 143
Chapter 5: Further Analysis of 16E1AE4 Threonine 57 
Phosphorylation
5.1 Introduction
The phosphorylation of 16E1AE4 at theonine 57 by MAPK was chosen to be further 
analysed because of its ability to induce a gel-shift that is likely to be due to a structural 
change. The effect of E5 on MAPK and threonine 57 phosphorylation was also 
studied. In, addition, the presence of homologous MAPK sites in other E1AE4 proteins, 
was investigated.
Gel-shifts caused by phosphorylation are a common phenomenon; examples of other 
proteins that have phosphorylation-induced gel-shifts include pRB (DeCaprio et al., 
1989), PKC (Borner et al., 1989), the cardiac muscle protein, phospholamban (Li et al.,
1998), and adenovirus El A (Smith et al., 1989). Most cases are likely to represent 
structural changes caused by an increased radius (stokes radius) of the polypeptide, as 
demonstrated for phospholamban by Li et al. (1998). In the case of 16E1AE4, 
biophysical studies (for example, intrinsic tryptophan fluorescence measurements) have 
in fact demonstrated that threonine 57 phosphorylation does induce a structural change 
(personal communication, Dr Pauline McIntosh, NIMR).
An alteration of protein structure is very likely to affect protein activity. It has already 
been shown by detergent fractionation that the T57-phosphorylated form (the upper 
band) is present in the insoluble fraction of the cell (Figure 4.7). Phosphorylation- 
induced insolubility may arise from the structural change per se, oligomerisation, a 
change in cellular location or association with other proteins to form an insoluble 
complex. Alternatively, it is possible that T57 phosphorylation occurs specifically in 
an insoluble cellular compartment such as on keratins. There is in fact, increasing 
evidence that intermediate filaments act as scaffolds for signalling pathways and 
several kinases are known to bind them, including, PKC, PKB and c-jun N-terminal 
kinase (JNK; Coulombe and Wong, 2004).
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It is known that 16E1AE4 binds keratin in cell culture and colocalises with keratin in 
vivo. Keratin is mostly an insoluble protein, although during mitosis it is 
phosphorylated and solubilised. In cultured HT29 cells (colon cancer cells), the 
distribution of keratins 8 and 18 is as follows; 5 % is soluble in detergent-free buffer, 
10 % is NP40-soluble, 45 % is Empigen-soluble and 40 % is Empigen-insoluble 
(Omary et al., 1998). This distribution of keratin between the Empigen-soluble and 
insoluble fractions is similar to the distribution of 16E1AE4 but the upper band of 
16E1AE4 is primarily in the insoluble fraction. It was hypothesised that T57 
phosphorylation may lead to 16E1AE4 having a greater propensity to associate with the 
insoluble keratins. The effect of T57 phosphorylation on keratin binding was therefore 
investigated in an in vitro assay using keratins 8 and 18 from SiHa cells and bacterially 
expressed His-E1AE4, both WT and the phosphorylation mimic, T57D. Keratins 8 and 
18 are typically expressed in simple epithelia (for example, the gastrointestinal tract 
and liver) and not in keratinocytes (Omary et al., 1998), however, they are present in 
the SiHa cancer cell line. 16E1AE4 has been previously shown to colocalise with and 
directly bind keratin 8 and 18, although the direct binding to keratin 8 was considerably 
weaker (Doorbar et al., 1991; Wang et al., 2004).
The order of 16E1AE4 phosphorylation events may prove to be significant. For 
example, phosphorylation mapping data in Chapter 4 suggested that in SiHa cells, 
threonine 57 phosphorylation occurs before serine 32 phosphorylation, since 
phosphorylated serine 32 was not detected in the mono-phosphorylated form. This 
could occur due to less CDK 1/2 activity compared to MAPK activity. More 
interestingly, the reason could be that threonine 57 phosphorylation by MAPK 
improves the rate at which 16E1AE4 is phosphorylated by CDK 1/2. To investigate this, 
CDK2/cyclin A kinase assays were performed using the T57A and T57D His-E1AE4 
mutants. Also, it is known that 16E1AE4 can colocalise with cyclin A/B (Davy et al., 
2006; Davy et al., 2005), so the potential of T57A to colocalise with cyclin (in this 
case, cyclin A) was analysed.
In a HPV16 infection, E1AE4 is expressed alongside other viral proteins (Doorbar,
2005), so its activities should be considered in the context of the viral life cycle. In 
vivo, transcripts that encode both 16E1AE4 and 16E5 are detected (Doorbar et al., 1990; 
Vormwald-Dogan et al., 1992), so it is likely that these two proteins are co-expressed at
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some stage of the viral life cycle. Since 16E5 is known to increase MAPK signalling, 
its ability to increase 16E1AE4 phosphorylation was tested. The effects of 16E5- 
induced MAPK signalling may contribute viral replication and virus production and 
this may partly be through regulation of viral proteins such as 16E1AE4.
5.2 T57D binds keratin more strongly than WT does
To test the binding of 16E1AE4 to keratin and the effect of T57 phosphorylation, 
keratins were immunoprecipitated from cultured cells and incubated with WT His- 
E1AE4 or the phosphorylation mimic, T57D His-E1AE4. Keratins 8 and 18 were 
immunoprecipitated from SiHa cells using the monoclonal mouse antibody, L2A1, and 
protein G-sepharose beads. The keratin-bound beads were washed and 0.4 pg of WT 
or T57D were added to the beads. After two hours, the beads were washed, then 
analysed by SDS-PAGE and Western blotting with the anti-El AE4 antibody, TVG402.
The results show that both His-E1AE4 proteins could associate with the 
immunoprecipitated keratins, but the T57D mutant could bind with greater affinity 
(Figure 5.1). This was repeated twice more (data not shown) and each time, the T57D 
bound more strongly than WT to the keratin-bound beads.
5.3 Immunostaining of keratin and 16E1AE4 in SiHa cells
The observation that the T57D phosphorylation mimic bound keratin more strongly 
than the WT protein in the in vitro assay (see 5.2), prompted the comparison of the 
colocalisation of T57A, T57D and WT with keratin in cells. However, when T57A, 
T57D and WT 16E1AE4 were transfected into SiHa cells and immunostained at 24 h 
post-transfection, no differences in the degree of keratin-16E1AE4 colocalisation or 
16ElAE4-mediated keratin collapse were detected (see 4.6.3). It was therefore decided 
to test later timepoints to see whether, with time, the T57D or WT protein would show 
increased keratin colocalisation or collapse in comparison to the T57A mutant.
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Figure 5.1 Binding of His-El AE4 to immunoprecipitated keratin
Keratins 8 and 18 were immunoprecipitated from SiHa cells using the L2A1 anti­
keratin antibody. A solution of WT or T57D His-ElAE4 was added to the 
keratin-bound beads (middle panel: Western blot of 10 % of the total His-El AE4 
added). Following a 2 h incubation with His-ElAE4, the beads were washed and 
the bound keratin and E1AE4 analysed by Western blotting using a rabbit 
polyclonal anti-keratin antibody (8592) and TVG402 respectively.
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SiHa cells were transfected with pM V ll constructs expressing WT, T57A or T57D 
16E1AE4. Cells were harvested at 48 h or 72 h post-transfection and immunostained to 
detect keratin and 16E1AE4. 16ElAE4-positive cells were counted and classed into one 
of four categories: i) keratin and 16E1AE4 colocalisation and no keratin collapse, ii) 
keratin colocalisation and partial keratin collapse, iii) keratin colocalisation and full 
keratin collapse and iv) no keratin colocalisation. The experiments were carried out in 
triplicate with an approximate total of 300 cells analysed for each type of 16E1AE4. 
More cells showed keratin collapse at 48 h and 72 h post-transfection (Figure 5.2) 
compared to that seen at 24 h (Figure 4.7b). The total percentage of cells showing 
collapse (partial or full collapse) was similar for each type of 16E1AE4 (at 48 h, the 
mean values were 55.5 % for WT, 60 % for T57A, and 58.25 % for T57D). For each 
type of 16E1AE4, fewer cells showed collapse at 72 h compared to 48 h. At 72 h, there 
was a higher number of dead or dying cells, characterised by their fragmented nuclei. 
These cells were not included in the analysis, but these were the cells that frequently 
had high levels of 16E1AE4 and collapsed keratin, explaining the apparent decrease in 
keratin collapse at 72 h. As with the 24 h experiment, this experiment did not include 
the analysis of very low-level 16E1AE4 that is difficult to visualise by immunostaining.
5.4 T57A shows less colocalisation with cyclin A than WT does
To test whether threonine 57 is important for cyclin A binding, SiHa cells were 
transfected with pM V ll expressing either WT or T57A 16E1AE4. The cells were 
harvested and fixed at 48 h post-transfection and then immunostained to detect 
16E1AE4 and cyclin A. The 48 h timepoint (post-transfection) was chosen as it was 
previously found to be optimal for 16E1AE4 and cyclin A colocalisation (Davy et al.,
2006). Cells that were positive for both 16E1AE4 and cyclin A were analysed for the 
presence or absence of cyclin A-16E1AE4 colocalisation. The experiments were 
performed in triplicate, with an approximate total of 200 cells analysed for each type of 
16E1AE4. It was found that an average of 82 % of the WT-containing cells showed 
some degree of cyclin A colocalisation, while the figure was only 44 % for the T57A 
mutant (Figure 5.3). This difference was statistically significant (/3 = 3.84,P  = 0.031).
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□  no keratin colocalisation
Figure 5.2 Keratin and E1AE4 colocalisation at 48 h and 72 h post-transfection
SiHa cells were immunostained for E1AE4 and keratin at 48 h and 72 h post­
transfection of WT, T57A and T57D constructs. The staining patterns were classed 
into four categories: ‘keratin and E1AE4 colocalisation and no keratin collapse’, 
‘keratin colocalisation and partial collapse’, ‘keratin colocalisation and full collapse’ 
or ‘no keratin colocalisation’. The percentage of cells in each category were recorded 
and the mean values represented in a bar graph. The error bars 
indicate the standard deviation.
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Figure 5.3 Colocalisation of cyclin A with WT and T57A E l AE4
SiHa cells were transfected with WT or T57A constructs and analysed at 48 h post­
transfection for El AE4 and cyclin A colocalisation. An example of non-colocalisation 
and an example of colocalisation are shown above, with E1AE4 in green and cyclin A 
in red. The percentage of cells showing colocalisation and non-colocalisation were 
recorded and the mean values represented in a bar graph. The error 
bars represent the standard deviation.
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5.5 WT, T57A and T57D are phosphoryiated by CDK2/Cyclin A at a 
similar rate
Following the observation that the T57A mutant shows reduced colocalisation with 
cyclin A (Figure 5.3) and the hypothesis that threonine 57 phosphorylation occurs 
before serine 32 phosphorylation by CDK (See 4.7), it was decided to compare the 
phosphorylation of WT, T57A and T57D His-El AE4 by CDK2/cyclin A. For each type 
of 16E1AE4, kinase assays were performed for 2, 5, 10 and 20 min, using 0.5 p,g of 
substrate, radioactive ATP and 30 units of kinase in each reaction. The samples were 
analysed by SDS-PAGE and a Phosphorlmager (Figure 5.4). The autoradiograph 
showed that the increase in phosphorylation over time was similar for all the His- 
El AE4s, so there appears to be no differences in their potential to be phosphoryiated.
5.6 HPV16 E5 can enhance threonine 57 phosphorylation of 16E1AE4
To test whether 16E5 expression can cause an increase in 16E1AE4 phosphorylation, 
the two proteins were co-expressed. A 16E5-expressing SiHa cell line was produced 
(by Dr Qian Wang, NIMR) and used only at an early passage number (less than 
nine/ten passages). Using reverse-transcriptase PCR (RT-PCR), E5-encoding RNA 
was detected in this cell line but not in the negative untransfected SiHa cells (Figure 
5.5a). As a positive control for the PCR reaction, the E5-encoding plasmid, 
pMT3H16E5KC, was used as a template. 16E1AE4 was then expressed using 
rAdElAE4 in E5-positive SiHa cells at an early passage and E5-negative cells. 16E5 
has been shown to activate MAPK in the presence of EGF or sorbitol (Crusius et al., 
1997; Crusius et al., 2000), so at 24 h post-infection, the SiHa cells were incubated with 
10 ng/ml EGF or 0.5 M sorbitol for 10 min. Then the cells were harvested and prepared 
for analysis by SDS-PAGE and Western blotting. Samples were run on a 12 % gel for 
detection of active p42/p44MAPK and GAPDH and on a 15 % gel for separation of the 
upper and lower bands of 16E1AE4. The anti-ACTIVE® MAPK antibody recognises 
phosphoryiated T183/Y185 of p42MAPK and phosphoryiated T202/Y204 of 
p44MAPK. These residues are phosphoryiated by MEK and this leads to MAPK
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Figure 5.4 In vitro phosphorylation of WT, T57A and T57D His-El AE4 by 
CDK2/cyclin A
Autoradiograph following CDK2/cyclin A in vitro kinase assays using 0.5 pg of WT, 
T57A or T57D His-E1AE4 as substrates. The inset shows a silver stain of 0.5 pg of 
each substrate. The reactions were carried out for 2, 5, 10 and 20 min for each type of 
substrate.
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activation. The results showed that the level of active p42/p44MAPK was higher in the 
E5-positive cells than in the E5-negative cells (Figure 5.5b). As expected, a 
consequence of this was that T57 phosphorylation of 16E1AE4 was increased, as shown 
by an increased intensity of the upper bands in relation to the lower bands (Figure 
5.5b).
These results could be reproduced only when using a 16E5-positive SiHa clone at an 
early passage number. When using cells that had been passaged more than nine/ten 
times, there appeared to be no effect on MAPK or 16E1AE4 (data not shown) and the 
likely explanation is loss of 16E5 expression, although this was not checked by RT- 
PCR. The cause of this loss could be due to 16E5 giving the cells a growth 
disadvantage, a phenomenon also observed with primary keratinocytes stably 
expressing codon-optimised 16E5 (Disbrow et al., 2003).
5.7 Searching for homologous MAPK phosphorylation sites in other 
E1AE4 proteins
Since MAPK phosphorylation appears to be functionally important for 16E1AE4, it is 
likely that other E1AE4 proteins are also regulated by MAPK. It is already known that 
threonine 53 of 11E1AE4 is phosphoryiated by MAPK and mutating this residue 
reduces the filamentous appearance of the protein and inhibits multimerisation (Bryan 
et al., 2000). E1AE4 sequence alignments were therefore performed to check for the 
presence of MAPK sites (P-X-S/T-P, X-X-S/T-P) homologous to threonine 57 of 
16E1AE4 or threonine 53 of 11E1AE4.
Interestingly, for HPV16, it appears that E5 can increase E1AE4 phosphorylation 
through the activation of the MAPK pathway, so it is possible that the E5 protein of 
other HPV types have also evolved to increase the phosphorylation of E1AE4. 
Recently, Schiffman et al. (2005) conducted a phylogenetic analysis of 
anogenital/mucosal HPVs and noted whether or not each HPV type contained an E5 
ORF (see Appendix.6). To see whether there is a relationship between E5 presence and 
an E1AE4 MAPK site, alignments were performed, firstly using 16E1AE4 and 11E1AE4 
and five other E1AE4 types from other E5-positive viruses, and then using 16E1AE4
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Figure 5.5 Effects of E5 on MAPK and E1AE4 phosphorylation
(a) Agarose gel electrophoresis showing RT-PCR products; E5-coding mRNA was 
detected from a SiHa clone stably transfected with an E5-expressing vector. The 
negative control used untransfected SiHa cells and the positive control used the E5- 
encoding plasmid, pMT3H16E5KC, as PCR templates, (b) Western blots of 
activated p42 and p44 MAPK, GAPDH loading controls and E1AE4, following 
treatment of rAdElAE4-infected E5-positive and E5-negative SiHa cells with EGF 
or sorbitol.
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and 11E1AE4 and five E5-negative viruses (Figure 5.6a). The ‘Multalin’ programme 
was used for the alignments (http://prodes.toulouse.inra.fr/multalin/multalin.html; 
Corpet, 1988). El and E4 sequences were obtained from the HPV database 
(http://www. stdgen.lanl.gov/stdgen/virus/hpv/) and the E1AE4 sequences were 
generated using the predicted splice sites (Doorbar and Myers, 1996).
The first alignment using E5-positive types revealed that 11E1AE4, 44E1AE4 16E1AE4 
and 31E1AE4 have homologous threonine residues that all fit the MAPK consensus site 
(indicated by a black arrow; Figure 5.6a). HPV11 and 44 are both members of the alO 
species of anogenital/mucosal HP Vs and HPV 16 and 31 are cx9 viruses. HPV 18, 45 
(a7) and HPV34 (a l 1) do not have a homologous MAPK site, although 45E1AE4 does 
have a nearby MAPK site at threonine 63 and 34E1AE4 has one at serine 54. None of 
the E5-negative HPVs aligned have a homologous MAPK site, although 54E1AE4 does 
have a nearby site at threonine 62, 57E1AE4 has one at serine 66, 61E1AE4 has one at 
serine 63 and 29E1AE4 has one at serine 70 (Figure 5.6a). Given that three of the E5- 
positive types tested did not have a MAPK site homologous to threonine 57 of 
16E1AE4, there does not appear to be a clear correlation between E5 and the presence 
of the homologous MAPK site. However, it is of course possible that E5 enhances 
phosphorylation of a non-homologous MAPK site, to cause similar biological effects.
The E1AE4 proteins that do possess a homologous MAPK site, are members of the a9 
and alO species, so it was decided to align other members of these species with each 
other (Figure 5.6b). The first alignment is of a9  members and shows that 31, 35, 52 
and 58E1AE4 have a MAPK site homologous to threonine 57 of 16E1AE4. 33E1AE4 
does not have a homologous residue but has nearby MAPK consensus sites at serine 43 
and threonine 52. The second alignment is of alO  members and shows that 6, 13, 44 
and 55E1AE4 have a MAPK site homologous to threonine 53 of 11E1AE4. 
Interestingly, fifteen of the nineteen E1AE4 sequences analysed possess a threonine 
residue that aligns with threonine 57 of 16E1AE4, although only ten of them (including 
16E1AE4) are in MAPK consensus sites. None of the proteins with a homologous 
MAPK site has a serine residue at that site, despite the fact that MAPK can 
phosphorylate both serines and threonines. This suggests that there is functional 
importance of the unphosphorylated threonine as well as roles for phosphoryiated
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Figure 5.6 E1AE4 amino acid sequence alignments
E1AE4 sequences were aligned using MultAlin (http://prodes.toulouse. 
inra.fr/multalin/multalin.html) to search for MAPK phosphorylation sites 
homologous to HPV11 and HPV 16. The region homologous to the MAPK 
site o f 11E1AE4 and 16E1AE4 is indicated by an arrow. All MAPK 
consensus sites are underlined in green, (a) In the top alignment, HPV 11 
and HPV 16 were aligned with examples of anogenital HP Vs (a  species) that 
were described as having an E5 ORF by Schiffman et al. (2005). HP Vs 11 
and 44 are a  10 viruses, HPVs 16 and 31 are a9  virus, HPV34 is an a l l  
virus, and HPVs 18 and 45 are a7  viruses. In the bottom alignment, HPVs 
11 and 16 were aligned with examples o f types that do not have a 
homologous E5 ORF. HPV54 is an a  13 virus, HPVs 57 and 27 are a 4  
viruses, HPV61 is an a3  virus and HPV29 is an a l  virus, (b) In the top 
alignment, 16E1AE4 was aligned with other a9  E lAE4s, and in the bottom 
alignment, 11E1AE4 was aligned with other alO  E lAE4s.
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threonine and a serine residue may not substitute. Alternatively, a serine residue may 
not be tolerated because of its effect on the E2 ORF (which overlaps that of E4).
5.8 Discussion
The finding that threonine 57 phosphorylation causes a gel-shift in SDS-PAGE, led to 
further interest in this phosphorylation event. Other observations, for example, the fact 
that this slow-migrating form appears to be more insoluble, and that it is detected 
following 16E1AE4 expression in several cell lines, suggested that it has functional 
relevance. For these reasons, threonine 57 phosphorylation was further investigated.
In summary, it was found that the T57D phosphorylation mimic could bind keratin 
more strongly than the WT unphosphorylated protein could in vitro, and that WT 
16E1AE4 could colocalise more frequently with cyclin A than the T57A mutant could 
in SiHa cells. In addition, 16E5 has the ability to increase threonine 57 
phosphorylation of 16E1AE4 in SiHa cells through activation of p42/p44MAPK. Taken 
together, these results suggest that threonine 57 phosphorylation may be regulated in 
vivo and has important functional effects. It can be hypothesised that 16E5 activates 
16E1AE4 phosphorylation in vivo which leads to an increase in 16E1AE4 association 
with keratins and with cyclins.
5.8.1 Biological effects of threonine 57 phosphorylation
In this study, it has been shown that a phosphorylation mimic of 16E1AE4, bacterially- 
expressed T57D His-El AE4, can bind to immunoprecipitated cellular keratins 8 and 18 
more strongly than the unphosphorylated 16E1AE4 can. This suggests that threonine 
57 phosphorylation may cause increased keratin binding in vivo.
The binding of phosphoryiated 16E1AE4 to keratin has been previously described. 
Wang et al. (2004) reported that 16E1AE4 (both lower and upper bands) could be 
coimmunoprecipitated from the NP40-soluble fraction of 16ElAE4-expressing cells 
using an anti-keratin 8/18 rabbit serum. When the cells were not treated with OA (a 
phosphatase inhibitor), only the lower band (13 kDa) of 16E1AE4 was detected. In this 
study, it has been found that the threonine 57-phosphorylated upper band (14 kDa) is
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predominantly found in the insoluble fraction (see 4.6.2), so in the experiment by Wang 
at al. (2004), the upper band may have detected because only the NP40-soluble fraction 
was analysed. However, when the cells were treated with OA, the upper band was 
present in the NP40-soluble fraction, as only the upper band was 
coimmunoprecipitated. The explanation could be that the cells contained more of the 
upper band form than the lower band form following OA treatment. Alternatively, the 
upper band had bound to keratin with greater affinity than the lower band did. The 
latter would support the findings in this study.
To further investigate the possibility that threonine 57 phosphorylation can regulate 
keratin binding, cultured cells were transfected with WT, T57A and T57D in order to 
visualise keratin-16E1AE4 patterns by immunostaining. However, the immunostaining 
patterns did not reveal a stronger association of T57D with keratin compared to WT or 
T57A with keratin. It could be that this phenomenon is specific to histidine-tagged 
T57D as the histidine tag was present in the in vitro experiment but not in the 
transfection experiment, or it may be that cellular factors dampen the ability of T57D to 
form strong associations with keratin. The more likely explanation is that in the 
transfection experiments, the vast majority of the 16E1AE4 was already bound to 
keratin, so that any increased ability of T57D to bind keratin was not detectable. The 
level of 16E1AE4 was perhaps too high to be able to detect subtle differences in activity 
between the WT, phosphorylation mutant and phosphorylation mimic, since expression 
was from a CMV promoter. The alternative could be to express 16E1AE4 from the 
HPV 16 genome or a system where transcription can be better controlled, such as the 
tet-on system where transcription can be activated by doxycyclin in a dose-dependent 
manner (Gossen et al., 1995).
Interestingly, the fact that biological effects of phosphorylation can be affected by the 
method of protein expression, has been previously described for BPV1 E2 (McBride 
and Howley, 1991). Serine 301 of BPV1 E2 is phosphoryiated by CKII and functional 
effects of substituting serine 301 with alanine (S301 A) were investigated. When E2 
was expressed in CV-1 cells (north African green monkey fibroblast cell line) from a 
plasmid containing a SV40 promoter, there were no differences in transactivation 
ability between WT and S301A E2. However, when BPV1 genomes were used in the 
same transactivation assays, the genome containing the S301A mutation caused greater
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transactivation than the WT genome did. S301A BPV1 E2 shows increased 
transactivation (and viral DNA replication) because it is targeted less by the ubiquitin- 
proteasome pathway in comparison to WT, so possesses a longer half-life than WT 
does. However, expression of E2 from an SV40 promoter had led to protein levels that 
were too high to detect effects of the change in protein turnover.
The observation that cyclin A colocalisation is lower for the T57A mutant compared 
with the WT protein, is another phenomenon that may become more apparent when 
lower levels of 16E1AE4 are analysed. 16E1AE4 has been shown to cause cell-cycle 
arrest in G2 (Davy et al., 2002) and the mechanism is likely to be through binding of 
cyclins (Davy et al., 2006; Davy et al., 2005). The possible role of threonine 57 itself 
or threonine 57 phosphorylation in cell-cycle arrest is therefore important to 
investigate. Ultimately, it will be necessary to analyse the phosphorylation mutant and 
the phosphorylation mimic in the context of the viral genome, ideally in a raft system 
which represents an infected epithelium.
It was already known that CDK2/cyclin A can phosphorylate WT 16E1AE4 at serine 32 
in vitro (see Chaper 3). Now it was important to answer whether the T57A mutant has 
a reduced affinity for this kinase complex and would therefore be phosphoryiated at a 
slower rate. This would give an explanation for the reduced cyclin A binding. Also, 
since data in Chapter 4 (see 4.7) suggested that threonine 57 phosphorylation may 
occur before serine 32 phosphorylation, it was considered important to test whether the 
T57D phosphorylation mimic would be phosphoryiated at serine 32 at a faster rate 
compared to WT. CDK2/cyclin A in vitro kinase assays were therefore performed 
using WT, T57A and T57D His-E1AE4 as substrates. The results showed, however, 
that at least in vitro, T57A does not have a reduced ability to be phosphoryiated by 
CDK2/cyclin A compared to WT, and T57D is not phosphoryiated more easily.
The finding that T57A colocalises with cyclin A less frequently than WT, may 
therefore be independent of its ability to be phosphoryiated by CDK2/cyclin A. The 
T57A mutant may be phosphoryiated just as readily but have a lowered cyclin A 
binding potential. This could be confirmed by in vitro binding experiments for 
example by using GST-tagged WT and T57A 16E1AE4 to pull-down cyclin A from 
cells. Similar experiments were performed to show binding between cyclin B and
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16E1AE4 (Davy et al., 2005). Alternatively, the reason for the apparent reduction in 
T57A binding to cyclin A could be a secondary effect of the activity of the T57A 
mutant. For example, if T57A differs from WT in the way it forms multimers or 
associates with keratins or other cellular proteins, then the degree of cyclin 
colocalisation may be affected.
In a previous screen for the ability of 16E1AE4 mutants to induce G2-arrest in S. pombe, 
threonine 57 was not shown to be required for arrest since a A52-57 mutant could still 
cause arrest (Davy et al., 2002). Threonine 57 itself or threonine 57 phosphorylation 
may not be essential for cyclin binding and G2-arrest, but it may act as an stimulatory 
factor for these events. The residue that was found to be crucial for cyclin binding and 
G2-arrest was threonine 23 (Davy et al., 2005; Davy et al., 2002).
The fact CDK2/cyclin A phosphorylates the T57D mutant and the WT protein equally 
well, suggests that threonine 57 phosphorylation is not required for serine 32 to be 
phosphoryiated by CDK2/cyclin A. The absence of detectable serine 32 
phosphorylation in the mono-phosphorylated 16E1AE4 extracted from SiHa cells (see 
4.7) may therefore be due to 16E1AE4 having a greater affinity for MAPK than for 
CDK/cyclin or because MAPK activity levels are high in these cells. Alternatively, the 
T57D mutant may not be resembling phosphorylation appropriately so may not be 
behaving in the same way as threonine 57-phosphorylated 16E1AE4 (see 5.8.2).
5.8.2 Does the T57D mutant mimic threonine 57 phosphorylation?
The T57D mutant migrates slower than WT 16E1AE4 in a similar fashion to threonine 
57-phosphorylated 16E1AE4 (Figure 4.6a). This suggests that this mutant protein has a 
similar structural conformation to the threonine 57-phosphorylated form. It is therefore 
reasonable to assume that any behaviour of threonine 57-phosphorylated 16E1AE4 that 
is dependent on the tertiary structure of the protein, can be reproduced with the T57D 
mutant. Any activity dependent on the negatively charged phosphate group should also 
be reproducible by substitution with aspartic acid. However, an activity sensitive to the 
exact size of phosphoryiated threonine 57 or dependent on threonine atoms as well as 
the phosphate group, may not be mimicked by aspartic acid. In this case, glutamic acid 
may be a better substitute or it may not be possible to mimic phosphorylation.
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It is important to consider that glutamic acid may mimic phosphoryiated threonine 57 
better than aspartic acid can. Indeed, there are several reports of differing biological 
effects depending on whether aspartic acid or glutamic acid have been used to mimic 
phosphorylation in proteins (Carlson et al., 2001; Gradin et al., 2002). Therefore, for 
future projects, the activity of phosphoryiated 16E1AE4 should be compared to both 
aspartic acid and glutamic acid mutants.
5.8.3 Regulation of 16E1AE4 phosphorylation by 16E5
The level of threonine 57 phosphorylation was higher when 16E1AE4 was expressed in 
a 16E5-expressing cell line compared with a 16E5-negative cell line. This was co­
incident with the activation of p42/44MAPK. The increase in 16E1AE4 
phosphorylation is therefore a novel role for 16E5. The fact that an increased level of 
endogenous active p42/44MAPK was associated with increased 16E1AE4 
phosphorylation, provides further support that these kinases phosphorylate 16E1AE4.
E5 proteins may therefore be important for E1AE4 activity in vivo. Indeed, a 31E5 
knockout genome appeared to have an effect on 31E1AE4 levels (Fehrmann et al., 
2003). Rafts supporting the HPV31 life cycle showed a reduced number of 31E1AE4- 
positive cells when 31E5 was mutated, as detected by immunostaining. Also, after 
methylcellulose treatment of cells, 24 % of WT-containing cells stained for 31E1AE4, 
compared with 14.5 % for mutant 31E5-containing cells. It would be interesting to 
analyse the extent of 31E1AE4 phosphorylation in the presence or absence of 31E5 to 
decipher whether 31E1AE4 phosphorylation is related to its levels. 31E1AE4 does in 
fact have a MAPK consensus site homologous to threonine 57 of 16E1AE4 (Figure 
5.6).
It could be that effects of E5 on E1AE4 may be different in different HPV types, since 
loss of 16E5 did not cause a decrease in 16E1AE4 levels in HPV 16-containing rafts 
(Genther et al., 2003). Whether 16E5 co-expression or mutation affects 16E1AE4 
activities such as keratin or cyclin association or cell cycle arrest could be investigated 
in future experiments.
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It was interesting to consider that E5 roles may be conserved between different HPVs 
and there is a requirement for E5 activity in order to achieve E1AE4 phosphorylation by 
MAPK. Examples of E5-positive and E5-negative HPVs were analysed to see if more 
E5-positive HPVs had a MAPK site homologous to threonine 57 of 16E1AE4. This 
was the case, but not all of the E5-positive types analysed had a homologous MAPK 
site, so the correlation was weak. However, most E lAE4s analysed, had MAPK 
consensus sites in neighbouring regions so it is likely that E5 can still activate 
phosphorylation by MAPK to cause a structural change, but not necessarily at a site 
homologous to threonine 57 of 16E1AE4.
5.8.4 Homologous phosphorylation sites
Of the E1AE4 types analysed, those found to possess MAPK sites homologous to 
threonine 57 of 16E1AE4, are the a9  types, 31, 35, 52 and 58 and the alO  types, 6, 11 
(already shown to be a MAPK site in vivo by Bryan et al. (2000)), 13, 44 and 55. The 
a9  viruses are all high- risk types that can cause cancer whereas the a  10 viruses are 
rarely associated with malignancy. However, both types of viruses may regulate their 
E1AE4 activites through MAPK phosphorylation. HPVs 11, 31 and 45 have been 
analysed for E lAE4-keratin association, and colocalisation has been detected in cell 
culture (personal communication, Peter Laskey). Bryan et al. (2000) described how 
mutating the MAPK site in 11E1AE4 caused the protein to have a diffuse distribution 
instead of a filamentous pattern. Therefore, E5-enhanced, MAPK phosphorylation may 
affect keratin binding of other E lAE4s in the same way that it is thought to affect 
keratin binding of 16E1AE4.
Interestingly, the other phosphorylation sites mapped in this study (CDK site at serine 
32, PKA site at serine 43) are not conserved between 16E1AE4 and other a9  members. 
Of course, CDK and PKA could phosphorylate other E lAE4s in non-homologous sites. 
The threonine 57 MAPK site perhaps is more frequently conserved between different 
E lAE4s, compared to other phosphorylation sites, because the biological effects of this 
phosphorylation event are dependent on a structural change. For a conformational 
change to occur, surrounding amino acids are involved, so the location of the 
phosphorylation site is important. MAPK phosphorylation at a non-homologous site
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may not produce a similar structural change and therefore not have the same functional 
effects.
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Chapter 6: Final Discussion
The objectives of this study were to investigate whether 16E1AE4 is phosphoryiated in 
cells, to map the phosphorylation site(s) and to decipher the role of 16E1AE4 
phosphorylation in the virus life cycle. The outcomes of the study have included the 
characterisation of several phosphorylation sites of 16E1AE4 and the finding that the 
protein is phosphoryiated by at least two kinases in cells; CDK 1/2 and p42/p44MAPK. 
Phosphorylation by p42/p44MAPK induces a conformational change in 16E1AE4 
(personal communication, Dr Pauline McIntosh, NIMR) and is important for regulation 
of keratin binding and cyclin colocalisation. Furthermore, the level of 16E1AE4 
phosphorylation can be enhanced by activation of p42/p44MAPK by 16E5.
By improving our understanding of the regulation of HPV proteins by phosphorylation, 
there will be increased opportunity to develop agents that interefere with this 
regulation. As a consequence, this may lead to the development of novel therapies to 
treat HPV infections and HPV-related cancers.
6.1 Kinases involved in E1AE4 phosphorylation
The HPV life cycle is dependent on the differentiation status of keratinocytes in the 
epithelium, and protein kinase signalling is integral to the growth, differentiation and 
survival of keratinocytes. As well as regulating keratinocyte differentiation to ensure 
suitable conditions for viral growth, protein kinases can influence HPV more directly 
by phosphorylation of viral proteins.
Previously, 1E1AE4 has been shown to be phosphoryiated by PKA (Grand et al., 1989), 
and 11E1AE4 has been found to be phosphoryiated by both PKA and p42MAPK 
(Bryan et al., 2000). This study has shown that the E1AE4 protein of HPV 16 can be 
phosphoryiated in vitro by CDK1 and CDK2 at serine 32, by p42MAPK at threonine 
57, by PKA at serine 43, and by PKCa at a site between amino acids 35 and 59. Of 
these events, phosphorylation of threonine 57 and serine 32 occurs when the protein is 
expressed in a HPV16-transformed cervical cancer cell line (SiHa cells), and 
p42/44MAPK and CDK 1/2 are the respective kinases involved.
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It is important to consider that in vivo, the 16E1AE4 phosphorylation status may vary 
depending on the differentiation status of the epithelium and on which other HPV 
proteins are active. All the kinases discussed above are expressed in the epithelium and 
are important in keratinocyte signal transduction. These kinases and their activities in 
normal and HPV-infected keratinocytes are reviewed below.
6.1.1 Kinases in normal epithelium
PKC
Of the nine PKC genes in humans, five (a, 6, s, r\, £) are expressed in keratinocytes 
(Reynolds et al., 1994). PKCa is a classical PKC isoform, meaning that it is activated 
by calcium and by diacylglycerol or phorbol esters. PKC6, e and r\ are novel isoforms 
(calcium-independent but activated by diacylglycerol/phorbol esters), while PKC£ is an 
atypical isoform (independent of both calcium and diacylglycerol/phorbol esters). 
PKCa is found in the suprabasal layer where it triggers irreversible growth arrest 
(Bollag et al., 1993; Tibudan et al., 2002). Furthermore, PKCa activity is required for 
expression of differentiation markers such as involucrin (Yang et al., 2003). The 
activation of other PKC isoforms, in particular, PKCr| (Kashiwagi et al., 2002) and 
PKC6 (Deucher et al., 2002), have also been shown to be necessary for expression of 
keratinocyte terminal differentiation markers.
The importance of PKC in epithelial differentiation is demonstrated by the fact that 
PKC activators are necessary for ensuring a complete keratinocyte differentiation 
programme in raft cultures (Meyers et al., 1992). It is also required for capsid protein 
expression (Meyers et al., 1992; Pray and Laimins, 1995) and the treatment of HPV31- 
containing rafts with a synthetic diacylglycerol, even caused a slight increase in E1AE4 
levels (Pray and Laimins, 1995).
CDK
CDKs and their associated cyclins are active in all proliferating cells, so are important 
in the basal layer of the epithelium. In order to exit from the cell cycle and progress 
towards differentiation, CDKs and cyclins must be regulated. In a study where 
keratinocytes in culture were induced to differentiate using high extracellular calcium, 
D-type cyclins, cyclin E and CDK2 protein levels decreased (along with associated
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kinase activity), but CDK4 and CDK6 levels remained unchanged (Martinez et al.,
1999). In the same study, the interactions between CDK inhibitors and CDKs was also 
investigated. It was found that upon differentiation, all three CDK inhibitors analysed 
(p21, p27 and p57), increased the extent to which they associated with CDK4, CDK6 
and CDK2. This suggests that downregulation of most CDK/cyclin activity is required 
for differentiation. In fact, one of the activites of PKCq in keratinocytes is the 
association with cyclin E/CDK2/p21 complexes and this appears to inactivate CDK2 
(Kashiwagi et al., 2000).
MAPK
In keratinocytes, MAPK pathways can be activated by various signals (Figures 1.4 and 
4.12a). For example, EGF can activate p42/p44MAPK (Mitev et al., 1995), UVB can 
stimulate JNK (Assefa et al., 1997) and osmotic stress can activate p38MAPK (Garmyn 
et al., 2001). All these MAPK isoforms function to regulate keratinocyte proliferation, 
survival and differentiation. Seo et al. (2004) reported that all these MAPK pathways 
are induced during calcium-dependent differentiation of keratinocytes, as measured by 
phosphoryiated (active) p42/p44MAPK, p38MAPK and JNK. Inhibition of MEK1/2 
(which is upstream of p42/p44MAPK) or p38MAPK prevented expression of 
differentiation markers such as loricrin and filaggrin, but inhibition of JNK 1/2 had no 
effect. Interestingly, overexpression of PKCa (in low calcium) led to activation of 
p42/p44MAPK and JNK 1/2 but not p38MAPK, as well as expression of differentiation 
markers. This suggests that in vivo, much of the PKCa-induced keratinocyte 
differentiation could be mediated by MAPK signalling. Similarly, PKC6 and r\ have 
been shown to activate p38MAPK and PKC6 activation of involucrin was blocked by 
expression of a dominant-negative p38MAPK (Efimova et al., 2002).
PKA
PKA has an ubiquitous distribution and is central to many cellular processes such as 
transcription regulation, ion conductance, membrane trafficking and cell motility 
(Shabb, 2001). However, the physiological role of PKA in the epithelium is not well 
understood. PKA is activated by the binding of c-AMP, a secondary messenger 
generated by G-protein activity. In HaCaT cells, raising the level of intracellular c- 
AMP led to the expression of the differentiation markers, involucrin, keratins 1 and 10, 
and transglutaminase (Mammone et al., 1998). Also in the same study, the use of PKA
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inhibitors prevented the expression of keratins 1 and 10. PKA can regulate other signal 
transduction pathways and this is likely to contribute to its effects in the epithelium. 
For example, it can regulate intracellular calcium by phosphorylation of calcium 
channels such as inositol 1,4,5 trisphosphate (IP3) receptors (Nakade et al., 1994; 
Tertyshnikova and Fein, 1998), and it can inhibit p42/p44MAPK signalling by 
phosphorylating raf (Dhillon et al., 2002).
6.1.2 Kinase activity in HPV-infected cells
The kinase activity in HPV-infected epithelium is influenced by the activities of the 
HPV proteins themselves. As previously discussed (see 1.13), several of the viral 
proteins have effects on the cell cycle or signalling pathways, so they could also affect 
16E1AE4 phosphorylation.
Active p42/p44MAPK can be upregulated by 16E5 as observed in this study and 
previously reported by others (Crusius et al., 1997; Gu and Matlashewski, 1995). E6 of 
HPVs 16, 18 and 31, can also increase the level of phosphoryiated p42/p44MAPK 
(Chakrabarti et al., 2004). Also, when cDNA microarrays were used to analyse the 
effects of 16E6 and 16E7 on gene expression in keratinocytes, upregulation of 
p38MAPK, p42/p44MAPK, CDK1, cyclin B1 and cyclin A was observed (Nees et al., 
2001). The activation of CDK2/cyclin A and CDK2/cyclin E by 16E7 has also been 
reported (previously discussed; see 1.13.2.2).
6.2 The roles of E1AE4 phosphorylation
The E1AE4 protein has been implicated in a variety of roles including cell cycle arrest, 
viral DNA replication, expression of capsid proteins, and association with and 
disruption of keratins and cornified envelopes. Cell cycle arrest mediated by cyclin 
binding, could be necessary to sustain a cellular environment that allows for viral DNA 
replication, while the disruption of keratins and cornified envelopes could aid virus 
release from cells. Overall, these functions support completion of the viral life cycle 
rather than malignancy. Indeed, E1AE4 is absent in high grade cervical biopsies 
(Middleton, 2003).
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The regulation of E1AE4 expression and activities is not well understood. 
Traditionally, E1AE4 is described as a Tate protein’, as it becomes abundant following 
activation of the differentiation-dependent promoter, and its staining in lesions 
coincides with the start of LI expression. Upon closer examination however, it has 
been found that 16E1AE4 is functionally important for early events such as viral DNA 
replication. This event occurs in the lower, undifferentiated epithelial layers. In such 
cells, Western blotting, but not immunostaining, can detect 16E1AE4 (Nakahara et al., 
2005). It is therefore important to consider that phosphorylation may have different 
roles depending on whether 16E1AE4 is at the low level phase or the abundant phase.
Also, phosphorylation itself may be a regulator of the change in 16E1AE4
levels/distribution.
This study has found that threonine 57 phosphorylation by p42/p44MAPK induces a 
structural change in 16E1AE4 (personal communication, Dr Pauline McIntosh, NIMR) 
that is manifested as a gel-shift in SDS-PAGE. The result is the accumulation of the 
phosphoryiated form in the insoluble fraction of the cell. It is likely that this form has a 
greater affinity for keratin and accelerates the formation of 16E1AE4 multimers on 
keratin filaments (Figure 6.1). This hypothesis is based on the ability of the T57D
phosphorylation mimic to bind keratin in vitro more strongly than the
unphosphorylated protein does. p42MAPK phosphorylation of 11E1AE4 is likely to 
regulate keratin binding in a similar fashion, since mutation of the MAPK site reduces 
the formation of 1 lE lAE4-containing filamentous structures (Bryan et al., 2000). Once 
16E1AE4 has formed keratin-associated filaments/aggregates, it becomes easier to 
visualise by immunostaining with TVG405 and appears to be abundant in the cell. In 
vivo, MAPK phosphorylation may therefore act as a switch to trigger the accumulation 
of 16E1AE4 on keratins. An important future experiment would be to characterise 
active MAPK expression in the epithelium to see if there is correlation with the onset of 
high-level 16E1AE4.
16E1AE4 accumulation on keratin is likely to be important for its biological functions. 
The association with keratin filaments disrupts normal keratin dynamics and in vivo, 
this is manifested by the collapse or reorganisation of keratin networks (Doorbar et al., 
1991; Wang et al., 2004). This is hypothesised to weaken the cell and aid virus release. 
The association of 16E1AE4 with keratins may also facilitate other 16E1AE4 activities,
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Figure 6.1 A model for the accumulation of E l AE4 on keratin
The hypothesis for the effect of p42/p44MAPK phosphorylation of E1AE4 is illustrated. Following E5-enhanced phosphorylation of E1AE4 
b y
MAPK, there is preferential binding of the phosphoryiated E1AE4 to keratin. This allows E1AE4 to accumulate on keratins, causing the 
disruption of keratin dynamics as described by Wang et al. (2004). The accumulation of E1AE4 on keratin may facilitate other E1AE4 functions
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given that keratins are increasingly regarded as a ‘scaffold’ for many cellular events. 
For example, keratin binding or the way phosphoryiated 16E1AE4 arranges itself on 
keratins, may allow cyclins A or B to be tethered more tightly, thus increasing the 
ability of 16E1AE4 to cause cell cycle arrest. This could explain the poorer 
colocalisation of the MAPK phosphorylation mutant (T57A) with cyclin A.
To validate the hypothesised functions of 16E1AE4 phosphorylation, HPV 16 genomes 
containing phosphorylation mutations, could be analysed by raft culture. A virus with 
the 16E1AE4 MAPK site mutated would be predicted to have reduced keratin- 
associated structures, so by immunostaining, the raft cells may appear to have less 
16E1AE4. There may also be lowered cyclin colocalisation, thus less cell cycle arrest, 
resulting in aberrations such as reduced viral DNA replication and amplification. 
Currently, an HPV 16 genome mutated to substitute threonine 57 of E1AE4 with 
isoleucine, is being produced in the laboratory (by Alan Kennedy, NIMR). Isoleucine 
and not alanine is being used, since substitution with alanine would alter the E2 protein 
sequence.
As discussed in 6.1, a number of kinases are active in the epithelium, and as found in 
this study, a number of kinases can phosphorylate 16E1AE4. The biological functions 
of CDK 1/2 phosphorylation need to be further investigated and whether other kinases 
such as PKC can phosphorylate 16E1AE4 in the epithelium, needs to be determined. 
Further work, such as phosphospecific antibody production (ongoing, see Appendix. 5) 
will shed further light on the role of phosphorylation on 16E1AE4 regulation. Future 
experiments are discussed below.
6.3 Future experiments
6.3.1 To clarify the role of 16 E1AE4 threonine 57 phosphorylation in keratin 
binding
The T57D phosphorylation mimic of 16E1AE4 binds keratin with a higher affinity than 
the WT unphosphorylated protein, however increased keratin association was not seen 
when T57D was analysed in SiHa cells. By immunofluorescence, the 16E1AE4 that is 
easily visible, is the form that has formed structures, such as filamentous structures or
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collapsed aggregates. In the immunofluorescence analysis in this study, only cells with 
visible 16E1AE4 were counted, so perhaps only the cells with keratin-bound 16E1AE4 
were included. Therefore, any differences in keratin association between WT and 
mutant proteins, may have gone unnoticed.
One strategy to solve this is to express WT and phosphorylation mutant 16ElAE4s 
using a pIRES-GFP (internal ribosomal entry site -  green fluorescent protein) vector. 
This system would allow translation of 16E1AE4 but also allow GFP translation from 
the same mRNA. Therefore, any cell that expresses GFP should also be expressing 
16E1AE4. The percentage of GFP-positive cells that have visible 16E1AE4, can be 
counted. These cells would be the ones that are likely to contain keratin-associated 
16E1AE4. If WT, T57A and T57D are compared in this way, differences in visible 
16E1AE4 and hence differences in keratin-binding, can be deduced. This work has 
been started by Alan Kennedy (NIMR).
Another approach is to fluorescently tag WT and T57A 16E1AE4, but use different 
fluorescent proteins (e.g. DsRed, a red fluorescent protein, and GFP) for each type so 
that they can be coexpressed and distinguished from each other. When expressed 
separately, they may both bind keratin, as the 16E1AE4 proteins expressed from 
pMVl 1 did in this study. However, when coexpressed, WT 16E1AE4 (which should be 
phosphorylated) may show greater affinity for keratins and therefore occupy keratin 
binding sites more readily than the T57A protein does. This system may therefore help 
to visualise whether keratin preferentially binds to T57-phosphorylated 16E1AE4. A 
similar method was used by Bryan et al. (2000) to show that the MAPK mutant of 
11E1AE4 does not colocalise with filaments or with WT 11E1AE4.
6.3.2 To clarify the role of 16E1AE4 threonine 57 phosphorylation in cyclin 
colocalisation
In this study, the T57A mutant colocalised with cyclin A less frequently than the WT 
protein did (mean of 44 % and 82 % respectively). This suggests that T57A has a 
lower affinity for cyclin A, either because of the lack of phosphorylation or the absence 
of threonine. A future experiment should be the analysis of colocalisation of T57D 
with cyclin A, to help determine if the difference is due to phosphorylation. Kinase
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assays showed that WT, T57A and T57D are phosphorylated at a similar rate by 
CDK2/cyclin A, but the degree of phosphorylation may not reflect the degree of 
binding between the 16E1AE4 proteins and cyclin A. To determine if there are 
differences in binding affinity to cyclin A, tagged (e.g. with GST or histidine), 
bacterially expressed WT, T57A and T57D could be compared for their ability to pull­
down cyclin A from cell extracts. Alternatively, cyclin A could be immunoprecipitated 
from cells to see if it preferentially co-immunoprecipitates threonine 57-phosphorylated 
16E1AE4. It would also be important to determine whether threonine 57 is also 
important for cyclin B binding.
6.3.3 To further investigate CDK1/2 phosphorylation of 16E1AE4
The role of serine 32 phosphorylation by CDK1/2 is unknown. Considering the 
importance of CDK/cyclin binding of 16E1AE4 in cell cycle arrest, the effects of serine 
32 phosphorylation on cyclin A/B colocalisation and cell cycle arrest should be 
investigated.
An interesting investigation would be to find whether both CDK1 and CDK2 
phosphorylate 16E1AE4 in vivo and whether 16E1AE4 is preferentially phosphorylated 
by either. Instead of using kinase inhibitors which often have non-specific effects (see 
4.9.1), another approach is to use engineered kinases that use specific ATP analogues. 
Such kinases are mutated at their ATP binding site, so that they no longer accept 
normal ATP but bind an ATP analogue, N6-benzyl-substituted ATP. Therefore, after 
incubating a cell extract with the mutant kinase and the radioactive ATP analogue, any 
radiolabelled protein must be a specific substrate of this kinase. This technique was 
used to show that a Kaposi’s sarcoma-associated herpesvirus (KSHV) protein, K-bZIP, 
is phosphorylated by CDK1, and to a lesser degree by CDK2 (Poison et al., 2001). 
These CDKs were mutated to substitute phenylalanine 80 with glycine (F80G), the 
mutation being homologous to that used in v-src (a tyrosine kinase), the first kinase to 
be engineered in this way.
6.3.4 To find the 16E1AE4 in vitro PKC phosphorylation site and investigate PKC 
phosphorylation in vivo
By MALDI, the in vitro PKCa phosphorylation site in 16E1AE4 was mapped to a
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region spanning amino acids 35 and 59. Serines 43 and 44 fall in PKC consensus sites, 
but the S43/44A mutant was still phosphorylated in vitro by PKCa (Figure 3.13b). To 
map the exact phosphorylation site, the other serine or threonine mutants of this region 
(S49A, T51A, T54A, T57A, T54/57A, T51/54/57A) need to be tested for 
phosphorylation in vitro, although threonine 57 is unlikely to be involved because its 
phosphorylation causes a gel-shift.
Once the site is mapped, the PKCa phosphorylation mutant can be expressed in cells 
and a number of properties analysed (for example, its solubility, keratin or cyclin 
binding, and its ability to cause cell cycle arrest). Phosphospecific antibodies could 
also be produced for further investigations, especially for the probing of infected 
lesions or rafts.
6.3.5 To find the effects of 16E1AE4 phosphorylation on the virus life cycle
To find the ultimate effects of phosphorylation on the HPV16 life cycle, studies should 
be conducted using epithelial systems, either real, infected lesions, or HPV16- 
containing organotypic raft cultures. For both systems, the use of phosphospecific 
antibodies would provide valuable information on the distribution and abundance of 
different phosphorylated or unphosphorylated forms of 16E1AE4. Phosphospecific 
antibodies are currently being produced, specific for serine 32 and threonine 57 
phosphorylation (Appendix. 5). This, together with the immunostaining of epithelial 
protein kinases (e.g. MAPK, PKC, CDK1/2 and PKA) would give insights into the 
functional role of different 16E1AE4 phosphorylation sites and the kinases involved.
To assess the functional roles more thoroughly, HPV16 genomes mutated to be 
deficient in a 16E1AE4 phosphorylation event or mimic a phosphorylation event, could 
be studied in raft culture. Genomes, mutated for serine 32 phosphorylation or threonine 
57 phosphorylation, are being produced by Alan Kennedy (NIMR). These will be 
transfected into keratinocytes from which raft cultures will be grown.
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6.4 The targeting of kinases in cancer therapy
Components of the cell signalling pathways are often overexpressed or constitutively 
active in cancer. This leads to aberrant cell signalling and therefore, uncontrolled 
growth, survival and metastasis. An increasingly popular method of cancer therapy is 
to target protein kinases to prevent disregulated proliferation and instead to promote 
growth arrest or apoptosis.
The EGFR is frequently overexpressed in epithelial cancers (Salomon et al., 1995). 
The development of reagents that can prevent EGFR activation, for example by 
inhibiting ligand binding or EGFR tyrosine kinase activity, is in high demand. One 
example of such a drug is Herceptin®, a humanised monoclonal antibody directed 
against a member of the EGFR family, HER-2 (Carter et al., 1992; Cobleigh et al., 
1999). Herceptin® is being used to treat breast cancer and has received wide publicity. 
Gefitinib (Iressa) is another agent that inhibits EGFR activation and its mechanism is to 
block the tyrosine kinase activity (Barker et al., 2001). This drug is still being tested in 
trials but has been approved for use in advanced non-small-cell lung carcinoma in some 
countries.
Downstream of EGFR signalling, is the raf/MEK/MAPK pathway, for which a range of 
inhibitors are being tested. The raf genes are commonly overexpressed and overactive 
in cancers, for example b-raf has activating mutations in 70 % of malignant melanomas 
and 15 % of colon cancers (Davies et al., 2002). One raf inhibitor that is in clinical 
development, is BAY 43-9006 (Sorafenib), which has shown antitumour activity 
against a range of cancer types including renal cell cancers and colorectal cancers 
(Wilhelm et al., 2004). MEK inhibitors are also being investigated for their 
performance in clinical trials. Examples include Cl-1040 (Rinehart et al., 2004), PD- 
0325901 (Lorusso et al., 2005) and ARRY-142886/AZD6244 (Wallace et al., 2004).
Another type of kinase that can be inhibited for cancer therapy is the CDK family. 
CDKs are required for cell cycling so blocking their action in malignant cancers would 
be very effective. Flavopiridol (Kaur et al., 1992; Shapiro, 2004) and Roscovitine 
(McClue et al., 2002) both inhibit CDK by preventing ATP binding and both have 
shown promise in clinical trials to date.
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The PKC isoforms have roles in cellular proliferation, differentiation and apoptosis, so 
these kinases have also been targeted for cancer treatment. However, the expression 
profiles and functions of specific isoforms vary according to the type of cancer and the 
tissue involved, so targeting PKC is not so straightforward. For example, PKCa is 
frequently overexpressed in bladder and prostate cancers but downregulated in breast 
and liver cancers, whereas PKC6 is upregulated in liver cancers and downregulated in 
bladder cancers (Koivunen et al., 2005). As a result, therapeutics that target PKC 
molecules are being designed to target specific PKC isoforms. For example, ISIS 3521 
(Aprinocarsen) is an oligonucleotide that can bind PKCa mRNA so prevent expression 
of the kinase and is currently being tested in trials (Advani et al., 2004; Dean and 
McKay, 1994).
As well as kinase inhibitors, kinase activators can also play a role in cancer therapies, 
for example, a PKC6 activator, PEP500, has been shown to induce apoptosis in 
leukaemia cell lines (Hampson et al., 2005). Similarly, Gemcitabine (a pyrimidine 
analogue that is incorporated into DNA and blocks DNA synthesis), which is widely 
used in chemotherapy, appears to depend on p38MAPK activation for its apoptotic 
effects (Habiro et al., 2004).
Considering the extent to which the HPV life cycle and protein function is dependent 
on signalling pathways, the targeting of kinases in the treatment of HPV infections or 
HPV-induced cancers, is an attractive approach. For example, if E1AE4 activity can be 
shown to be enhanced in vivo by modulators of kinase activity, HPV infections could 
be directed towards late viral events instead of cancer. For this technology to be 
developed in the future, the regulation of virus protein function by protein kinases must 
continue to be investigated.
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The papillomavirus phylogenetic tree taken from de Villiers et al. (2004). The 
outermost semi-circles indicate the papillomavirus genus and the number at the 
inner semi-circles refers to the papillomavirus species. The numbers at the ends 
of branches identifies the HPV type, ‘c’ refers to candidate HPVs and 
abbreviations are names of animal papillomaviruses.
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Appendix.2 Sequencing results for His-E1AE4 mutants
S32A S43A S43AS44A
P A P
S49A
A
L A S  L A A D
T54AT51A
Q A P E A P
T57A
A PA
T54AT57A
E A P A A P
T51AT5 4AT57A
A P E A P A A P
T57D
DA P
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Appendix.3 Sequencing results for pMVll E1AE4 mutants
S32A S43/44A T57A T57D
C C G G C G C CT G C CO C AC CA
A A P
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Appendix.4 pAdEasy-1 vector map
pB K 322 o r ig in  1 8 5 4 -2 5 2 1  
a m p .a l i . r i  r e s is ta n c e  (b io ) ORF 2 6 6 9 -3 5 2 9  
A d5  r ig h t a r m  h o m o lo g y  3 7 1 6 -5 7 2 1  
h o m o lo g y  3 2 4 8 3 -3 3 4 7 1
pBK322 on 
rompia'liin 
r l  rC la l*
left arm homology-i /Poe I
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pA dEasy-1
3 3 .5  kb
Plasmid map indicates that the adenoviral genes, El and E3, are deleted (taken 
from  http ://www. stratagene .com/products/di splay Product. aspx?pid=86).
Appendix 181
Appendix.5 Phosphospecific antibody production
The peptides, 1661, 1662, 1665 and 1666 were synthesised, conjugated to 
mcKLH and used to immunise rabbits. Their sequences are shown below. 
1661 and 1662 were designed to be specific for unphosphorylated and 
phosphorylated S32 respectively, and 1665 and 1666 were designed to be 
specific for unphosphorylated and phosphorylated T57 respectively.
1661 and 1662 peptides contained a cysteine residue at their C-terminus which 
is not part of the 16E1AE4 sequence, but was required for conjugation to 
mcKLH.
PEPTIDE
1661
1662
1665
1666
SEQUENCE
26 37
R P I P K P S P W  A P K C  
R P I P K P S P P W A P K C
52 61
P E T P A T P L S C
52 p 61
P E T P A T  P L S C
After the immunisation programme, the unpurified terminal bleeds were used in 
Western blots (at a 1:250 dilution) to test for their reactivity against a 
rAdElAE4-infected SiHa cell extract. The anti-N-terminus rabbit polyclonal 
was also used for comparison. Anti-1661, -1662 and -1665 appeared immuno- 
reactive to E 1AE4, but anti-1666 did not detect the protein. These antibodies 
need to be purified using peptide affinity purification to produce anti-ElAE4 
antibodies specific for unphosphorylated
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Appendix.6 Phylogenetic analysis of anogenital HPVs
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Phylogenetic analysis of anogenital HPV types taken from Schiffman et al. (2005). 
The presence (+) or absence (-) of an E5 ORF, is indicated. +/- is used to depict 
the presence of an E5 ORE but the absence of a translation start codon.
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